var title_f30_28_31168="Acute meningococcemia";
var content_f30_28_31168=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F52107&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F52107&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Purpura fulminans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 249px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Skin lesions in acute meningococcemia can begin as papules but quickly progress to petechiae and purpura. As seen here, the purpuric lesions can coalesce.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles V Sanders. (The Skin and Infection: A Color Atlas and Text, Sanders, CV, Nesbitt, LT Jr (Eds), Williams &amp; Wilkins, Baltimore, 1995).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_28_31168=[""].join("\n");
var outline_f30_28_31168=null;
var title_f30_28_31169="Condylomata lata2";
var content_f30_28_31169=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F79092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F79092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Condylomata lata",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 258px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from&nbsp;Lynne J Margesson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_28_31169=[""].join("\n");
var outline_f30_28_31169=null;
var title_f30_28_31170="Celiac plexus intervention";
var content_f30_28_31170=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81618&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81618&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Celiac plexus intervention",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 302px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An artist's rendition of endosonography-guided celiac plexus intervention. The position of the needle tip corresponds with the site of therapy when performing celiac plexus neurolysis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mike King. Copyrighted and used with permission of Mayo Foundation for Medical Education and Research.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_28_31170=[""].join("\n");
var outline_f30_28_31170=null;
var title_f30_28_31171="Erythromycin (topical): Drug information";
var content_f30_28_31171=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Erythromycin (topical): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/47/756?source=see_link\">",
"    see \"Erythromycin (topical): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/6/30818?source=see_link\">",
"    see \"Erythromycin (topical): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8086237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Akne-mycin&reg;;",
"     </li>",
"     <li>",
"      Ery",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8086238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sans Acne&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8089314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Acne Products;",
"     </li>",
"     <li>",
"      Antibiotic, Macrolide;",
"     </li>",
"     <li>",
"      Antibiotic, Topical;",
"     </li>",
"     <li>",
"      Topical Skin Product;",
"     </li>",
"     <li>",
"      Topical Skin Product, Acne",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8086396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Acne:",
"     </b>",
"     Topical: Usual dosage range: Apply over the affected area twice daily after the skin has been thoroughly washed and patted dry",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8086395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/6/30818?source=see_link\">",
"      see \"Erythromycin (topical): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Topical: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8086397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8086447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical: 2% (30 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Akne-mycin&reg;: 2% (25 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Pledget, topical: 2% (60s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ery: 2% (60s) [contains ethanol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical: 2% (60 mL)",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F8086448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sans Acne&reg;: 2% (60 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8086240\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes ointment",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8086241\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Treatment of acne vulgaris",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8085307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Erythromycin may be confused with azithromycin, clarithromycin",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8086295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     1% to 10%: Dermatologic: Erythema, desquamation, dryness, pruritus",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8086279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to erythromycin, any macrolides antibiotics, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299282\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8086299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8086242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9793457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Erythromycin has been shown to cross the placenta following oral dosing. Refer to the Erythromycin (Systemic) monograph for details. The amount of erythromycin available systemically following topical application is considered to be very low. Systemic absorption would be required in order for erythromycin to cross the placenta and reach the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8086245\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution (AAP considers \"compatible\"; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9793460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The manufacturer recommends that caution be exercised when administering erythromycin topical gel to nursing women. Erythromycin has been shown to enter breast milk following oral dosing. Refer to the Erythromycin (Systemic) monograph for details. The amount of erythromycin available systemically following topical application is considered to be very low. Systemic absorption would be required in order for erythromycin to enter breast milk and reach the nursing infant.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F8086450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Erythromycin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (30 g): $25.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Akne-Mycin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (25 g): $153.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pads",
"     </b>",
"     (Erythromycin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (60): $94.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Erythromycin External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2% (60 mL): $47.63",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F12707703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acne Hermal (GR);",
"     </li>",
"     <li>",
"      Acnederm (IN);",
"     </li>",
"     <li>",
"      Acnederm Ery Gel (DE);",
"     </li>",
"     <li>",
"      Acnefug-EL (CZ, EE);",
"     </li>",
"     <li>",
"      Acneryne (BE);",
"     </li>",
"     <li>",
"      Acnetrim (IL, TW);",
"     </li>",
"     <li>",
"      Akne-Mycin (HK, IL, MY, NL, PT, SG);",
"     </li>",
"     <li>",
"      Aknemycin (BE, CZ, DE);",
"     </li>",
"     <li>",
"      Aknilox (CH, TR);",
"     </li>",
"     <li>",
"      Bonac Gel (PE);",
"     </li>",
"     <li>",
"      Egery (FR);",
"     </li>",
"     <li>",
"      Elimicina Dermica (PY);",
"     </li>",
"     <li>",
"      Eryacne (AR, AU, CO, FR, GR, IT, KP, NZ, PY, SG, TH, VE);",
"     </li>",
"     <li>",
"      Eryacnen (BR, CN, CR, DO, GT, HN, NI, PA, PE, SV);",
"     </li>",
"     <li>",
"      Eryaknen (CH);",
"     </li>",
"     <li>",
"      Eryderm (NL);",
"     </li>",
"     <li>",
"      Erydermec (DE);",
"     </li>",
"     <li>",
"      Eryfluid (CZ, FR);",
"     </li>",
"     <li>",
"      Erylik (HK);",
"     </li>",
"     <li>",
"      Erymed (ID);",
"     </li>",
"     <li>",
"      Iloticina (AR, CO);",
"     </li>",
"     <li>",
"      Ilotycin T.S. (ZA);",
"     </li>",
"     <li>",
"      Inderm Gel (BE, DE);",
"     </li>",
"     <li>",
"      Stiemycin (BR, GB, IE, KP, NZ, PH, SG, TH, UY, ZA);",
"     </li>",
"     <li>",
"      Stimycine (BE, FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8089427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits RNA-dependent protein synthesis at the chain elongation step; binds to the 50S ribosomal subunit resulting in blockage of transpeptidation",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?30/28/31171/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9119 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-89.218.100.194-E4F9E9D48D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_28_31171=[""].join("\n");
var outline_f30_28_31171=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086237\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086238\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8089314\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086396\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086395\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086397\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086447\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086448\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086240\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086241\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8085307\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086295\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086279\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299282\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086299\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086242\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9793457\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086245\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9793460\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8086450\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12707703\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8089427\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9119\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9119|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/51/26419?source=related_link\">",
"      Erythromycin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/61/4052?source=related_link\">",
"      Erythromycin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/41/42642?source=related_link\">",
"      Erythromycin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?25/6/25705?source=related_link\">",
"      Erythromycin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/23/22901?source=related_link\">",
"      Erythromycin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?21/32/22025?source=related_link\">",
"      Erythromycin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/47/756?source=related_link\">",
"      Erythromycin (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/6/30818?source=related_link\">",
"      Erythromycin (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_28_31172="Fetal membrane roll";
var content_f30_28_31172=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76740&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76740&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    The fetal membranes are rolled around the tips of a pair of forceps",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Drucilla J Roberts, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_28_31172=[""].join("\n");
var outline_f30_28_31172=null;
var title_f30_28_31173="TM embryology";
var content_f30_28_31173=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74065&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74065&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    TM embryology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 439px; height: 343px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The external auditory canal is separated from the tympanic cavity by the tympanic membrane, which has an inner layer of endoderm, a middle layer of mesoderm, and an outer layer of ectoderm. The tympanic cavity has expanded around the ossicles. The membranous labyrinth is contained within the bony labyrinth. The perilympathic fluid that conducts sound to the cochlea communicates acoustic energy through the oval and round windows.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_28_31173=[""].join("\n");
var outline_f30_28_31173=null;
var title_f30_28_31174="Patho nerve sheath C";
var content_f30_28_31174=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F71091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F71091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Intradural nerve sheath tumor: Wavy spindle cells that may be seen in schwannoma or neurofibroma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_28_31174=[""].join("\n");
var outline_f30_28_31174=null;
var title_f30_28_31175="Transfusion transmitted HIV infection and AIDS";
var content_f30_28_31175=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Transfusion transmitted HIV infection and AIDS",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/28/31175/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/28/31175/contributors\">",
"     Steven Kleinman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/28/31175/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/28/31175/contributors\">",
"     Arthur J Silvergleid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/28/31175/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/28/31175/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/28/31175/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tremendous progress has been made in understanding, as well as decreasing, the risk of human immunodeficiency virus (HIV) transmission from blood transfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/1\">",
"     1",
"    </a>",
"    ]. The major interventions that are used to minimize this risk include questioning of donors concerning HIV risk behaviors and laboratory testing of each donated unit of blood for antibodies to HIV-1 and HIV-2 and for HIV-1 RNA by pooling of 6 to 16 specimens (minipool nucleic acid testing, or MP-NAT). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26106?source=see_link\">",
"     \"Procedures used for blood donor screening: Protection of potential blood donors and recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/14/11498?source=see_link\">",
"     \"Blood donor medical history\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/41/40601?source=see_link\">",
"     \"Laboratory testing of donated blood\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The rate of HIV seropositivity in the blood donor population has been shown to be approximately 0.5 per 10,000 donations, a value much lower than the rate of 3.5 per 10,000 donations shortly after the introduction of routine HIV antibody screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/2\">",
"     2",
"    </a>",
"    ]. When analyzed in first time blood donors, the rate is 1 per 10,000 donors and has remained stable for a decade (1999-2008) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/3\">",
"     3",
"    </a>",
"    ]. Because of careful donor selection criteria, it has been calculated that HIV seroprevalence in blood donors is less than 2 percent of that expected in the adult American population.",
"   </p>",
"   <p>",
"    Despite these procedures, HIV transmission may still occur for three theoretical reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Donations may be collected during the window period of infection, defined as the interval of time shortly after HIV infection, when the donor is infectious but has not yet developed positive HIV laboratory tests.",
"     </li>",
"     <li>",
"      Infection with variant strains of HIV that may escape detection by current screening assays.",
"     </li>",
"     <li>",
"      Testing or clerical errors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK OF HIV INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;When considering the risk of acquiring HIV infection from a transfusion, it is useful to consider the data from before and after the use of HIV antibody testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Before HIV antibody testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data obtained in 1985 prior to the availability of HIV testing showed that approximately 90 percent of transfused recipients acquired HIV infection when given an HIV seropositive blood component [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/4\">",
"     4",
"    </a>",
"    ]. Transmission rates of HIV are equivalent from red cells, platelets, or plasma. However, red cells stored for more than 21 days or red cells that are saline washed (and therefore have lower leukocyte concentrations) may transmit HIV infection at a lower rate than other stored components [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/1,5\">",
"     1,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Assuming that patients survive their underlying disease long enough to develop AIDS, the Centers for Disease Control and Prevention (CDC) estimated that 12,000 to 25,000 cases of transfusion-associated AIDS cases may have resulted from HIV untested blood components transfused prior to the use of antibody testing, which began in 1985 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/6\">",
"     6",
"    </a>",
"    ]. HIV-infected transfusion recipients developed AIDS at the same rate as age matched cohorts infected by HIV via other transmission routes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     After HIV antibody testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;As early as 1988, case reports of transfusion transmitted AIDS from HIV seronegative blood were being investigated by the CDC. Through June 1992, the CDC had received 201 AIDS case reports in which the only acknowledged mode of HIV exposure was one or more transfusions received from 1986 through 1991 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/8\">",
"     8",
"    </a>",
"    ]. However, upon further investigation, only 14 of these 201 cases were confirmed to be due to infections from screened blood transfusions. In many of these cases, an infected donor was identified who had given blood shortly following a high-risk exposure, ie, in the preseroconversion infectious window period.",
"   </p>",
"   <p>",
"    After adjustment for noninvestigated cases, the CDC investigators estimated that approximately five AIDS cases per year were due to infections from anti-HIV screened blood transfusions. Since AIDS case reports underestimate the number of HIV transfusion transmissions, several studies have attempted to directly study or estimate this risk. Prior to 1995, there were multiple published estimates of the risk of HIV transmission from antibody negative blood; these ranged from a risk of one in 36,000 units to a risk of one in 225,000 units [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. The two major reasons for the differences in these estimates are the time period of data collection and the geographic location in which the study was performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Improvements in donor testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the mid-1990s, two independent estimates for nationwide HIV risk were made by the CDC and the Retrovirus Epidemiology Donor Study (REDS) using data obtained after the implementation of more sensitive recombinant antigen-based third generation anti-HIV tests that are capable of detecting early IgM and IgG responses to HIV infection. These estimates were based upon the transfusion of HIV-infected units donated during the preseroconversion window period and were determined by multiplying the length of the HIV window period by the annual incidence of HIV infection in blood donors.",
"   </p>",
"   <p>",
"    The CDC estimated the HIV risk per unit to be one in 450,000 to 650,000 units; REDS estimated a similar risk of one in 493,000 units [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The concordance of these two estimates suggested that they were likely to be generalizable on a national level. With the implementation of HIV-1 p24 antigen testing in 1996, which has subsequently been discontinued, these estimates needed to be corrected for the anticipated further benefit provided by this test; an adjustment of the REDS estimate gave a per unit risk of one in 677,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After implementation of HIV-1 p24 antigen testing in the United States in 1996, the detection rate of HIV infected donors by this assay occurred at a rate of one in six million donations, which was lower than that predicted from mathematical modeling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/15\">",
"     15",
"    </a>",
"    ]. In retrospect, the model assumed that seroconverting donors donate at a rate consistent with their previous donation behavior during the preseroconversion period. However, since this phase of HIV infection is frequently characterized by clinical or subclinical illness (the acute HIV syndrome), it now appears that HIV-1 p24 antigenemic donors were less likely to donate, possibly because of their febrile symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/14,16\">",
"     14,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 1999, the HIV window period was further reduced by adding a second type of testing that uses detection of plasma HIV RNA in samples that are pooled together from 6 to 16 blood donors (or a larger number of plasma donors) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/17\">",
"     17",
"    </a>",
"    ]. This assay, known as minipool nucleic acid testing (MP-NAT), detects HIV earlier than the p24 viral protein or anti-HIV antibody. Due to the increased sensitivity of HIV MP-NAT for detecting early window period infection, the risk of HIV infection from transfusion has further decreased. The 2005 revised estimate for the risk of transfusion-transmitted HIV infection was one in approximately two million units [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/3,18,19\">",
"     3,18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the first three years (1999 to 2002) after implementation of HIV MP-NAT in the United States, 12 HIV RNA positive, HIV antibody negative units were identified, for a rate of one HIV RNA positive, antibody negative unit per 3.1 million units tested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/20\">",
"     20",
"    </a>",
"    ]. HIV MP-NAT is estimated to have prevented five transfusion-transmitted cases annually, at an estimated cost of 1.5 to 4.3 million dollars per quality-adjusted year of life saved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/21\">",
"     21",
"    </a>",
"    ]. Nevertheless, rare cases of HIV infection from transfusion have still been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/1,2,22,23\">",
"     1,2,22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effectiveness of NAT testing to narrow the HIV window depends upon the analytical sensitivity of the assay method and the dilution factor of the sample (ie, the size of the plasma pool). It has been estimated that the most common screening system in the US detects approximately 500 HIV RNA",
"    <span class=\"nowrap\">",
"     copies/mL,",
"    </span>",
"    95 percent of the time, in each of the specimens entering the pool [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/19\">",
"     19",
"    </a>",
"    ]. The fact that all HIV-1 p24 antigen positive samples were identified as HIV positive by HIV MP-NAT has allowed for discontinuation of p24 antigen testing as part of blood donor screening.",
"   </p>",
"   <p>",
"    The approach of using minipools for NAT has been adopted in place of individual donation (ID) HIV NAT due to the difficulty in achieving adequate throughput even with the automated testing systems that have been developed, the cost of ID testing, and the relatively low incremental yield. HIV risk in the US with MP NAT testing in place is one in 1.4 million [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/3\">",
"     3",
"    </a>",
"    ]. The further window period closure to be achieved by ID NAT relative to MP NAT has been estimated to be 3.4 days (ie, reducing the window period to eight days); implementation of this testing would be expected to detect two to three HIV infectious units per year, resulting in an HIV risk of one in three to four million [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/19\">",
"     19",
"    </a>",
"    ]. A cost effectiveness analysis, taking MP-NAT as the baseline, indicated that the marginal cost of introducing ID-NAT for HIV in combination with HCV and HBV would exceed $12 million per quality associated life year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/24\">",
"     24",
"    </a>",
"    ]. In some countries with a very high HIV incidence (eg, South Africa), ID NAT has been implemented.",
"   </p>",
"   <p>",
"    Additional discussion of testing of donated blood is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/41/40601?source=see_link&amp;anchor=H8#H8\">",
"     \"Laboratory testing of donated blood\", section on 'Infectious disease screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Defining the HIV window period",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first approach used to generate an estimate for the infectious window period preceding HIV seroconversion used the mathematical relationship between the window period, the interdonation interval (the interval between seronegative and seropositive donations in an HIV seroconverting donor) and whether the seronegative unit transmitted HIV infection to a recipient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/25\">",
"     25",
"    </a>",
"    ]. Based upon evaluation of recipients of blood units from donors who later developed HIV antibody, this window period was estimated to be 56 days with the first generation antibody assays introduced in 1985 and 42 days with the second generation assays introduced in 1987 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/26\">",
"     26",
"    </a>",
"    ]. Addition of MP-NAT testing reduced the window period to 11 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is important not to equate the viremic preseroconversion window period determined by the above methodologies with the time period from exposure to seroconversion. Data from animal models indicate that there is a period of days to weeks following HIV exposure during which virus is replicating in regional lymphoid tissue prior to dissemination into peripheral blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/28\">",
"     28",
"    </a>",
"    ]. Thus, the \"exposure-to-seroconversion\" window period is longer than the \"infectious\" window period.",
"   </p>",
"   <p>",
"    Another issue is that data related to infections transmitted by intravascular infusions of 20 to 200 mL of plasma from blood components produced from a donor in the high titer viremic preseroconversion stage of primary infection cannot be directly extrapolated to other exposure routes and inoculation volumes (eg, needlestick exposure, injection drug use, and sexual exposure) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/50/26410?source=see_link\">",
"     \"Nonoccupational exposure to HIV in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     OTHER POTENTIAL REASONS FOR HIV TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transfusion of window period units are thought to account for virtually all current cases of HIV transfusion-transmission. Lack of transmission from other sources is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     HIV genetic variation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The importance of HIV genetic variation for transfusion safety relates to whether screening assays can detect either the genetic material of various HIV subtypes and clades, or can detect antibodies to these different subtypes that may be present in the ethnically and geographically diverse population that donates blood. HIV can be classified into broad groups based upon nucleic acid sequence analysis of envelope (env) and core (gag) genes; HIV-1 and HIV-2 are at the extremes of this diversity. An overview of genetic variation is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/63/5112?source=see_link\">",
"     \"Overview of genetic variation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The HIV-1 family is phylogenetically subclassified into main (M), outlier (O), and non-major and non-outlier (N) groups. Group M is further divided into nine distinct subtypes, or clades, designated A through K (with E and I having been reclassified as circulating recombinant strains (CRFs)); group O is also composed of a set of divergent clades [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HIV-1 clade B is by far the predominant subtype in the United States. For this reason, HIV antibody assays use HIV-1 clade B viral lysate or recombinant proteins derived from HIV-1 clade B as the antigenic material. These assays are highly sensitive to infection due to HIV-1 clades A-H. However, these assays fail to detect occasional samples from more diverse variants, such as HIV-2 and HIV-1 group O [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HIV-2 was discovered in 1985 in West Africa and subsequently in Western Europe. Although HIV-1 has had an extremely prominent role in blood safety, this is not the case for HIV-2. While there have been thousands of cases of transfusion transmitted HIV-1 infection, there have been fewer than 50 such cases attributed to HIV-2 (occurring primarily in Portugal), and none from units donated during the window period since the implementation of combined HIV-1 and HIV-2 serologic testing in Europe and North America [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HIV-1 and HIV-2 crossreact immunologically to a great extent; as a result, up to 90 percent of sera from HIV-2-infected persons test positive on FDA-licensed HIV-1-based screening assays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/32\">",
"     32",
"    </a>",
"    ]. However, because the sensitivity of HIV-1 antibody assays for HIV-2 is less than 100 percent, a combined assay using both HIV-1 and HIV-2 antigens was introduced into routine blood donor screening in the United States in 1992. HIV-2 infection has remained extremely rare in US blood donors. In 10 years of HIV-2 testing, fewer than five HIV-2 infected blood donors were reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/35\">",
"     35",
"    </a>",
"    ]. HIV-2 is also rare in European blood donors; for example, only 1 percent of HIV seropositive donors in France were infected with HIV-2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In mid-1994, French investigators reported that some persons infected with HIV-1 group O, a variant endemic in some central African countries, tested negative on a number of HIV-1 antibody and",
"    <span class=\"nowrap\">",
"     HIV-1/HIV-2",
"    </span>",
"    antibody combination assays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/33\">",
"     33",
"    </a>",
"    ]. In July 1996, the first case of group O infection in North America was reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/37\">",
"     37",
"    </a>",
"    ]. Due to the rarity of group O infection and the ability of current HIV antibody assays to crossreact with most group O infected donors, the contribution of such genetically divergent infections to transfusion transmitted HIV risk will be negligible. Nevertheless, the FDA in December 1996 implemented policies to exclude from donation persons from countries in Africa in which group O variants are endemic. The FDA is encouraging HIV antibody test manufacturers to enhance their tests with antigens that can detect antibodies to all group O isolates. Some of these newer tests are now available and, when used, allow blood centers to no longer solicit information about exposure to HIV through travel to these endemic African countries.",
"   </p>",
"   <p>",
"    A national study that performed HIV-1 genetic typing of 316 HIV seropositive donors from 1997-2000 revealed that only 2 percent were infected with HIV-1, non-clade B strains. Four of the seven non-clade B donors appeared to have acquired their infection in Africa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/38\">",
"     38",
"    </a>",
"    ]. Studies of HIV infected donors from 1999 through 2007 have shown very similar findings with only 3 percent of HIV-infected blood donors demonstrating non-clade B infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. These data are consistent with other studies indicating the rarity of non-clade B infection in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Technical error",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with any test, the possibility of technical error exists with HIV blood donor screening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/41\">",
"     41",
"    </a>",
"    ]. However, since HIV screening currently includes two independent assays, any errors in antibody testing would be very unlikely to occur in both test systems simultaneously. Therefore, testing error should make no contribution to HIV risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/41/40601?source=see_link&amp;anchor=H9#H9\">",
"     \"Laboratory testing of donated blood\", section on 'HIV-1 and HIV-2'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     VIRAL INACTIVATION OF BLOOD COMPONENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV is inactivated by the purification process used to produce plasma derivatives such as albumin and intravenous immune globulin (IVIG). Thus, there has never been a documented case of HIV transmission from albumin or immune globulin preparations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/22/38247?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathogen inactivation of blood products\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prior to 1984, HIV transmission to hemophiliacs from infected antihemophilic factor (AHF) concentrates was common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/42\">",
"     42",
"    </a>",
"    ]. Since the implementation of improved viral inactivation procedures (eg, pasteurization, chromatography,",
"    <span class=\"nowrap\">",
"     solvent/detergent",
"    </span>",
"    treatment) for plasma derivatives in the mid 1980s, as well as their gradual improvement in the ensuing few years, there have been no documented HIV transmissions from AHF concentrates. In vitro data demonstrate that these procedures kill HIV in a logarithmic fashion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/43\">",
"     43",
"    </a>",
"    ]. Testing of individual donors is still required in order to exclude plasmas with extremely high viral titers, which might otherwise escape these inactivation procedures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/22/38247?source=see_link\">",
"     \"Pathogen inactivation of blood products\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since HIV can be readily inactivated in plasma derivatives, considerable effort has been directed towards inactivating HIV and other pathogens in blood components. With respect to plasma transfusion, an alternative to fresh frozen plasma is the use of solvent detergent-treated fresh frozen plasma",
"    <span class=\"nowrap\">",
"     (S/D",
"    </span>",
"    plasma) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/44\">",
"     44",
"    </a>",
"    ]. This product is prepared from plasma pools of approximately 1500 donors and is subjected to the same solvent detergent viral inactivation technique used for plasma derivatives; as a result, it demonstrates the same HIV safety (ie, zero risk) as solvent detergent treated coagulation factor concentrates.",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    plasma has been available for many years in Europe, and the United States Food and Drug Administration approved such an",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    product in 2013. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/22/38247?source=see_link\">",
"     \"Pathogen inactivation of blood products\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    With respect to platelets and red cells, efforts are underway to develop methods that will completely inactivate viruses such as HIV while still preserving the function of the transfused cells. One approach is the addition of psoralen compounds to an individual blood component; upon photoactivation, the nucleic acid of HIV and other viruses is altered to achieve viral inactivation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31175/abstract/45\">",
"     45",
"    </a>",
"    ]. Pathogen inactivated platelets (either using the psoralen approach or through a second approach using riboflavin and UV light) are licensed and used in many countries, but the product is not licensed in the United States. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/22/38247?source=see_link&amp;anchor=H17#H17\">",
"     \"Pathogen inactivation of blood products\", section on 'Pathogen inactivation of platelets'",
"    </a>",
"    .) There are not yet any pathogen inactivated red cell products available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/12/26820?source=see_link\">",
"       \"Patient information: Blood donation and transfusion (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15466266\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tremendous progress has been made in understanding and decreasing the risk of human immunodeficiency virus (HIV) transmission from blood transfusion. The major interventions used to minimize this risk include questioning donors concerning HIV risk behaviors, laboratory testing for HIV antibody and minipool nucleic acid testing (MP-NAT), and inactivation of HIV in plasma derivatives (eg, albumin, intravenous immunoglobulin, and plasma-derived clotting factors). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26106?source=see_link\">",
"       \"Procedures used for blood donor screening: Protection of potential blood donors and recipients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/14/11498?source=see_link\">",
"       \"Blood donor medical history\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/41/40601?source=see_link\">",
"       \"Laboratory testing of donated blood\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      HIV transmission may still occur for the following reasons (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Other potential reasons for hiv transmission'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Donations may be collected during the window period of infection, when the donor is infectious but has not yet developed positive HIV laboratory tests.",
"     </li>",
"     <li>",
"      Infection with variant strains of HIV that may escape detection by current assays.",
"     </li>",
"     <li>",
"      Testing or clerical errors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transfusion of window period units (ie, units from individuals who have been infected but who are in the window during which testing has not yet become positive) accounts for virtually all cases of transfusion-transmitted HIV. The window period is approximately 11 days with combined HIV antibody and MP-NAT testing.",
"     </li>",
"     <li>",
"      The risk of transfusion-transmitted HIV infection is one in approximately 1.4 million units. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Risk of HIV infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Implementation of individual donor nucleic acid testing (ID-NAT) in the US would be expected to detect only two to three HIV infectious units per year. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Improvements in donor testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/1\">",
"      Kleinman SH, Lelie N, Busch MP. Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion. Transfusion 2009; 49:2454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/2\">",
"      Phelps R, Robbins K, Liberti T, et al. Window-period human immunodeficiency virus transmission to two recipients by an adolescent blood donor. Transfusion 2004; 44:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/3\">",
"      Zou S, Dorsey KA, Notari EP, et al. Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion 2010; 50:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/4\">",
"      Donegan E, Stuart M, Niland JC, et al. Infection with human immunodeficiency virus type 1 (HIV-1) among recipients of antibody-positive blood donations. Ann Intern Med 1990; 113:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/5\">",
"      Donegan E, Lenes BA, Tomasulo PA, et al. Transmission of HIV-1 by component type and duration of shelf storage before transfusion. Transfusion 1990; 30:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/6\">",
"      Kalbfleisch JD, Lawless JF. Estimating the incubation time distribution and expected number of cases of transfusion-associated acquired immune deficiency syndrome. Transfusion 1989; 29:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/7\">",
"      Operskalski EA, Stram DO, Lee H, et al. Human immunodeficiency virus type 1 infection: relationship of risk group and age to rate of progression to AIDS. Transfusion Safety Study Group. J Infect Dis 1995; 172:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/8\">",
"      Selik RM, Ward JW, Buehler JW. Trends in transfusion-associated acquired immune deficiency syndrome in the United States, 1982 through 1991. Transfusion 1993; 33:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/9\">",
"      Ward JW, Holmberg SD, Allen JR, et al. Transmission of human immunodeficiency virus (HIV) by blood transfusions screened as negative for HIV antibody. N Engl J Med 1988; 318:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/10\">",
"      Nelson KE, Donahue JG, Mu&ntilde;oz A, et al. Transmission of retroviruses from seronegative donors by transfusion during cardiac surgery. A multicenter study of HIV-1 and HTLV-I/II infections. Ann Intern Med 1992; 117:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/11\">",
"      Cumming PD, Wallace EL, Schorr JB, Dodd RY. Exposure of patients to human immunodeficiency virus through the transfusion of blood components that test antibody-negative. N Engl J Med 1989; 321:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/12\">",
"      Lackritz EM, Satten GA, Aberle-Grasse J, et al. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med 1995; 333:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/13\">",
"      Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996; 334:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/14\">",
"      Kleinman S, Busch MP, Korelitz JJ, Schreiber GB. The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection. Transfus Med Rev 1997; 11:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/15\">",
"      Stramer S, Salemi B, Brodsky JP, et al. Comparison of four seroconverting blood donors identified by HIV-1 p24 antigen screening. Transfusion 1998; 38(Suppl):2S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/16\">",
"      Schreiber GB, Glynn SA, Satten GA, et al. HIV seroconverting donors delay their return: screening test implications. Transfusion 2002; 42:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/17\">",
"      Stramer SL, Caglioti S, Strong DM. NAT of the United States and Canadian blood supply. Transfusion 2000; 40:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/18\">",
"      Dodd RY, Notari EP 4th, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002; 42:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/19\">",
"      Busch MP, Glynn SA, Stramer SL, et al. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors. Transfusion 2005; 45:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/20\">",
"      Stramer SL, Glynn SA, Kleinman SH, et al. Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Engl J Med 2004; 351:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/21\">",
"      Marshall DA, Kleinman SH, Wong JB, et al. Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States. Vox Sang 2004; 86:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/22\">",
"      Delwart EL, Kalmin ND, Jones TS, et al. First report of human immunodeficiency virus transmission via an RNA-screened blood donation. Vox Sang 2004; 86:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/23\">",
"      Centers for Disease Control and Prevention (CDC). HIV transmission through transfusion --- Missouri and Colorado, 2008. MMWR Morb Mortal Wkly Rep 2010; 59:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/24\">",
"      Jackson BR, Busch MP, Stramer SL, AuBuchon JP. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 2003; 43:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/25\">",
"      Glynn SA, Kleinman SH, Wright DJ, et al. International application of the incidence rate/window period model. Transfusion 2002; 42:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/26\">",
"      Petersen LR, Satten GA, Dodd R, et al. Duration of time from onset of human immunodeficiency virus type 1 infectiousness to development of detectable antibody. The HIV Seroconversion Study Group. Transfusion 1994; 34:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/27\">",
"      Busch MP, Lee LL, Satten GA, et al. Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors. Transfusion 1995; 35:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/28\">",
"      Niu MT, Stein DS, Schnittman SM. Primary human immunodeficiency virus type 1 infection: review of pathogenesis and early treatment intervention in humans and animal retrovirus infections. J Infect Dis 1993; 168:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/29\">",
"      Busch MP, Satten GA. Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Am J Med 1997; 102:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/30\">",
"      Korber BT, MacInnes K, Smith RF, Myers G. Mutational trends in V3 loop protein sequences observed in different genetic lineages of human immunodeficiency virus type 1. J Virol 1994; 68:6730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/31\">",
"      Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM. The challenge of HIV-1 subtype diversity. N Engl J Med 2008; 358:1590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/32\">",
"      O'Brien TR, George JR, Holmberg SD. Human immunodeficiency virus type 2 infection in the United States. Epidemiology, diagnosis, and public health implications. JAMA 1992; 267:2775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/33\">",
"      Loussert-Ajaka I, Ly TD, Chaix ML, et al. HIV-1/HIV-2 seronegativity in HIV-1 subtype O infected patients. Lancet 1994; 343:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/34\">",
"      Soriano V, Gomes P, Heneine W, et al. Human immunodeficiency virus type 2 (HIV-2) in Portugal: clinical spectrum, circulating subtypes, virus isolation, and plasma viral load. J Med Virol 2000; 61:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/35\">",
"      Sullivan MT, Guido EA, Metler RP, et al. Identification and characterization of an HIV-2 antibody-positive blood donor in the United States. Transfusion 1998; 38:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/36\">",
"      Assal A, Barlet V, Deschaseaux M, et al. Sensitivity of two hepatitis B virus, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) nucleic acid test systems relative to hepatitis B surface antigen, anti-HCV, anti-HIV, and p24/anti-HIV combination assays in seroconversion panels. Transfusion 2009; 49:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/37\">",
"      Centers for Disease Control and Prevention (CDC). Identification of HIV-1 group O infection--Los Angeles county, California, 1996. MMWR Morb Mortal Wkly Rep 1996; 45:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/38\">",
"      Delwart EL, Orton S, Parekh B, et al. Two percent of HIV-positive U.S. blood donors are infected with non-subtype B strains. AIDS Res Hum Retroviruses 2003; 19:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/39\">",
"      Brennan CA, Stramer SL, Holzmayer V, et al. Identification of human immunodeficiency virus type 1 non-B subtypes and antiretroviral drug-resistant strains in United States blood donors. Transfusion 2009; 49:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/40\">",
"      Brennan CA, Yamaguchi J, Devare SG, et al. Expanded evaluation of blood donors in the United States for human immunodeficiency virus type 1 non-B subtypes and antiretroviral drug-resistant strains: 2005 through 2007. Transfusion 2010; 50:2707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/41\">",
"      Busch MP, Watanabe KK, Smith JW, et al. False-negative testing errors in routine viral marker screening of blood donors. For the Retrovirus Epidemiology Donor Study. Transfusion 2000; 40:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/42\">",
"      Kroner BL, Rosenberg PS, Aledort LM, et al. HIV-1 infection incidence among persons with hemophilia in the United States and western Europe, 1978-1990. Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1994; 7:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/43\">",
"      Horowitz B, Prince AM, Hamman J, Watklevicz C. Viral safety of solvent/detergent-treated blood products. Blood Coagul Fibrinolysis 1994; 5 Suppl 3:S21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/44\">",
"      Klein HG, Dodd RY, Dzik WH, et al. Current status of solvent/detergent-treated frozen plasma. Transfusion 1998; 38:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31175/abstract/45\">",
"      Stramer SL, Hollinger FB, Katz LM, et al. Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 2009; 49 Suppl 2:1S.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7945 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.18-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_28_31175=[""].join("\n");
var outline_f30_28_31175=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15466266\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK OF HIV INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Before HIV antibody testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      After HIV antibody testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Improvements in donor testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Defining the HIV window period",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      OTHER POTENTIAL REASONS FOR HIV TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      HIV genetic variation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Technical error",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      VIRAL INACTIVATION OF BLOOD COMPONENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15466266\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/14/11498?source=related_link\">",
"      Blood donor medical history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/41/40601?source=related_link\">",
"      Laboratory testing of donated blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/50/26410?source=related_link\">",
"      Nonoccupational exposure to HIV in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/63/5112?source=related_link\">",
"      Overview of genetic variation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/22/38247?source=related_link\">",
"      Pathogen inactivation of blood products",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/12/26820?source=related_link\">",
"      Patient information: Blood donation and transfusion (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26106?source=related_link\">",
"      Procedures used for blood donor screening: Protection of potential blood donors and recipients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_28_31176="Diseases of the central nervous system caused by prions";
var content_f30_28_31176=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diseases of the central nervous system caused by prions",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/28/31176/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/28/31176/contributors\">",
"     Henry G Brown, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/28/31176/contributors\">",
"     John M Lee, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/28/31176/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/28/31176/contributors\">",
"     Steven T DeKosky, MD, FAAN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/28/31176/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/28/31176/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/28/31176/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 17, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prion diseases are neurodegenerative diseases that have long incubation periods and progress inexorably once clinical symptoms appear. Five human prion diseases are currently recognized: kuru, Creutzfeldt-Jakob disease (CJD), variant Creutzfeldt-Jakob disease (vCJD also known as new variant CJD), Gerstmann-Str&auml;ussler-Scheinker syndrome (GSS), and fatal familial insomnia (FFI) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Bovine spongiform encephalopathy (BSE), one of a number of prion infections affecting animals, was responsible for bringing these agents to more widespread public attention with its possible link to vCJD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These human prion diseases share certain common neuropathologic features including neuronal loss, proliferation of glial cells, absence of an inflammatory response, and the presence of small vacuoles within the neuropil, which produces a spongiform appearance. The current theory is that prion diseases are associated with the accumulation of an abnormal form of a host cell protein, the normal form is designated PrPc, and the abnormal form is designated PrPSc (for Scrapie) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of the prion diseases Kuru, GSS, and FFI will be reviewed here. CJD and variant CJD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/62/30698?source=see_link\">",
"     \"Creutzfeldt-Jakob disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/49/40728?source=see_link\">",
"     \"Variant Creutzfeldt-Jakob disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The biology of prions and the genetics of prion diseases are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7017?source=see_link\">",
"     \"Biology and genetics of prions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     KURU",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kuru was the first transmissible neurodegenerative disease to be identified and well studied; it has served as the prototype of human prion diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kuru, which was endemic in Papua New Guinea among the Fore tribes, was felt to be transmitted from person to person by ritual cannibalism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/8\">",
"     8",
"    </a>",
"    ]. The cessation of these practices in the 1950s had been thought to end incident cases of kuru; however, increased active surveillance in Papua New Guinea led to the identification of 11 new cases of kuru between July 1996 and June 2004, with a likely incubation period of more than 50 years in some cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/9\">",
"     9",
"    </a>",
"    ]. Kuru also remains important because of some overlapping clinical and pathologic features with iatrogenic CJD, vCJD, and GSS that provide clues to the pathogenesis of other human prion diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike some of the other prion diseases such as CJD, kuru occurs in predictable stages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/8\">",
"     8",
"    </a>",
"    ]. The early or ambulatory phase is characterized by tremors, ataxia, and postural instability. The tremors resemble shivering, which accounts for the name of the disease (kuru = shivering). The sedentary stage follows as the disease progresses with loss of ambulation resulting from increased tremors and ataxia. Involuntary movements, including myoclonus, choreoathetosis, and fasciculations, also appear. Dementia, which usually begins as slowing of the mental processes, progresses in the late stages of the disease. Patients may exhibit indifference or seem unconcerned with their disease. Frontal release signs, cerebellar type dysarthria, and inability to get out of bed mark the terminal stage, with death typically due to pneumonia occurring within 9 to 24 months from the onset of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few laboratory studies have been performed on patients with kuru, and neuroimaging has not been reported. The cerebrospinal fluid (CSF) is unremarkable. The electroencephalogram (EEG) is abnormal, but it is not characterized by the periodic sharp wave complexes found in some of the other human prion diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;While limited molecular genetic studies of patients with kuru have been undertaken, no mutations in the prion protein (PRNP) gene have been reported. Homozygosity at the polymorphic codon 129 of the PRNP gene has been detected at a higher than expected frequency in kuru and also in patients with iatrogenic CJD, sporadic CJD, and vCJD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/11\">",
"     11",
"    </a>",
"    ]. Individuals who were exposed to kuru and survived the epidemic were usually heterozygotes at a known resistance factor site at codon 129. A genetic study undertaken in Papua, New Guinea identified a novel PRNP variant, G127V, which appeared to confer protection from kuru among geographically and genetically at risk families [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/12\">",
"     12",
"    </a>",
"    ]. The fact that this allele was found exclusively in individuals from a kuru-prevalent geographic region indicates that this is an acquired genetic response through selection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7017?source=see_link\">",
"     \"Biology and genetics of prions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathologic hallmark of kuru is PrPSc-reactive plaques occurring with the greatest frequency in the cerebellum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/11\">",
"     11",
"    </a>",
"    ]. Kuru plaques are unicentric and round with radiating spicules and are periodic acid-Schiff (PAS) positive. Neuronal loss and hypertrophy of astrocytes is also observed",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     GERSTMANN-STR&Auml;USSLER-SCHEINKER SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gerstmann-Str&auml;ussler-Scheinker syndrome (GSS) is a rare human prion disease with an incidence of 1 to 10 cases per 100 million population per year.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Epidemiology and clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;GSS is inherited in an autosomal dominant pattern with virtual complete penetrance. At least 24 separate kindreds have been identified throughout the world.",
"   </p>",
"   <p>",
"    The hallmark of the clinical disease is progressive cerebellar degeneration accompanied by differing degrees of dementia in patients entering midlife (mean age 43 to 48 years), although the onset of symptoms in older patients has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. The course of the illness typically advances for approximately five years before culminating in death. Cerebellar manifestations include clumsiness, incoordination, and gait ataxia. Dysesthesia, hyporeflexia, and proximal weakness in the legs are also early signs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/17\">",
"     17",
"    </a>",
"    ]. Myoclonus is typically absent in GSS. Whether and to what degree dementia ensues varies among affected families and individuals within the same family [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. Part of the variability of expression of this illness may be due to differences in the underlying PRNP mutation or the associated polymorphisms in codon 129. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7017?source=see_link\">",
"     \"Biology and genetics of prions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A diagnosis of GSS cannot be made from laboratory or imaging studies. The cerebrospinal fluid (CSF) is normal in GSS. The electroencephalogram (EEG) may show slowing, but does not typically show the periodic sharp wave complexes characteristic of sporadic CJD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/62/30698?source=see_link&amp;anchor=H22#H22\">",
"     \"Creutzfeldt-Jakob disease\", section on 'Electroencephalogram'",
"    </a>",
"    .) The magnetic resonance imaging (MRI) is not specific or sensitive but may show areas of decreased T2 signal in the striatum and midbrain in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/21\">",
"     21",
"    </a>",
"    ]. Single photon emission computed tomography (SPECT) may demonstrate diffusely decreased blood flow; in one study, findings on SPECT that were very sensitive for GSS early in the disease course included decreased flow in the occipital lobe and spinal cord [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Demonstration of PRNP gene mutations appears to be a sensitive and highly specific way to diagnose GSS since the vast majority of cases are familial, and all patients with definite GSS have been found to have PRNP mutations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7017?source=see_link\">",
"     \"Biology and genetics of prions\"",
"    </a>",
"    .) Neuropathology can be useful, and immunostaining of brain tissue for PrPSc is positive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Neuropathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;GSS displays neuropathologic features consistent with other forms of human prion diseases. However, the presence of kuru-like plaques in highest density in the cerebellum but also elsewhere in the brain is a common finding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/22\">",
"     22",
"    </a>",
"    ]. These plaques are often multicentric with radiating spicules and are accompanied by microglial changes; they stain for PrPSc and are PAS (periodic acid-Schiff) positive. Neurofibrillary tangles and neuropil threads, identical to those seen in Alzheimer disease, have been seen in brains from several kindreds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/20,23\">",
"     20,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     FATAL FAMILIAL INSOMNIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fatal familial insomnia (FFI) was first identified in Italian families, but kindreds have now been reported throughout the world. Sporadic cases are also described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/24-26\">",
"     24-26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Epidemiology and clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;FFI is a rapidly fatal disease with a mean duration of 13 months, which generally occurs in midlife, median age at onset 56 years (range 23 to 73 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Disease onset is earlier and duration is shorter in those who are homozygous for methionine at codon 129. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7017?source=see_link\">",
"     \"Biology and genetics of prions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients characteristically develop progressive insomnia with loss of the normal circadian sleep-activity pattern, which may manifest as a dream-like confusional state during waking hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/29\">",
"     29",
"    </a>",
"    ]. Mental status and behavioral changes include inattention, impaired concentration and memory, confusion, and hallucinations, but overt dementia is rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/30\">",
"     30",
"    </a>",
"    ]. As the disease progresses, motor disturbances such as myoclonus, ataxia, and spasticity can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Methionine-homozygous patients are more likely to have hallucinations and myoclonus as prominent disease features, while methionine-heterozygous patients are more likely to develop early problems with ataxia, bulbar signs, and nystagmus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    FFI is the only prion disease to produce dysautonomia and endocrine disturbances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/27,31,32\">",
"     27,31,32",
"    </a>",
"    ]. Dysautonomia may induce hyperhidrosis, hyperthermia, tachycardia, and hypertension. Endocrine disturbances include decreases in ACTH secretion, increases in cortisol secretion, and loss of the normal diurnal variations in levels of growth hormone, melatonin, and prolactin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory testing and routine imaging with CT or MRI are not helpful in making the diagnosis of FFI. The CSF is unremarkable, and 14-3-3 protein is usually not detectable in the CSF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/33\">",
"     33",
"    </a>",
"    ]. EEGs do not show periodic sharp wave complexes, and MRI shows no distinctive abnormalities. Fluorodeoxyglucose PET has been reported to show decreased glucose utilization in the thalamus, which may be detectable even before the development of clinical symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. Sleep studies demonstrate a dramatic reduction in total sleep time and disruption of the normal sleep architecture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While FFI like other prion diseases has been transmitted to experimental animals, genetic studies are now the diagnostic procedure of choice. Most cases are associated with the D178N PRNP gene mutation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7017?source=see_link\">",
"     \"Biology and genetics of prions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spongiform degeneration, which is a characteristic feature of most of the human prion diseases, is rarely detected in FFI, particularly in those with the methionine-homozygous genotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/28\">",
"     28",
"    </a>",
"    ]. Neuronal loss and gliosis that is maximal within the thalamus are consistent findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/27,28,31\">",
"     27,28,31",
"    </a>",
"    ]. These changes can also occur in the cerebellar cortex, cerebellar nuclei, and olivary nuclei. Brain tissue stains for PrPSc, but the intensity of staining, which correlates with the amount of protein present, appears to be reduced compared with most other human prion diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/28,31,37\">",
"     28,31,37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CJD AND VARIANT CJD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Creutzfeldt Jakob Disease (CJD) and variant CJD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/62/30698?source=see_link\">",
"     \"Creutzfeldt-Jakob disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/49/40728?source=see_link\">",
"     \"Variant Creutzfeldt-Jakob disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     VARIABLY PROTEASE SENSITIVE PRIONOPATHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A new prion disease, proteinase-sensitive prionopathy, was described in a 2008 case series of 11 patients identified by the National Prion Disease Pathology Surveillance Center [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/38\">",
"     38",
"    </a>",
"    ]. Patients presented at a mean of 62 years with a dementia with prominent neuropsychiatric manifestations and progressive motor decline (ataxia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    parkinsonism). Death followed symptoms onset within a mean of 20 months. A family history of dementia was present in seven patients, suggesting a possible genetic origin. CSF 14-3-3 was negative in the five patients in whom it was tested, MRI demonstrated diffuse atrophy without restricted diffusion, and EEGs were normal or showed only diffuse slowing. Neuropathologic examination revealed spongiform degeneration in the cerebral cortex, basal ganglia, and thalamus with relative sparing of the brainstem and cerebellum. There was a similar anatomic distribution of PrP immunostaining that was characterized by a distinctive pattern of cluster-forming granules. Immunoreactivity was virtually abolished by protein digestion. All 11 of these cases had the 129VV genotype. A similar case in the Netherlands was reported subsequently [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A case series of 15 additional cases were reported in 2010 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/40\">",
"     40",
"    </a>",
"    ]. While six cases had the 129VV genotype as in the original 11, three were 129MM, and six were 129MV. While clinical features were similar across genotypes, distinguishing features included a longer mean disease duration (45 months) and older age of onset (72 years) among those with the 129MV genotype compared with the other two groups. Patients with the 129MM phenotype had less severe or absent neuropsychiatric symptoms. The prion proteins associated with the 129MV and 129MM genotypes are also relatively protease resistant compared to those associated with the 129VV genotype.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H925119\">",
"    <span class=\"h1\">",
"     OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A mother and daughter have been described with a prion disease with a rare PRNP mutation (Q160x) that resulted in production of a truncated PrP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/41\">",
"     41",
"    </a>",
"    ]. The clinical presentation was similar to that of early-onset Alzheimer disease (ages 42 and 59 at symptom onset) with progressive short term memory impairment over three years, followed by impairments in other cognitive domains and mild parkinsonism. Mother and daughter died eight years after first clinical symptoms. Neuropathologic examination revealed extensive tau-positive neurofibrillary tangles and neuritic plaques; the latter were immunonegative for beta amyloid but stained positive for PrP.",
"   </p>",
"   <p>",
"    A novel 12-octapeptide repeat insertion in the prion protein gene was discovered in the proband of a kindred of three family members (two sisters and their father) who presented with a clinical syndrome characterized by progressive cognitive decline characteristic of frontotemporal dementia, along with ataxia and seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/42\">",
"     42",
"    </a>",
"    ]. Neuropathologic examination revealed prion protein positive plaques and tau-positive tangles.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TREATMENT OF PRION DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;No effective treatment has been identified for human prion diseases, which are universally fatal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/43\">",
"     43",
"    </a>",
"    ]. Care for patients with prion disease is supportive. Isolated case reports of stabilization or improvement following treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/44\">",
"     44",
"    </a>",
"    ], vidarabine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/45\">",
"     45",
"    </a>",
"    ], and methisoprinol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/46\">",
"     46",
"    </a>",
"    ] have not been confirmed. Reports of treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    , interferons, polyanions, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    have also failed to show benefit in human cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/47-49\">",
"     47-49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Animal models and cell culture systems that are used for studying prion diseases may assist in the testing of new agents for the treatment of prion diseases. The dye Congo red, anthracyclines, DMSO, glycerol, polyene antibiotics, and copper chelation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/6/4200?source=see_link\">",
"     penicillamine",
"    </a>",
"    have all shown efficacy in delaying PrPSc accumulation or disease development in cell culture or animal models, but none have been tried in human disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/50-53\">",
"     50-53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Flupirtine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Flupirtine maleate is a centrally acting, nonopioid analgesic that has displayed cytoprotective activity in vitro in neurons inoculated with a prion protein fragment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/54\">",
"     54",
"    </a>",
"    ]. The mechanism of neuroprotective action is unknown, but it may involve up-regulation of the anti-apoptotic protein bcl-2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Alternatively, its N-methyl-D-aspartate antagonist properties might limit glutamate-mediated neurotoxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Flupirtine is not currently available in the United States. In a European study, 28 patients with CJD were randomly assigned to treatment with flupirtine (n=13) or placebo (n = 15) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/57\">",
"     57",
"    </a>",
"    ]. One patient in each group had familial CJD, the remainder were sporadic cases. Diagnosis was based upon the World Health Organization (WHO) criteria for \"probable\" CJD. Flupirtine treatment was initiated at 100 mg per day, and increased over three days to a maintenance dose of 300 to 400 mg per day, which was continued for a median treatment duration of 29 days. There was no significant effect of flupirtine treatment on survival time compared with placebo. However, the patients treated with flupirtine performed significantly better on the cognitive part of the Alzheimer Disease Assessment Scale (ADAS-Cog). Flupirtine-treated patients also did better on the Mini Mental Status Examination, but the difference did not reach statistical significance. Caregiver's impressions were also significantly better in the flupirtine-treated group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Chlorpromazine and quinacrine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific derivatives of acridine and phenothiazine were found to inhibit PrPSc formation in a cultured neuroblastoma cell line (ScN2a) chronically infected with prions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/58\">",
"     58",
"    </a>",
"    ]. Effective compounds included",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    and quinacrine. Quinacrine was approximately 10 times more potent than chlorpromazine in inhibiting scrapie formation in culture.",
"   </p>",
"   <p>",
"    Despite the promise of quinacrine in cell models of infection, subsequent studies did not show benefit in animal models of CJD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Similarly, early results in humans have been disappointing. Observational studies and a small randomized trial have not found a benefit for quinacrine for either sporadic CJD or variant CJD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/61,62\">",
"     61,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three groups are investigating quinacrine in the treatment of CJD in clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     New targets",
"    </span>",
"    &nbsp;&mdash;&nbsp;The scientific advances in the understanding of the molecular pathogenesis of prion diseases have led to the identification of new targets for therapy. Some of these potential targets include the steps in the conversion of PrPC to PrPSc, binding of PrPSc with PrPC, binding of protein X, removal of PrPC, or the steps in the transport of PrPSc to the nervous system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/56,63\">",
"     56,63",
"    </a>",
"    ]. Immunotherapeutic approaches have also shown promise. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      iPrP13, a peptide that can break a beta-sheet conformation, was shown to reduce the protease resistance of PrPSc and to delay the onset of symptoms in transmission experiments in mice [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Depletion of endogenous PrPC in mice with established prion infection reversed spongiform change, prevented neuronal loss, and prevented progression to clinical disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study reported a prion protein epitope that is selectively exposed in the pathologic conformation (tyr-tyr-arg), opening the possibility that antibodies could be used as therapeutic agents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/66\">",
"       66",
"      </a>",
"      ]. The treatment, however, had an ameliorative effect only on mice that had yet to exhibit symptoms, and a rebound effect occurred when the treatment was halted [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a murine scrapie model, anti-PrP monoclonal antibodies reduced PrPSc levels and prion infectivity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      DNA, RNA, and peptide aptamers have been created with combinatorial chemistry and yeast, two hybrid systems that may be useful for diagnosis and therapy of prion disorders, but these have yet to move out of the in vitro experimental stage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/69\">",
"       69",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There has also been limited success in murine models using adenovirus vector platforms that express PrPc single-chain fragment (scFv) antibodies. Mice treated with the vector, and subsequently infected inoculated with PrPSc had delayed pathogenesis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      High throughput drug screening to isolate small molecules with potential therapeutic action is also ongoing [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/28/31176/abstract/71\">",
"       71",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7017?source=see_link\">",
"       \"Biology and genetics of prions\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7761132\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prion diseases are neurodegenerative diseases that have long incubation periods and progress inexorably once clinical symptoms appear. Five human prion diseases are currently recognized: kuru, Creutzfeldt-Jakob disease (CJD), variant Creutzfeldt-Jakob disease (vCJD also known as new variant CJD), Gerstmann-Str&auml;ussler-Scheinker syndrome (GSS), and fatal familial insomnia (FFI).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Kuru, which was endemic in Papua New Guinea among the Fore tribes, is felt to be transmitted from person to person by ritual cannibalism (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Kuru'",
"      </a>",
"      above.).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Symptoms begin with tremors, ataxia, and postural instability, followed by loss of ambulation and involuntary movements. Dementia progresses in the late stages of the disease, with death typically occurring within 9 to 24 months from the onset.",
"     </li>",
"     <li>",
"      Diagnostic testing has not been well characterized in this disorder. Characteristic pathologic findings have been described.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gerstmann-Str&auml;ussler-Scheinker syndrome (GSS) is inherited in an autosomal dominant pattern with virtual complete penetrance (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Gerstmann-Str&auml;ussler-Scheinker Syndrome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In midlife, affected patients develop a progressive cerebellar degeneration accompanied by differing degrees of dementia. Death usually occurs within five years after the onset of symptoms.",
"     </li>",
"     <li>",
"      A diagnosis of GSS cannot be made from the usual laboratory or imaging studies. Demonstration of PRNP gene mutations appears to be a sensitive and highly specific way to diagnose GSS. Neuropathology can also be useful.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fatal familial insomnia (FFI) is a rapidly fatal disease with a mean duration of 13 months, which generally occurs in midlife, median age at onset is 56 years. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Fatal familial insomnia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients characteristically develop progressive insomnia with loss of the normal circadian pattern. Mental status and behavioral changes include inattention, impaired concentration and memory, confusion, and hallucinations, but overt dementia is rare. As the disease progresses, motor disturbances such as myoclonus, ataxia, and spasticity can occur, along with dysautonomia and endocrine disturbances.",
"     </li>",
"     <li>",
"      A diagnosis of FFI cannot be made from the usual laboratory or imaging studies. Genetic studies are the diagnostic procedure of choice. Neuropathological studies do not show typical spongiform findings.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Creutzfeldt-Jakob disease (CJD) is the most frequent of the human prion diseases. CJD most often occurs as a sporadic disorder although familial forms have been described. It is clinically manifest by a rapidly progressive mental deterioration, often with behavioral abnormalities, and myoclonus. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/62/30698?source=see_link\">",
"       \"Creutzfeldt-Jakob disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Variant CJD is a distinct disorder that represents bovine-to-human transmission of bovine spongiform encephalopathy, most patients acquiring the disorder through ingestion of infected meat products. Clinical, diagnostic and pathologic features are distinct from CJD. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/49/40728?source=see_link\">",
"       \"Variant Creutzfeldt-Jakob disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      No effective treatment has been identified for human prion diseases, which are universally fatal. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Treatment of prion diseases'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/37/14934?source=see_link\">",
"       \"Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/1\">",
"      Haywood AM. Transmissible spongiform encephalopathies. N Engl J Med 1997; 337:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/2\">",
"      Prusiner SB. Shattuck lecture--neurodegenerative diseases and prions. N Engl J Med 2001; 344:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/3\">",
"      O'Brien C. Mad cow disease. Scant data cause widespread concern. Science 1996; 271:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/4\">",
"      Collinge J. Variant Creutzfeldt-Jakob disease. Lancet 1999; 354:317.",
"     </a>",
"    </li>",
"    <li>",
"     Prusiner SB. The prion hypothesis. In: Prions, Prusiner, SB, McKinley, MP (Eds), Academic Press, San Diego 1987. p.17.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/6\">",
"      GAJDUSEK DC, ZIGAS V. Degenerative disease of the central nervous system in New Guinea; the endemic occurrence of kuru in the native population. N Engl J Med 1957; 257:974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/7\">",
"      Prusiner SB, Gajdusek C, Alpers MP. Kuru with incubation periods exceeding two decades. Ann Neurol 1982; 12:1.",
"     </a>",
"    </li>",
"    <li>",
"     Gajdusek DC. Infectious amyloids: Subacute spongiform encephalopathies as transmissible cerebral amyloidoses. In: Fields Virology, 3rd, Fields, BN, Knipe, DM, Howley, PM (Eds), Lippincott-Raven, New York 1996. p.2851.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/9\">",
"      Collinge J, Whitfield J, McKintosh E, et al. Kuru in the 21st century--an acquired human prion disease with very long incubation periods. Lancet 2006; 367:2068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/10\">",
"      Cobb WA, Hornabrook RW, Sanders S. The EEG of kuru. Electroencephalogr Clin Neurophysiol 1973; 34:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/11\">",
"      Hainfellner JA, Liberski PP, Guiroy DC, et al. Pathology and immunocytochemistry of a kuru brain. Brain Pathol 1997; 7:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/12\">",
"      Mead S, Whitfield J, Poulter M, et al. A novel protective prion protein variant that colocalizes with kuru exposure. N Engl J Med 2009; 361:2056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/13\">",
"      Brown P, Goldfarb LG, Brown WT, et al. Clinical and molecular genetic study of a large German kindred with Gerstmann-Str&auml;ussler-Scheinker syndrome. Neurology 1991; 41:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/14\">",
"      Ghetti B, Dlouhy SR, Giaccone G, et al. Gerstmann-Str&auml;ussler-Scheinker disease and the Indiana kindred. Brain Pathol 1995; 5:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/15\">",
"      Johnson RT, Gibbs CJ Jr. Creutzfeldt-Jakob disease and related transmissible spongiform encephalopathies. N Engl J Med 1998; 339:1994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/16\">",
"      Webb TE, Poulter M, Beck J, et al. Phenotypic heterogeneity and genetic modification of P102L inherited prion disease in an international series. Brain 2008; 131:2632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/17\">",
"      Arata H, Takashima H, Hirano R, et al. Early clinical signs and imaging findings in Gerstmann-Str&auml;ussler-Scheinker syndrome (Pro102Leu). Neurology 2006; 66:1672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/18\">",
"      Unverzagt FW, Farlow MR, Norton J, et al. Neuropsychological function in patients with Gerstmann-Str&auml;ussler-Scheinker disease from the Indiana kindred (F198S). J Int Neuropsychol Soc 1997; 3:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/19\">",
"      Lyketsos CG, Kraus M. The dementia of Gerstmann-Str&auml;ussler-Scheinker syndrome: clinical variability demonstrated by two case reports. J Neuropsychiatry Clin Neurosci 1995; 7:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/20\">",
"      Jansen C, Voet W, Head MW, et al. A novel seven-octapeptide repeat insertion in the prion protein gene (PRNP) in a Dutch pedigree with Gerstmann-Str&auml;ussler-Scheinker disease phenotype: comparison with similar cases from the literature. Acta Neuropathol 2011; 121:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/21\">",
"      Wimberger D, Uranitsch K, Schindler E, Kramer J. Gerstmann-Str&auml;ussler-Scheinker syndrome: MR findings. J Comput Assist Tomogr 1993; 17:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/22\">",
"      Guiroy DC, Wakayama I, Liberski PP, Gajdusek DC. Relationship of microglia and scrapie amyloid-immunoreactive plaques in kuru, Creutzfeldt-Jakob disease and Gerstmann-Str&auml;ussler syndrome. Acta Neuropathol 1994; 87:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/23\">",
"      Collins S, McLean CA, Masters CL. Gerstmann-Str&auml;ussler-Scheinker syndrome,fatal familial insomnia, and kuru: a review of these less common human transmissible spongiform encephalopathies. J Clin Neurosci 2001; 8:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/24\">",
"      Mehta LR, Huddleston BJ, Skalabrin EJ, et al. Sporadic fatal insomnia masquerading as a paraneoplastic cerebellar syndrome. Arch Neurol 2008; 65:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/25\">",
"      Mastrianni JA, Nixon R, Layzer R, et al. Prion protein conformation in a patient with sporadic fatal insomnia. N Engl J Med 1999; 340:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/26\">",
"      Parchi P, Capellari S, Chin S, et al. A subtype of sporadic prion disease mimicking fatal familial insomnia. Neurology 1999; 52:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/27\">",
"      Manetto V, Medori R, Cortelli P, et al. Fatal familial insomnia: clinical and pathologic study of five new cases. Neurology 1992; 42:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/28\">",
"      Krasnianski A, Bartl M, Sanchez Juan PJ, et al. Fatal familial insomnia: Clinical features and early identification. Ann Neurol 2008; 63:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/29\">",
"      Plazzi G, Schutz Y, Cortelli P, et al. Motor overactivity and loss of motor circadian rhythm in fatal familial insomnia: an actigraphic study. Sleep 1997; 20:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/30\">",
"      Gallassi R, Morreale A, Montagna P, et al. \"Fatal familial insomnia\": neuropsychological study of a disease with thalamic degeneration. Cortex 1992; 28:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/31\">",
"      Medori R, Tritschler HJ, LeBlanc A, et al. Fatal familial insomnia, a prion disease with a mutation at codon 178 of the prion protein gene. N Engl J Med 1992; 326:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/32\">",
"      Lugaresi E, Medori R, Montagna P, et al. Fatal familial insomnia and dysautonomia with selective degeneration of thalamic nuclei. N Engl J Med 1986; 315:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/33\">",
"      Zerr I, Giese A, Windl O, et al. Phenotypic variability in fatal familial insomnia (D178N-129M) genotype. Neurology 1998; 51:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/34\">",
"      Perani D, Cortelli P, Lucignani G, et al. [18F]FDG PET in fatal familial insomnia: the functional effects of thalamic lesions. Neurology 1993; 43:2565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/35\">",
"      Cortelli P, Perani D, Parchi P, et al. Cerebral metabolism in fatal familial insomnia: relation to duration, neuropathology, and distribution of protease-resistant prion protein. Neurology 1997; 49:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/36\">",
"      Cortelli P, Perani D, Montagna P, et al. Pre-symptomatic diagnosis in fatal familial insomnia: serial neurophysiological and 18FDG-PET studies. Brain 2006; 129:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/37\">",
"      Brown P, Kenney K, Little B, et al. Intracerebral distribution of infectious amyloid protein in spongiform encephalopathy. Ann Neurol 1995; 38:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/38\">",
"      Gambetti P, Dong Z, Yuan J, et al. A novel human disease with abnormal prion protein sensitive to protease. Ann Neurol 2008; 63:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/39\">",
"      Jansen C, Head MW, van Gool WA, et al. The first case of protease-sensitive prionopathy (PSPr) in The Netherlands: a patient with an unusual GSS-like clinical phenotype. J Neurol Neurosurg Psychiatry 2010; 81:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/40\">",
"      Zou WQ, Puoti G, Xiao X, et al. Variably protease-sensitive prionopathy: a new sporadic disease of the prion protein. Ann Neurol 2010; 68:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/41\">",
"      Jayadev S, Nochlin D, Poorkaj P, et al. Familial prion disease with Alzheimer disease-like tau pathology and clinical phenotype. Ann Neurol 2011; 69:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/42\">",
"      Kumar N, Boeve BF, Boot BP, et al. Clinical characterization of a kindred with a novel 12-octapeptide repeat insertion in the prion protein gene. Arch Neurol 2011; 68:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/43\">",
"      Stewart LA, Rydzewska LH, Keogh GF, Knight RS. Systematic review of therapeutic interventions in human prion disease. Neurology 2008; 70:1272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/44\">",
"      Sanders WL, Dunn TL. Creutzfeldt-Jakob disease treated with amantidine. A report of two cases. J Neurol Neurosurg Psychiatry 1973; 36:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/45\">",
"      Furlow TW Jr, Whitley RJ, Wilmes FJ. Repeated suppression of Creutzfeldt-Jakob disease with vidarabine. Lancet 1982; 2:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/46\">",
"      Villa G, Caltagirone C, Macchi G. Unusual clinical course in a case of Creutzfeldt-Jakob disease. Ital J Neurol Sci 1982; 3:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/47\">",
"      David AS, Grant R, Ballantyne JP. Unsuccessful treatment of Creutzfeldt-Jakob disease with acyclovir. Lancet 1984; 1:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/48\">",
"      Kovanen J, Haltia M, Cantell K. Failure of interferon to modify Creutzfeldt-Jakob disease. Br Med J 1980; 280:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/49\">",
"      Masullo C, Macchi G, Xi YG, Pocchiari M. Failure to ameliorate Creutzfeldt-Jakob disease with amphotericin B therapy. J Infect Dis 1992; 165:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/50\">",
"      Adjou KT, Demaimay R, Deslys JP, et al. MS-8209, a water-soluble amphotericin B derivative, affects both scrapie agent replication and PrPres accumulation in Syrian hamster scrapie. J Gen Virol 1999; 80 ( Pt 4):1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/51\">",
"      Beringue V, Lasm&eacute;zas CI, Adjou KT, et al. Inhibiting scrapie neuroinvasion by polyene antibiotic treatment of SCID mice. J Gen Virol 1999; 80 ( Pt 7):1873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/52\">",
"      Caspi S, Halimi M, Yanai A, et al. The anti-prion activity of Congo red. Putative mechanism. J Biol Chem 1998; 273:3484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/53\">",
"      Sigurdsson EM, Brown DR, Alim MA, et al. Copper chelation delays the onset of prion disease. J Biol Chem 2003; 278:46199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/54\">",
"      Perovic S, Schr&ouml;der HC, Pergande G, et al. Effect of flupirtine on Bcl-2 and glutathione level in neuronal cells treated in vitro with the prion protein fragment (PrP106-126). Exp Neurol 1997; 147:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/55\">",
"      M&uuml;ller WE, Romero FJ, Perovic S, et al. Protection of flupirtine on beta-amyloid-induced apoptosis in neuronal cells in vitro: prevention of amyloid-induced glutathione depletion. J Neurochem 1997; 68:2371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/56\">",
"      Korth C, Peters PJ. Emerging pharmacotherapies for Creutzfeldt-Jakob disease. Arch Neurol 2006; 63:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/57\">",
"      Otto M, Cepek L, Ratzka P, et al. Efficacy of flupirtine on cognitive function in patients with CJD: A double-blind study. Neurology 2004; 62:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/58\">",
"      Korth C, May BC, Cohen FE, Prusiner SB. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease. Proc Natl Acad Sci U S A 2001; 98:9836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/59\">",
"      Collins SJ, Lewis V, Brazier M, et al. Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann Neurol 2002; 52:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/60\">",
"      Doh-ura K, Ishikawa K, Murakami-Kubo I, et al. Treatment of transmissible spongiform encephalopathy by intraventricular drug infusion in animal models. J Virol 2004; 78:4999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/61\">",
"      Ha&iuml;k S, Brandel JP, Salomon D, et al. Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects. Neurology 2004; 63:2413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/62\">",
"      Collinge J, Gorham M, Hudson F, et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial. Lancet Neurol 2009; 8:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/63\">",
"      Trevitt CR, Collinge J. A systematic review of prion therapeutics in experimental models. Brain 2006; 129:2241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/64\">",
"      Soto C, Kascsak RJ, Sabor&iacute;o GP, et al. Reversion of prion protein conformational changes by synthetic beta-sheet breaker peptides. Lancet 2000; 355:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/65\">",
"      Mallucci G, Dickinson A, Linehan J, et al. Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis. Science 2003; 302:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/66\">",
"      Paramithiotis E, Pinard M, Lawton T, et al. A prion protein epitope selective for the pathologically misfolded conformation. Nat Med 2003; 9:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/67\">",
"      Sadowski MJ, Pankiewicz J, Prelli F, et al. Anti-PrP Mab 6D11 suppresses PrP(Sc) replication in prion infected myeloid precursor line FDC-P1/22L and in the lymphoreticular system in vivo. Neurobiol Dis 2009; 34:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/68\">",
"      White AR, Enever P, Tayebi M, et al. Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature 2003; 422:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/69\">",
"      Gilch S, Sch&auml;tzl HM. Aptamers against prion proteins and prions. Cell Mol Life Sci 2009; 66:2445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/70\">",
"      Wuertzer CA, Sullivan MA, Qiu X, Federoff HJ. CNS delivery of vectored prion-specific single-chain antibodies delays disease onset. Mol Ther 2008; 16:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31176/abstract/71\">",
"      Bertsch U, Winklhofer KF, Hirschberger T, et al. Systematic identification of antiprion drugs by high-throughput screening based on scanning for intensely fluorescent targets. J Virol 2005; 79:7785.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5074 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-1FB45B5B38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_28_31176=[""].join("\n");
var outline_f30_28_31176=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7761132\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      KURU",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      GERSTMANN-STR&Auml;USSLER-SCHEINKER SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Epidemiology and clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Neuropathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      FATAL FAMILIAL INSOMNIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Epidemiology and clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CJD AND VARIANT CJD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      VARIABLY PROTEASE SENSITIVE PRIONOPATHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H925119\">",
"      OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TREATMENT OF PRION DISEASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Flupirtine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Chlorpromazine and quinacrine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      New targets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7761132\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7017?source=related_link\">",
"      Biology and genetics of prions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/62/30698?source=related_link\">",
"      Creutzfeldt-Jakob disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/37/14934?source=related_link\">",
"      Patient information: Dementia (including Alzheimer disease) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/49/40728?source=related_link\">",
"      Variant Creutzfeldt-Jakob disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_28_31177="Mycoplasma hominis, Mycoplasma genitalium, and Ureaplasma urealyticum infections";
var content_f30_28_31177=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mycoplasma hominis, Mycoplasma genitalium, and Ureaplasma urealyticum infections",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/28/31177/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/28/31177/contributors\">",
"     Stephen G Baum, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/28/31177/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/28/31177/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/28/31177/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/28/31177/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/28/31177/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/28/31177/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"mycoplasma\" is widely used to refer to any organism within the class Mollicutes, which is composed of eight genera (including Mycoplasma, Ureaplasma, Acholeplasma, Anaeroplasma, and Asteroloplasma). Over 200 named Mycoplasma species exist, and 13 Mycoplasma species, two Acholeplasma species, and two Ureaplasma species have been isolated from humans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/1\">",
"     1",
"    </a>",
"    ]. However, only six species, five of which inhabit the genitourinary tract, are established or presumed human pathogens; Mycoplasma pneumoniae is a respiratory tract pathogen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mycoplasma pneumoniae",
"     </li>",
"     <li>",
"      Mycoplasma hominis",
"     </li>",
"     <li>",
"      Mycoplasma genitalium",
"     </li>",
"     <li>",
"      Mycoplasma fermentans (incognitus strain)",
"     </li>",
"     <li>",
"      Ureaplasma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      &nbsp; &nbsp; Ureaplasma urealyticum",
"     </li>",
"     <li>",
"      &nbsp; &nbsp; Ureaplasma parvum",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical features and treatment of human infections with M. hominis and Ureaplasma will be reviewed here. M. pneumoniae and M. genitalium infections are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/5/3162?source=see_link\">",
"     \"Mycoplasma pneumoniae infection in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/13/40153?source=see_link\">",
"     \"Mycoplasma genitalium infection in men and women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although M. hominis and, to a lesser extent, Ureaplasma have been implicated in a number of conditions related to parturient women and their fetuses and newborns, the precise roles of Mycoplasma and Ureaplasma spp remain unproven, or even speculative, in many diseases for the following reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Many healthy asymptomatic adults have genitourinary colonization with Mycoplasma and Ureaplasma spp",
"     </li>",
"     <li>",
"      Published studies on the pathogenicity of these organisms commonly have important design limitations",
"     </li>",
"     <li>",
"      Detection of these organisms is difficult and complex",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    M. hominis, M. genitalium, and M. fermentans are part of the normal genital flora of many sexually experienced men and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/4\">",
"     4",
"    </a>",
"    ]. The percentage of women with vaginal colonization by M. hominis, M. genitalium, and Ureaplasma spp increases after puberty in proportion to the number of lifetime sexual partners. This was illustrated in a study in which genital colonization with M. hominis was found in 1 of 91 women without prior sexual activity compared with 15 of 97 women with multiple lifetime partners [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/4\">",
"     4",
"    </a>",
"    ]. Genital colonization may also be linked to lower socioeconomic status.",
"   </p>",
"   <p>",
"    The rate of colonization with M. hominis increases more rapidly with increasing sexual experience in women than in men, suggesting that women are more susceptible to colonization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/5\">",
"     5",
"    </a>",
"    ]. By adulthood, approximately 80 percent of healthy women have Ureaplasma spp and 50 percent have M. hominis in their cervical or vaginal secretions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/3\">",
"     3",
"    </a>",
"    ]. Sexually active men are also frequently asymptomatically colonized with M. hominis (25 percent in one series of 99 men attending a clinic for sexually transmitted diseases) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/6\">",
"     6",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Newborns who are colonized with Mycoplasma spp are presumed to have been exposed during passage through the birth canal, since colonization is less common in infants born by caesarean section. Neonatal colonization is transient and the proportion of infants colonized decreases proportionately with age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/7\">",
"     7",
"    </a>",
"    ]. Infants more than three months of age are rarely if ever colonized. M. hominis is seldom recovered from prepubertal boys, whereas a small percentage of prepubertal girls have been found to be colonized in some studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35510070\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mycoplasmas and ureaplasmas are the smallest free-living organisms. Because they lack a cell wall, neither mycoplasmas nor ureaplasmas can be visualized by Gram stain. In order to culture these organisms, specialized media containing animal serum is required. (See",
"    <a class=\"local\" href=\"#H725159\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Most species of Mycoplasma undergo similar biochemical reactions in the microbiology laboratory as many other bacterial species. However, there are a few biochemical tests that are useful for species identification. For example, Ureaplasma are unique because of their ability to hydrolyze urea. It is unknown whether there is a difference in pathogenicity between the two named species of Ureaplasma, U. urealyticum and U. parvum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although Mycoplasma and Ureaplasma spp normally exist in a state of adherence to mucosal epithelial cells of the respiratory or urogenital tracts, they can disseminate to other sites and cause infection when there is a disruption of the mucosa (eg, instrumentation, surgery, trauma)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an underlying immaturity in host defenses, such as in the developing fetus or premature infant. M. hominis and ureaplasmas have surface proteins that facilitate cytoadherence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/3\">",
"     3",
"    </a>",
"    ]. Ureaplasmas can attach to erythrocytes, white blood cells, host mucosal cells, and even spermatozoa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H407365\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES AND POSSIBLE DISEASE ASSOCIATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. hominis and Ureaplasma have been associated with genitourinary tract and nongenital infections.",
"   </p>",
"   <p>",
"    Infections that have been linked to M. hominis include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pelvic inflammatory disease (PID)",
"     </li>",
"     <li>",
"      Chorioamnionitis",
"     </li>",
"     <li>",
"      Postpartum and postabortal fever",
"     </li>",
"     <li>",
"      Pyelonephritis",
"     </li>",
"     <li>",
"      Central nervous system infections",
"     </li>",
"     <li>",
"      Septicemia",
"     </li>",
"     <li>",
"      Wound infections",
"     </li>",
"     <li>",
"      Joint infections",
"     </li>",
"     <li>",
"      Upper and lower respiratory tract infections",
"     </li>",
"     <li>",
"      Endocarditis",
"     </li>",
"     <li>",
"      Neonatal bacteremia and meningitis",
"     </li>",
"     <li>",
"      Neonatal abscesses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ureaplasma spp have been linked to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chorioamnionitis",
"     </li>",
"     <li>",
"      Postpartum and postabortal fever",
"     </li>",
"     <li>",
"      Congenital pneumonia",
"     </li>",
"     <li>",
"      Neonatal bacteremia",
"     </li>",
"     <li>",
"      Neonatal abscesses",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These manifestations are discussed in greater detail in the following section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Genitourinary tract infections",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Cervicitis and pelvic inflammatory disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. hominis is commonly found in the genitourinary tract of both males and females. It is more often detected in women. The role of M. hominis as a cause of PID remains controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/2\">",
"     2",
"    </a>",
"    ]. In one study, M. hominis was isolated from 4 of 50 fluid samples taken directly from the fallopian tubes of women with salpingitis versus none of 50 samples from control woman [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/8\">",
"     8",
"    </a>",
"    ]. In the same study, significant rises or falls in antibody titers to M. hominis occurred in 9 of 16 women with salpingitis who had positive lower genital tract cultures for M. hominis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/8\">",
"     8",
"    </a>",
"    ]. The presence of infection in the absence of changes in antibody titers may reflect the localized nature of salpingitis. The significance of these findings is uncertain. M. hominis is rarely present in patients with salpingitis who do not also have evidence of concurrent chlamydial or gonococcal infections or bacterial vaginosis. As a result, its role as a primary pathogen in salpingitis is still uncertain. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11992?source=see_link\">",
"     \"Pathogenesis of and risk factors for pelvic inflammatory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H725181\">",
"    <span class=\"h3\">",
"     Non-gonococcal urethritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;U. urealyticum has been associated with NGU in some studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/9\">",
"     9",
"    </a>",
"    ], but not others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. In one study, U. urealyticum was significantly associated with NGU only in men with fewer than 10 lifetime heterosexual partners [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/12\">",
"     12",
"    </a>",
"    ]. The authors postulated that adaptive immunity may attenuate the clinical manifestations of U. urealyticum infection, so that men with more exposure to this organism are less likely to have symptoms of NGU from it. However, this hypothesis is not proven and other explanations are possible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/18/18728?source=see_link&amp;anchor=H11#H11\">",
"     \"Genital Chlamydia trachomatis infections in men\", section on 'Differential diagnosis of urethritis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/43/19126?source=see_link\">",
"     \"Infectious causes of dysuria in adult men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Urinary tract infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. hominis can frequently be recovered from the lower genitourinary tract in men and women, but a causal relationship to cystitis, epididymitis, or prostatitis has not been established. This organism may be responsible for up to 5 percent of cases of acute pyelonephritis, particularly when prior instrumentation has been performed or obstruction is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/2,13\">",
"     2,13",
"    </a>",
"    ]. Ureaplasma spp are thought to cause some upper urinary tract infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Chorioamnionitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is evidence that M. hominis and U. urealyticum are frequently found in the amniotic fluid of women with preterm labor, preterm premature rupture of membranes, spontaneous labor at term, premature rupture of membranes at term, or chorioamnionitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/14\">",
"     14",
"    </a>",
"    ]. Although these observations suggest that intrauterine colonization or infection is common, the role of these organisms in premature labor and chorioamnionitis remains incompletely understood. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/48/42761?source=see_link&amp;anchor=H6#H6\">",
"     \"Intraamniotic infection (chorioamnionitis)\", section on 'Microbiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One study found that 23 percent of 457 consecutive neonates who were born between 23 and 32 weeks of gestation had positive umbilical blood cultures for M. hominis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    U. urealyticum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/15\">",
"     15",
"    </a>",
"    ]. Neonates with positive cultures more often had evidence of neonatal systemic inflammatory response syndrome and their placentas more often had changes compatible with chorioamnionitis than babies with negative blood cultures.",
"   </p>",
"   <p>",
"    In a study of asymptomatic pregnant women who underwent amniocentesis during the second trimester, those in whom Ureaplasma spp was detected by PCR had a higher rate of subsequent preterm labor and preterm delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Nongenitourinary tract disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The portal of entry for the mycoplasmas and ureaplasmas that cause nongenitourinary manifestations is almost always the genitourinary tract.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H506234582\">",
"    <span class=\"h3\">",
"     Postpartum and postabortal fever and/or bacteremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been estimated that M. hominis causes approximately 10 percent of all cases of postpartum and postabortal fever. In one study, M. hominis was recovered from blood cultures in 4 of 51 women (8 percent) with fever after abortion; in contrast, blood cultures were negative for M. hominis in all control women who had a recent abortion without fever and from all 102 normal pregnant controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/17\">",
"     17",
"    </a>",
"    ]. Further evidence in support of M. hominis infection was a four-fold rise in antibody titers in approximately one-half of all women who had postabortal fever compared with only 2 of 53 controls who experienced abortion without fever. The higher frequency of antibody production than blood culture recovery suggests that many patients with postabortal fever develop nonbacteremic M. hominis infection.",
"   </p>",
"   <p>",
"    In another series, M. hominis was isolated from the blood in 10 of 327 women (3 percent) who had blood cultures taken a few minutes after delivery; none had fever, and all remained well without treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Central nervous system disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. hominis infection has been associated with nonfunctioning CNS shunts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/19\">",
"     19",
"    </a>",
"    ], brain abscess [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/20,21\">",
"     20,21",
"    </a>",
"    ], subdural empyema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/22\">",
"     22",
"    </a>",
"    ], and meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/23\">",
"     23",
"    </a>",
"    ]. Neonatal meningoencephalitis caused by M. hominis or U. parvum has also been described. (See",
"    <a class=\"local\" href=\"#H506234847\">",
"     'Meningoencephalitis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Arthritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. hominis arthritis can occur in women after childbirth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/24\">",
"     24",
"    </a>",
"    ], in conjunction with congenital immune defects, such as hypogammaglobulinemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/25\">",
"     25",
"    </a>",
"    ], in association with immunosuppression (eg, in solid organ transplant patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/2\">",
"     2",
"    </a>",
"    ] or lymphoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/26\">",
"     26",
"    </a>",
"    ], or following joint replacement surgery or trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    M. hominis arthritis is usually characterized by fever, leukocytosis, and a purulent joint effusion with large numbers of polymorphonuclear cells but a negative Gram stain. In a review of 16 cases of septic arthritis due to M. hominis, one-half had undergone manipulation of the urinary tract before the onset of infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/27\">",
"     27",
"    </a>",
"    ]. Delays in diagnosis were common, ranging from 5 to 37 days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Wound infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. hominis has been associated with infected pelvic hematoma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/28,29\">",
"     28,29",
"    </a>",
"    ], infected cesarean wounds, and sternal wound infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/19,30,31\">",
"     19,30,31",
"    </a>",
"    ]. A minority of sternal wound infections due to M. hominis have been anecdotally linked to cardiac and lung transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/32\">",
"     32",
"    </a>",
"    ]. M. hominis wound infections have also been described after maxillofacial, abdominal, vascular, neurosurgical, and plastic surgical procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In almost all cases, the clinical features of mycoplasma wound infection are nonspecific. Clues to the presence of M. hominis in such cases are indirect. They include the finding of abundant polymorphonuclear leukocytes with a negative Gram stain, negative routine cultures, and a poor response to beta-lactam or aminoglycoside therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Bacteremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to bacteremia in women with postpartum and postabortal fever, M. hominis has also been recovered from blood cultures in patients with recent trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/28\">",
"     28",
"    </a>",
"    ], and obstruction or surgery involving the genitourinary tract or perineal area. In addition, M. hominis can cause transient and self-limiting bacteremia in some postpartum women. (See",
"    <a class=\"local\" href=\"#H506234582\">",
"     'Postpartum and postabortal fever and/or bacteremia'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. hominis is a rare cause of prosthetic and native valve endocarditis with only five cases reported between 1966 and 2004 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. M. hominis endocarditis may also occur rarely in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/35\">",
"     35",
"    </a>",
"    ]. Because of difficulties in culturing M. hominis, such patients present with culture-negative endocarditis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34646?source=see_link\">",
"     \"Culture-negative endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Respiratory tract infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The significance of M. hominis in respiratory secretions must be interpreted with caution. M. hominis has been isolated from respiratory secretions in 1 to 3 percent of healthy persons, 8 percent of patients with chronic respiratory complaints, and 14 percent of persons engaging in orogenital sex [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/36\">",
"     36",
"    </a>",
"    ]. M. hominis can cause pharyngitis in volunteers whose nasopharynxes were experimentally inoculated with M. hominis. However, attempts to implicate M. hominis as a cause of naturally-occurring pharyngitis have been unsuccessful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A report described seven patients with ICU-acquired pneumonia during a four-year period who had cultures from bronchoalveolar lavage or pleural fluid that were positive for M. hominis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/38\">",
"     38",
"    </a>",
"    ]. This report and others describing the recovery of M. hominis from lower respiratory tract specimens",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    empyema fluid suggest that M. hominis is rarely capable of causing lower respiratory tract infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. A case report describes a lung transplant recipient with pneumonia and empyema whose bronchial brush specimen and pleural fluid grew M. hominis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/39\">",
"     39",
"    </a>",
"    ]. Another case report documents M. hominis as a cause of necrotizing pleuropneumonia in a previously healthy adolescent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/41\">",
"     41",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H506234682\">",
"    <span class=\"h3\">",
"     Prosthetic joint and bone infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few patients with prosthetic joint infections due to M. hominis have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/27,42\">",
"     27,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H506234689\">",
"    <span class=\"h3\">",
"     Fulminant bacteremia and systemic infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. fermentans, incognitus strain, a commensal in the genitourinary tract, has been shown to rarely cause fulminant and overwhelming infection in immunocompetent individuals and in people with AIDS, the patient population from which it was first isolated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H506234631\">",
"    <span class=\"h2\">",
"     Neonatal disease",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35510011\">",
"    <span class=\"h3\">",
"     Lung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ureaplasma spp are thought to cause congenital pneumonia in neonates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is controversy about whether colonization with Ureaplasma spp results in bronchopulmonary dysplasia in neonates. In a meta-analysis of 23 studies examining the possible relationship between Ureaplasma colonization and neonatal bronchopulmonary dysplasia, Ureaplasma colonization was associated with chronic lung infection manifesting as long-term oxygen requirements and radiographic changes typical of bronchopulmonary dysplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/45\">",
"     45",
"    </a>",
"    ]. However, the studies included in the meta-analysis were small and substantial differences between them make the results unreliable. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/0/21512?source=see_link&amp;anchor=H11#H11\">",
"     \"Neonatal pneumonia\", section on 'Possible link of Ureaplasma urealyticum to chronic lung disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H506234847\">",
"    <span class=\"h3\">",
"     Meningoencephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal meningoencephalitis caused by M. hominis or U. parvum has been described; infection was presumed to have been acquired in utero or via passage through the birth canal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/3,46\">",
"     3,46",
"    </a>",
"    ]. The frequency of neonatal infections may be higher than is generally appreciated. In one study, mycoplasma cultures were performed on 100 preterm infants who underwent lumbar puncture for suspected sepsis or meningitis: M. hominis was isolated from the cerebrospinal fluid in five [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H506234778\">",
"    <span class=\"h3\">",
"     Bacteremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ureaplasma spp are thought to be potential causes of bacteremia in neonates, especially in association with meningitis or pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H576534383\">",
"    <span class=\"h3\">",
"     Abscesses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcutaneous abscesses have been described in neonates in case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H725159\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The options for diagnosing infections caused by M. hominis and Ureaplasma spp are limited due to the shortcomings of both culture and PCR-based techniques. When available, specimens should be sent for both culture and PCR. Given the difficulty in obtaining a diagnosis, patients are often treated empirically. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Treatment'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105010013\">",
"    <span class=\"h2\">",
"     Culture",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sophisticated methods are required to detect mycoplasmas or ureaplasmas by culture; most hospital microbiology laboratories are not prepared to culture them. Clinical specimens should be inoculated immediately onto specialized broth culture media containing animal serum before they are allowed to dry. Antibiotics, such as penicillin (to which mycoplasmas are not susceptible), are routinely added to this medium to reduce the growth of contaminating organisms.",
"   </p>",
"   <p>",
"    Media used for culturing these organisms have pH&ndash;sensitive dye indicators that help distinguish the urea splitters (ureaplasmas) and ammonia metabolizers (M. hominis) that turn media alkaline, from glucose metabolizers (M. pneumoniae) that turn media acidic. Organisms should be subcultured onto blood agar plates for definitive identification. On agar, the genital mycoplasmas grow suboptimally under atmospheric conditions and colonies develop best in an atmosphere of 95 percent nitrogen and 5 percent CO",
"    <sub>",
"     2",
"    </sub>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/5\">",
"     5",
"    </a>",
"    ]. Ureaplasmas form tiny pinpoint colonies and were previously called T (for tiny) strains. M. hominis does not produce hemolysis and its colonies look like a &ldquo;fried egg,&rdquo; having a denser center and paler outer zone. These characteristics can be used to differentiate these mycoplasmas from M. pneumoniae, which grows as a spherical &ldquo;mulberry&rdquo; colony and does produce beta-hemolysis through elaboration of",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    . Ureaplasmas may grow in one to two days and M. hominis may grow in a week. M. hominis will escape detection using automated blood culture detection systems, such as",
"    <span class=\"nowrap\">",
"     BacT/ALERT",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/50\">",
"     50",
"    </a>",
"    ], unless cultures are routinely incubated for three to five days using special media",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    blind subcultures are made from blood cultures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H105010020\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;A limited number of small studies have demonstrated that the PCR is superior to traditional culture methods for detecting M. hominis in genital secretions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Although emphasis is often placed on the promise of nucleic acid amplification tests, such as real-time PCR-based assays, these are not commercially available and differ in sensitivity and specificity from one laboratory to another [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/53\">",
"     53",
"    </a>",
"    ]. In addition, sensitivity and specificity vary according to the site from which material was obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H466733115\">",
"    <span class=\"h1\">",
"     IN VITRO SUSCEPTIBILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In vitro susceptibility testing has not been standardized for mycoplasmas or ureaplasmas and in vitro susceptibility test results have not been well correlated with clinical outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1714648224\">",
"    <span class=\"h2\">",
"     Mycoplasma hominis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following antibiotic susceptibility patterns have been observed for M. hominis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      M. hominis is generally susceptible in vitro to tetracyclines (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/54\">",
"       54",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fluoroquinolones, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"       ciprofloxacin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/51/33584?source=see_link\">",
"       moxifloxacin",
"      </a>",
"      , are usually active in vitro against M. hominis, but resistance can be induced in vitro by increasing concentrations of fluoroquinolones [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/55,56\">",
"       55,56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?1/54/1897?source=see_link\">",
"       Chloramphenicol",
"      </a>",
"      minimum inhibitory concentrations are relatively high for M. hominis (2 to 25",
"      <span class=\"nowrap\">",
"       mcg/ml),",
"      </span>",
"      indicating that in vivo resistance will be encountered [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      M. hominis is generally resistant to the macrolides (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"       erythromycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      ), aminoglycosides, sulfonamides,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/19,54,57\">",
"       19,54,57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Limited information suggests that M. hominis is susceptible in vitro to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"       linezolid",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/17/34068?source=see_link\">",
"       quinupristin-dalfopristin",
"      </a>",
"      , although to our knowledge no clinical trials have been undertaken using these agents in patients with M. hominis infections [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"       Erythromycin",
"      </a>",
"      is not thought to be active against M. hominis; its activity against Ureaplasma is uncertain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The molecular basis for antimicrobial resistance in M. hominis strains is not well understood. Some studies in which introduction of resistance occurred via serial in vitro passages have shown that the presence or absence of resistance was related to specific ribosomal mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1804218961\">",
"    <span class=\"h2\">",
"     Ureaplasma urealyticum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ureaplasma spp are typically susceptible in vitro to the tetracyclines (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/54\">",
"     54",
"    </a>",
"    ]. They are also susceptible to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/60/35776?source=see_link\">",
"     ofloxacin",
"    </a>",
"    . Ureaplasma spp have higher minimum inhibitory concentrations for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    than the other agents listed above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with disease caused by a Mycoplasma or Ureaplasma spp should be treated. In contrast, patients who are found to be colonized with one of these organisms, but who do not have clinical disease, do not require treatment. Given the difficulty in obtaining a diagnosis, patients are often treated empirically. The treatment of choice is based upon the expected in vitro susceptibility pattern of the organism. As mentioned above, most mycoplasmas and ureaplasmas are susceptible in vitro to macrolides, tetracyclines, and fluoroquinolones. An exception is M. hominis, which is",
"    <strong>",
"     not",
"    </strong>",
"    susceptible to macrolides. (See",
"    <a class=\"local\" href=\"#H466733115\">",
"     'In vitro susceptibility'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1714648289\">",
"    <span class=\"h2\">",
"     Mycoplasma hominis",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. hominis, unlike other mycoplasmas and ureaplasmas, is",
"    <strong>",
"     not",
"    </strong>",
"    susceptible to macrolides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/54\">",
"     54",
"    </a>",
"    ]. Therefore, a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ) is the treatment of choice for infections caused by this organism. Virtually all treatment recommendations in humans are based upon anecdotal observations rather than clinical studies. Few comparative data from prospective treatment trials exist, nor are such data likely to appear since M. hominis infections are relatively infrequent and difficult to confirm prior to the institution of empiric therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1804219295\">",
"    <span class=\"h3\">",
"     Adults",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1804219460\">",
"    <span class=\"h4\">",
"     Genitourinary tract disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For adults with genitourinary tract disease caused by M. hominis,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    is the drug of choice. For outpatients diagnosed with urethritis, cervicitis, or PID, the United States Centers for Disease Control and Prevention guidelines recommend a regimen that includes doxycycline. Specific treatment recommendations for urethritis, cervicitis, and PID are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35832?source=see_link\">",
"     \"Treatment of pelvic inflammatory disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/43/19126?source=see_link&amp;anchor=H11#H11\">",
"     \"Infectious causes of dysuria in adult men\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/64?source=see_link&amp;anchor=H21041321#H21041321\">",
"     \"Acute cervicitis\", section on 'Recurrent or persistent disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1804219467\">",
"    <span class=\"h4\">",
"     Nongenitourinary tract disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite rare reports of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    -resistant strains of M. hominis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/3,61\">",
"     3,61",
"    </a>",
"    ], in adults, we generally use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg twice daily) either intravenously or orally. In patients who are unable to take or fail to respond to doxycycline,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    or a fluoroquinolone, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    , are suitable alternatives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/23,56,62\">",
"     23,56,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some cases of osteomyelitis caused by M. hominis have been successfully managed with debridement followed by long courses (six weeks or longer) of therapy with oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/27,42\">",
"     27,42",
"    </a>",
"    ]. For M. hominis sternal wound infections, resolution may require many months of antibiotic treatment with doxycycline and a fluoroquinolone in addition to debridement and drainage followed by omental or pectoral flap grafting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/48/1800?source=see_link\">",
"     \"Postoperative mediastinitis after cardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The duration of therapy is a matter of clinical judgment. We advise treatment until all clinical signs of infection have resolved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1804219288\">",
"    <span class=\"h3\">",
"     Neonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of M. hominis infections in neonates is particularly challenging, since",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    and fluoroquinolones are generally avoided due to concerns about toxicities. We favor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    since it has activity in vitro, it has been reported to be successful in the treatment of neonatal infections due to M. hominis, and it is not contraindicated in this age group.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/54/1897?source=see_link\">",
"     Chloramphenicol",
"    </a>",
"    has been reported to be successful in some cases of neonatal M. hominis meningitis, but not others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/3\">",
"     3",
"    </a>",
"    ]. M. hominis is relatively resistant to chloramphenicol as discussed above. (See",
"    <a class=\"local\" href=\"#H1714648224\">",
"     'Mycoplasma hominis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1714648296\">",
"    <span class=\"h2\">",
"     Ureaplasma spp",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    for infections caused by Ureaplasma spp in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/3\">",
"     3",
"    </a>",
"    ]. Macrolides (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    ) and fluoroquinolones (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    ) are appropriate alternatives.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    is not active against ureaplasmas. (See",
"    <a class=\"local\" href=\"#H1804218961\">",
"     'Ureaplasma urealyticum'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For neonates with infections caused by Ureaplasma spp,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    has been used most commonly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31177/abstract/3\">",
"     3",
"    </a>",
"    ]. However, we avoid erythromycin in neonates due to an association with pyloric stenosis. We suggest",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    for neonates with disease caused by Ureaplasma spp. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/29/3545?source=see_link&amp;anchor=H3#H3\">",
"     \"Infantile hypertrophic pyloric stenosis\", section on 'Macrolide antibiotics'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H296317\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term \"mycoplasma\" is widely used to refer to any organism within the class Mollicutes, which is composed of eight genera. Over 200 named Mycoplasma species exist. However, only about six species, five of which inhabit the genitourinary tract, are established or presumed human pathogens; M. pneumoniae is a respiratory tract pathogen. Mycoplasmas that are thought to cause disease in humans include M. pneumoniae, M. hominis, M. genitalium, M. fermentans (incognitus strain), U. urealyticum, and U. parvum. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mycoplasmas and ureaplasmas are the smallest free-living organisms. Because they lack a cell wall, neither mycoplasmas nor ureaplasmas can be visualized by Gram stain. In order to culture these organisms, specialized media containing animal serum is required. (See",
"      <a class=\"local\" href=\"#H35510070\">",
"       'Microbiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although M. hominis and, to a lesser extent, Ureaplasma have been implicated in a number of conditions related to parturient women and their fetuses and newborns, the precise roles of Mycoplasma and Ureaplasma spp remain unproven, or even speculative in many diseases for the following reasons:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Many healthy asymptomatic adults have genitourinary colonization with Mycoplasma and Ureaplasma spp",
"     </li>",
"     <li>",
"      Published studies on the pathogenicity of the these organisms commonly have important design limitations",
"     </li>",
"     <li>",
"      Detection of these organisms is difficult and complex (See",
"      <a class=\"local\" href=\"#H35510070\">",
"       'Microbiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Although Mycoplasma and Ureaplasma spp normally exist in a state of adherence to mucosal epithelial cells of the respiratory or urogenital tracts, they can disseminate to other sites and cause infection when there is a disruption of the mucosa",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an underlying defect in host defenses, such as in the developing fetus or premature infant. (See",
"      <a class=\"local\" href=\"#H35510070\">",
"       'Microbiology and pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      M. hominis has been associated with chorioamnionitis. A possible association with pelvic inflammatory disease (PID) is less well established. Nongenitourinary tract infections that have been reported include upper and lower respiratory infections, central nervous system infections, neonatal bacteremia and meningoencephalitis, and others. (See",
"      <a class=\"local\" href=\"#H407365\">",
"       'Clinical features and possible disease associations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ureaplasma spp have been linked to chorioamnionitis, postpartum and postabortal fever, and pneumonia, bacteremia, and abscesses in neonates. There is controversy about a possible association between Ureaplasma spp and bronchopulmonary dysplasia. (See",
"      <a class=\"local\" href=\"#H407365\">",
"       'Clinical features and possible disease associations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The options for diagnosing infections caused by M. hominis and Ureaplasma spp are limited due to the shortcomings of both culture and polymerase chain reaction (PCR)-based techniques. When available, specimens should be sent for both culture and PCR. Sophisticated methods are required to detect mycoplasmas or ureaplasmas by culture; most hospital microbiology laboratories are not prepared to culture them. Although PCR-based assays appear to be promising, they are not commercially available and differ in sensitivity and specificity from one laboratory to another. (See",
"      <a class=\"local\" href=\"#H725159\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In vitro susceptibility testing has not been standardized for mycoplasmas or ureaplasmas and in vitro susceptibility test results have not been well correlated with clinical outcomes. Most mycoplasmas and ureaplasmas are susceptible in vitro to macrolides, tetracyclines, and fluoroquinolones. An exception is M. hominis, which is",
"      <strong>",
"       not",
"      </strong>",
"      susceptible to macrolides.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       Azithromycin",
"      </a>",
"      has the greatest activity against M. genitalium compared with other antibiotics. (See",
"      <a class=\"local\" href=\"#H466733115\">",
"       'In vitro susceptibility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with disease caused by a Mycoplasma or Ureaplasma spp should be treated. In contrast, patients who are found to be colonized with one of these organisms, but who do not have clinical disease, do not require treatment. Given the difficulty in obtaining a diagnosis, patients are often treated empirically. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For nonpregnant adults with disease caused by M. hominis, we recommend",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1804219295\">",
"       'Adults'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For infants with disease caused by M. hominis, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1804219288\">",
"       'Neonates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For nonpregnant adults with disease caused by Ureaplasma spp, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1714648296\">",
"       'Ureaplasma spp'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For neonates with disease caused by Ureaplasma spp, we suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/43/33456?source=see_link\">",
"       azithromycin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"       clarithromycin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1714648296\">",
"       'Ureaplasma spp'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/1\">",
"      Waites KB, Katz B, Schelonka RL. Mycoplasmas and ureaplasmas as neonatal pathogens. Clin Microbiol Rev 2005; 18:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/2\">",
"      Taylor-Robinson D. Infections due to species of Mycoplasma and Ureaplasma: an update. Clin Infect Dis 1996; 23:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/3\">",
"      Waites KB, Schelonka RL, Xiao L, et al. Congenital and opportunistic infections: Ureaplasma species and Mycoplasma hominis. Semin Fetal Neonatal Med 2009; 14:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/4\">",
"      McCormack WM, Rosner B, Lee YH. Colonization with genital mycoplasmas in women. Am J Epidemiol 1973; 97:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/5\">",
"      Taylor-Robinson D, McCormack WM. The genital mycoplasmas (first of two parts). N Engl J Med 1980; 302:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/6\">",
"      Lee YH, Rosner B, Alpert S, et al. Clinical and microbiological investigation of men with urethritis. J Infect Dis 1978; 138:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/7\">",
"      Foy HM, Kenny GE, Levinsohn EM, Grayston JT. Acquisition of mycoplasmata and T-strains during infancy. J Infect Dis 1970; 121:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/8\">",
"      M&aring;rdh PA, Westr&ouml;m L. Tubal and cervical cultures in acute salpingitis with special reference to Mycoplasma hominis and T-strain mycoplasmas. Br J Vener Dis 1970; 46:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/9\">",
"      Povlsen K, Bj&oslash;rnelius E, Lidbrink P, Lind I. Relationship of Ureaplasma urealyticum biovar 2 to nongonococcal urethritis. Eur J Clin Microbiol Infect Dis 2002; 21:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/10\">",
"      Totten PA, Schwartz MA, Sj&ouml;str&ouml;m KE, et al. Association of Mycoplasma genitalium with nongonococcal urethritis in heterosexual men. J Infect Dis 2001; 183:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/11\">",
"      Bradshaw CS, Tabrizi SN, Read TR, et al. Etiologies of nongonococcal urethritis: bacteria, viruses, and the association with orogenital exposure. J Infect Dis 2006; 193:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/12\">",
"      Wetmore CM, Manhart LE, Lowens MS, et al. Ureaplasma urealyticum is associated with nongonococcal urethritis among men with fewer lifetime sexual partners: a case-control study. J Infect Dis 2011; 204:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/13\">",
"      Thomsen AC, Lindskov HO. Diagnosis of Mycoplasma hominis pyelonephritis by demonstration of antibodies in urine. J Clin Microbiol 1979; 9:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/14\">",
"      Romero R, Garite TJ. Twenty percent of very preterm neonates (23-32 weeks of gestation) are born with bacteremia caused by genital Mycoplasmas. Am J Obstet Gynecol 2008; 198:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/15\">",
"      Goldenberg RL, Andrews WW, Goepfert AR, et al. The Alabama Preterm Birth Study: umbilical cord blood Ureaplasma urealyticum and Mycoplasma hominis cultures in very preterm newborn infants. Am J Obstet Gynecol 2008; 198:43.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/16\">",
"      Gerber S, Vial Y, Hohlfeld P, Witkin SS. Detection of Ureaplasma urealyticum in second-trimester amniotic fluid by polymerase chain reaction correlates with subsequent preterm labor and delivery. J Infect Dis 2003; 187:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/17\">",
"      Harwick HJ, Purcell RH, Iuppa JB, Fekety FR Jr. Mycoplasma hominis and abortion. J Infect Dis 1970; 121:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/18\">",
"      McCormack WM, Rosner B, Lee YH, et al. Isolation of genital mycoplasmas from blood obtained shortly after vaginal delivery. Lancet 1975; 1:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/19\">",
"      Madoff S, Hooper DC. Nongenitourinary infections caused by Mycoplasma hominis in adults. Rev Infect Dis 1988; 10:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/20\">",
"      Payan DG, Seigal N, Madoff S. Infection of a brain abscess of Mycoplasma hominis. J Clin Microbiol 1981; 14:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/21\">",
"      Kupila L, Rantakokko-Jalava K, Jalava J, et al. Brain abscess caused by Mycoplasma hominis: a clinically recognizable entity? Eur J Neurol 2006; 13:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/22\">",
"      Chong JS, Tseung SY, Lam HS, et al. Successful treatment of multiple subdural empyemata caused by Mycoplasma hominis in a newborn. Neonatology 2009; 95:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/23\">",
"      Hata A, Honda Y, Asada K, et al. Mycoplasma hominis meningitis in a neonate: case report and review. J Infect 2008; 57:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/24\">",
"      Taylor-Robinson D, Thomas BJ, Furr PM, Keat AC. The association of Mycoplasma hominis with arthritis. Sex Transm Dis 1983; 10:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/25\">",
"      Steuer A, Franz A, Furr PM, et al. Common variable immunodeficiency presenting as a Mycoplasma hominis septic arthritis. J Infect 1996; 33:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/26\">",
"      McDonald MI, Moore JO, Harrelson JM, et al. Septic arthritis due to Mycoplasma hominis. Arthritis Rheum 1983; 26:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/27\">",
"      Luttrell LM, Kanj SS, Corey GR, et al. Mycoplasma hominis septic arthritis: two case reports and review. Clin Infect Dis 1994; 19:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/28\">",
"      Ti TY, Dan M, Stemke GW, et al. Isolation of Mycoplasma hominis from the blood of men with multiple trauma and fever. JAMA 1982; 247:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/29\">",
"      Cuch&iacute; E, Cherta I, Garau J. Mycoplasma hominis catheter-related infection in a patient with multiple trauma. Clin Microbiol Infect 2000; 6:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/30\">",
"      Lee YH, Nersasian RR, McDonald A, et al. Wound infection with Mycoplasma hominis. JAMA 1971; 218:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/31\">",
"      Mossad SB, Rehm SJ, Tomford JW, et al. Sternotomy infection with Mycoplasma hominis: a cause of \"culture negative\" wound infection. J Cardiovasc Surg (Torino) 1996; 37:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/32\">",
"      Hopkins PM, Winlaw DS, Chhajed PN, et al. Mycoplasma hominis infection in heart and lung transplantation. J Heart Lung Transplant 2002; 21:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/33\">",
"      Blasco M, Torres L, Marco ML, et al. Prosthetic valve endocarditis caused by Mycoplasma hominis. Eur J Clin Microbiol Infect Dis 2000; 19:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/34\">",
"      Fenollar F, Gauduchon V, Casalta JP, et al. Mycoplasma endocarditis: two case reports and a review. Clin Infect Dis 2004; 38:e21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/35\">",
"      Dominguez SR, Littlehorn C, Nyquist AC. Mycoplasma hominis endocarditis in a child with a complex congenital heart defect. Pediatr Infect Dis J 2006; 25:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/36\">",
"      MUFSON MA, LUDWIG WM, PURCELL RH, et al. EXUDATIVE PHARYNGITIS FOLLOWING EXPERIMENTAL MYCOPLASMA HOMINIS: TYPE 1 INFECTION. JAMA 1965; 192:1146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/37\">",
"      Mufson MA. Mycoplasma hominis: a review of its role as a respiratory tract pathogen of humans. Sex Transm Dis 1983; 10:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/38\">",
"      Garc&iacute;a C, Ugalde E, Monteagudo I, et al. Isolation of Mycoplasma hominis in critically ill patients with pulmonary infections: clinical and microbiological analysis in an intensive care unit. Intensive Care Med 2007; 33:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/39\">",
"      Lyon GM, Alspaugh JA, Meredith FT, et al. Mycoplasma hominis pneumonia complicating bilateral lung transplantation: case report and review of the literature. Chest 1997; 112:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/40\">",
"      Vogel U, L&uuml;neberg E, Kuse ER, et al. Extragenital Mycoplasma hominis infection in two liver transplant recipients. Clin Infect Dis 1997; 24:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/41\">",
"      Pascual A, Perez MH, Jaton K, et al. Mycoplasma hominis necrotizing pleuropneumonia in a previously healthy adolescent. BMC Infect Dis 2010; 10:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/42\">",
"      M&eacute;cha&iuml; F, Le Moal G, Duch&ecirc;ne S, et al. Mycoplasma hominis osteitis in an immunocompetent man. Eur J Clin Microbiol Infect Dis 2006; 25:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/43\">",
"      Hawkins RE, Rickman LS, Vermund SH, Carl M. Association of mycoplasma and human immunodeficiency virus infection: detection of amplified Mycoplasma fermentans DNA in blood. J Infect Dis 1992; 165:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/44\">",
"      Lo SC, Dawson MS, Wong DM, et al. Identification of Mycoplasma incognitus infection in patients with AIDS: an immunohistochemical, in situ hybridization and ultrastructural study. Am J Trop Med Hyg 1989; 41:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/45\">",
"      Schelonka RL, Katz B, Waites KB, Benjamin DK Jr. Critical appraisal of the role of Ureaplasma in the development of bronchopulmonary dysplasia with metaanalytic techniques. Pediatr Infect Dis J 2005; 24:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/46\">",
"      Alonso-Vega C, Wauters N, Vermeylen D, et al. A fatal case of Mycoplasma hominis meningoencephalitis in a full-term newborn. J Clin Microbiol 1997; 35:286.",
"     </a>",
"    </li>",
"    <li>",
"     Watts KB, Cox NR, Crouse DT. Mycoplasma infections of the central nervous system in humans and animal. In: Recent advances in mycoplasmology, Stanek G, Cassell GH, Tully JG, et al (Eds), Gustav Fischer Verla, Stuttgart, Germany 1990. p.379.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/48\">",
"      Abdel-Haq N, Asmar B, Brown W. Mycoplasma hominis scalp abscess in the newborn. Pediatr Infect Dis J 2002; 21:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/49\">",
"      Sacker I, Walker M, Brunell PA. Abscess in newborn infants caused by Mycoplasma. Pediatrics 1970; 46:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/50\">",
"      Waites KB, Canupp KC. Evaluation of BacT/ALERT system for detection of Mycoplasma hominis in simulated blood cultures. J Clin Microbiol 2001; 39:4328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/51\">",
"      Luki N, Lebel P, Boucher M, et al. Comparison of polymerase chain reaction assay with culture for detection of genital mycoplasmas in perinatal infections. Eur J Clin Microbiol Infect Dis 1998; 17:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/52\">",
"      Petrikkos GL, Hadjisoteriou M, Daikos GL. PCR versus culture in the detection of vaginal Ureaplasma urealyticum and Mycoplasma hominis. Int J Gynaecol Obstet 2007; 97:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/53\">",
"      Twin J, Taylor N, Garland SM, et al. Comparison of two Mycoplasma genitalium real-time PCR detection methodologies. J Clin Microbiol 2011; 49:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/54\">",
"      Taylor-Robinson D, Jensen JS. Mycoplasma genitalium: from Chrysalis to multicolored butterfly. Clin Microbiol Rev 2011; 24:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/55\">",
"      Bebear CM, Bov&eacute; JM, Bebear C, Renaudin J. Characterization of Mycoplasma hominis mutations involved in resistance to fluoroquinolones. Antimicrob Agents Chemother 1997; 41:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/56\">",
"      B&eacute;b&eacute;ar CM, de Barbeyrac B, Pereyre S, et al. Activity of moxifloxacin against the urogenital mycoplasmas Ureaplasma spp., Mycoplasma hominis and Mycoplasma genitalium and Chlamydia trachomatis. Clin Microbiol Infect 2008; 14:801.",
"     </a>",
"    </li>",
"    <li>",
"     Waites, KB, Taylor-Robinson, D. Mycoplasma and Ureaplasma. In: Manual of Clinical Microbiology, 9th ed, Murray, PR, Baron, et al.  (Eds), ASM Press, Washington DC 2007. p.1004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/58\">",
"      Kenny GE, Cartwright FD. Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones. Antimicrob Agents Chemother 2001; 45:2604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/59\">",
"      Pereyre S, Renaudin H, Charron A, et al. Emergence of a 23S rRNA mutation in Mycoplasma hominis associated with a loss of the intrinsic resistance to erythromycin and azithromycin. J Antimicrob Chemother 2006; 57:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/60\">",
"      D&eacute;grange S, Renaudin H, Charron A, et al. Reduced susceptibility to tetracyclines is associated in vitro with the presence of 16S rRNA mutations in Mycoplasma hominis and Mycoplasma pneumoniae. J Antimicrob Chemother 2008; 61:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/61\">",
"      Christiansson A, M&aring;rdh PA. Tetracycline resistance in Mycoplasma hominis. Sex Transm Dis 1983; 10:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/62\">",
"      McCarthy KL, Looke DF. Successful treatment of post-neurosurgical intracranial Mycoplasma hominis infection using gatifloxacin. J Infect 2008; 57:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31177/abstract/63\">",
"      Myers PO, Khabiri E, Greub G, Kalangos A. Mycoplasma hominis mediastinitis after acute aortic dissection repair. Interact Cardiovasc Thorac Surg 2010; 11:857.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5508 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-61DB87C3C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_28_31177=[""].join("\n");
var outline_f30_28_31177=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H296317\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35510070\">",
"      MICROBIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H407365\">",
"      CLINICAL FEATURES AND POSSIBLE DISEASE ASSOCIATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Genitourinary tract infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Cervicitis and pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H725181\">",
"      - Non-gonococcal urethritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Urinary tract infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Chorioamnionitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Nongenitourinary tract disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H506234582\">",
"      - Postpartum and postabortal fever and/or bacteremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Central nervous system disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Arthritis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Wound infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Bacteremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Endocarditis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Respiratory tract infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H506234682\">",
"      - Prosthetic joint and bone infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H506234689\">",
"      - Fulminant bacteremia and systemic infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H506234631\">",
"      Neonatal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35510011\">",
"      - Lung disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H506234847\">",
"      - Meningoencephalitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H506234778\">",
"      - Bacteremia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H576534383\">",
"      - Abscesses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H725159\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H105010013\">",
"      Culture",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H105010020\">",
"      Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H466733115\">",
"      IN VITRO SUSCEPTIBILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1714648224\">",
"      Mycoplasma hominis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1804218961\">",
"      Ureaplasma urealyticum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1714648289\">",
"      Mycoplasma hominis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1804219295\">",
"      - Adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1804219460\">",
"      Genitourinary tract disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1804219467\">",
"      Nongenitourinary tract disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1804219288\">",
"      - Neonates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1714648296\">",
"      Ureaplasma spp",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H296317\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/64?source=related_link\">",
"      Acute cervicitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34646?source=related_link\">",
"      Culture-negative endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/18/18728?source=related_link\">",
"      Genital Chlamydia trachomatis infections in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/29/3545?source=related_link\">",
"      Infantile hypertrophic pyloric stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/43/19126?source=related_link\">",
"      Infectious causes of dysuria in adult men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/48/42761?source=related_link\">",
"      Intraamniotic infection (chorioamnionitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/13/40153?source=related_link\">",
"      Mycoplasma genitalium infection in men and women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/5/3162?source=related_link\">",
"      Mycoplasma pneumoniae infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/0/21512?source=related_link\">",
"      Neonatal pneumonia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/45/11992?source=related_link\">",
"      Pathogenesis of and risk factors for pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/48/1800?source=related_link\">",
"      Postoperative mediastinitis after cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35832?source=related_link\">",
"      Treatment of pelvic inflammatory disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_28_31178="Overview of colonoscopy in adults";
var content_f30_28_31178=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of colonoscopy in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/28/31178/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/28/31178/contributors\">",
"     Linda Lee, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/28/31178/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/28/31178/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/28/31178/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/28/31178/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/28/31178/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/28/31178/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H133249352\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonoscopy is used both diagnostically and therapeutically and permits examination and treatment of the rectum, colon, and a portion of the terminal ileum. Performance of a high-quality colonoscopy examination requires understanding and mastery of cognitive and technical skills. A joint American Society of Gastrointestinal",
"    <span class=\"nowrap\">",
"     Endoscopy/American",
"    </span>",
"    College of Gastroenterology Taskforce on Quality in Endoscopy advocated the following quality indicators before, during, and after colonoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/1,2\">",
"     1,2",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H60870301\">",
"     'Quality indicators'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preprocedure &ndash; Attention must be paid to the general issues of timely scheduling, appropriate patient preparation, targeted history and physical examination, evaluation of bleeding risk, assessment for appropriate sedation, and team pause before commencing sedation. It is also important to understand appropriate indications and recommended surveillance intervals based upon the patient's risk factors (eg, family history of colorectal cancer, prior adenomatous polyps, hereditary colon cancer syndrome, or inflammatory bowel disease). Finally, obtaining informed consent with a detailed explanation of the risks associated with colonoscopy is essential.",
"     </li>",
"     <li>",
"      Intraprocedure &ndash; Performing a high-quality examination requires careful visualization of the entire colonic mucosa. Metrics such as cecal intubation rates, withdrawal times, and adenoma detection rates serve as surrogate, though imperfect, markers of careful visualization. In addition, a high-quality examination requires appropriate tissue acquisition (eg, surveillance biopsies in inflammatory bowel disease) and endoscopic removal of all polyps less than 2 cm. Removal of polyps larger than 2 cm may require special endoscopic skills.",
"     </li>",
"     <li>",
"      Postprocedure",
"      <strong>",
"      </strong>",
"      &ndash; There must be immediate, complete, and accurate documentation (both written and photographic) of preparation quality and findings, as well as explicit recommendations for follow-up. Tissue samples taken during colonoscopy must be documented. Pathology results should be reviewed with results and recommendations communicated to the patient and referring providers. Finally, there should be a system for tracking complications.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This topic will review factors associated with performing a colonoscopy including indications, patient preparation, technical aspects, and complications. Issues related to colon cancer screening recommendations, bowel preparations for colonoscopy, procedural sedation, and the management of antiplatelet or anticoagulant medications in patients undergoing endoscopy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37034?source=see_link\">",
"     \"Screening for colorectal cancer: Strategies in patients at average risk\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/41/9881?source=see_link\">",
"     \"Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/62/32746?source=see_link\">",
"     \"Approach to the patient with colonic polyps\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/39/27258?source=see_link\">",
"     \"Bowel preparation for colonoscopy and flexible sigmoidoscopy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/22/24936?source=see_link\">",
"     \"Overview of procedural sedation for gastrointestinal endoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/36/5702?source=see_link\">",
"     \"Management of antiplatelet agents in patients undergoing endoscopic procedures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/33/21014?source=see_link\">",
"     \"Management of anticoagulants in patients undergoing endoscopic procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H133249359\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient selection for colonoscopy focuses on the indication for the procedure and patient comorbidities to enable proper risk stratification.",
"   </p>",
"   <p>",
"    The American Society of Gastrointestinal Endoscopy has outlined general principles for the appropriate use of endoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/3\">",
"     3",
"    </a>",
"    ]. Endoscopy may be appropriate if any of the following criteria are fulfilled:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The results are likely to change the patient's management",
"     </li>",
"     <li>",
"      Empiric treatment of a benign disease has failed",
"     </li>",
"     <li>",
"      A therapeutic intervention is anticipated",
"     </li>",
"     <li>",
"      It is being used as an alternative to radiologic evaluation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On the other hand, endoscopy is not indicated when the results are not expected to impact management or for the follow-up of benign diseases that have healed, unless surveillance of a premalignant condition is appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H133249366\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonoscopy is performed for both diagnostic and therapeutic indications (",
"    <a class=\"graphic graphic_table graphicRef83296 \" href=\"mobipreview.htm?27/0/27659\">",
"     table 1",
"    </a>",
"    ). Diagnostic indications include screening or surveillance for colon cancer, evaluating signs and symptoms suggestive of possible colonic or distal small bowel disease, assessing a response to treatment in patients with known colonic disease (eg, inflammatory bowel disease), and evaluating abnormalities found on imaging studies. Therapeutic indications include stricture dilation, stent placement, colonic decompression, and foreign body removal. In addition, lesions found during diagnostic procedures may require therapeutic intervention (eg, polypectomy or treatment of a bleeding lesion). (See",
"    <a class=\"local\" href=\"#H133249437\">",
"     'Diagnostic and therapeutic maneuvers'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Screening or surveillance for colon cancer &ndash; Colonoscopy is considered the gold standard for colon cancer screening and surveillance. The age at which screening starts will depend upon the patient's medical and family history (",
"      <a class=\"graphic graphic_algorithm graphicRef59784 \" href=\"mobipreview.htm?12/22/12640\">",
"       algorithm 1",
"      </a>",
"      ). If polyps are found during colonoscopy, they should be removed endoscopically if possible. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37034?source=see_link\">",
"       \"Screening for colorectal cancer: Strategies in patients at average risk\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/41/9881?source=see_link\">",
"       \"Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25722?source=see_link\">",
"       \"Colorectal cancer surveillance in inflammatory bowel disease\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H70097991\">",
"       'Polypectomy'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      The interval for repeat screening or surveillance will again depend upon the patient's medical and family history, as well as the findings on prior colonoscopies (",
"      <a class=\"graphic graphic_table graphicRef73016 graphicRef51969 graphicRef58912 \" href=\"mobipreview.htm?26/4/26702\">",
"       table 2A-C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/62/32746?source=see_link\">",
"       \"Approach to the patient with colonic polyps\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28634?source=see_link\">",
"       \"Surveillance after colorectal cancer resection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lower gastrointestinal bleeding &ndash; Patients with active or recent hematochezia, positive fecal occult blood, or melena after an upper GI source has been excluded should undergo colonoscopy for diagnosis and, if a source of bleeding is identified, potentially endoscopic therapy. In addition, unexplained iron deficiency anemia should be evaluated with colonoscopy, as colon cancer is an important cause of iron deficiency anemia in adults. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30841?source=see_link\">",
"       \"Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/39/26234?source=see_link&amp;anchor=H37#H37\">",
"       \"Causes and diagnosis of anemia due to iron deficiency\", section on 'Search for source of blood and iron loss'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Lower gastrointestinal symptoms &ndash; Colonoscopy should be performed in patients with chronic, clinically significant diarrhea without an explanation. Random colon biopsies should be obtained throughout the colon to rule out microscopic colitis. Colonoscopy is generally not indicated as part of the evaluation for chronic constipation unless warning signs are present (eg, anemia, weight loss) or the patient has not undergone recommended screening or surveillance. Whether to perform a colonoscopy in a patient with chronic abdominal pain will depend upon patient risk factors (eg, age &gt;50 years), the character and location of the pain, and associated signs and symptoms. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/55/43897?source=see_link&amp;anchor=H25#H25\">",
"       \"Approach to the adult with chronic diarrhea in developed countries\", section on 'Colonoscopy versus sigmoidoscopy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/22/13673?source=see_link&amp;anchor=H14#H14\">",
"       \"Etiology and evaluation of chronic constipation in adults\", section on 'Endoscopy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/36/19018?source=see_link\">",
"       \"Diagnostic approach to abdominal pain in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abnormal imaging &ndash; Colonoscopy is indicated to evaluate abnormalities detected on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      enema, abdominal computed tomography (CT), positron emission tomography CT, magnetic resonance imaging, or other imaging studies. Radiographic findings requiring colonoscopic evaluation include thickening of the wall of the colon or terminal ileum (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef79520 \" href=\"mobipreview.htm?27/3/27697\">",
"       image 1",
"      </a>",
"      ), mass lesions (",
"      <a class=\"graphic graphic_figure graphicRef83618 \" href=\"mobipreview.htm?39/12/40131\">",
"       figure 1",
"      </a>",
"      ), filling defects (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef75818 \" href=\"mobipreview.htm?8/14/8431\">",
"       image 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef82202 \" href=\"mobipreview.htm?10/14/10478\">",
"       image 3",
"      </a>",
"      ), and strictures (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef63411 \" href=\"mobipreview.htm?9/60/10191\">",
"       image 4",
"      </a>",
"      ). In addition, colonoscopy may be indicated in patients found to have polyps on CT colonography (virtual colonoscopy), depending upon the size of the polyp (",
"      <a class=\"graphic graphic_picture graphicRef71187 \" href=\"mobipreview.htm?3/18/3374\">",
"       picture 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/49/36632?source=see_link&amp;anchor=H14#H14\">",
"       \"Computed tomographic colonography\", section on 'Guidelines'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Evaluation for synchronous or metachronous cancer in patients with colon cancer &ndash; Patients with colon cancer are at risk for synchronous cancer. As a result, patients with colon cancer require a complete examination of the colon. Ideally, this is done prior to surgery, though in some patients complete preoperative colonoscopy will not be possible (eg, due to inability to pass the colonoscope beyond an obstructing tumor). Such patients require colonoscopy soon after resection of the primary tumor. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28634?source=see_link&amp;anchor=H22#H22\">",
"       \"Surveillance after colorectal cancer resection\", section on 'Perioperative colonoscopy'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Following treatment of the primary tumor, patients require routine surveillance to look for new polyps or metachronous cancer (",
"      <a class=\"graphic graphic_table graphicRef58912 \" href=\"mobipreview.htm?20/53/21341\">",
"       table 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28634?source=see_link&amp;anchor=H23#H23\">",
"       \"Surveillance after colorectal cancer resection\", section on 'Postoperative endoscopic surveillance'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28634?source=see_link&amp;anchor=H24#H24\">",
"       \"Surveillance after colorectal cancer resection\", section on 'Guidelines from major groups'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intraoperative lesion localization &ndash; Colonoscopy may be performed intraoperatively to identify a lesion identified on imaging or prior colonoscopy that is not apparent at surgery, such as a bleeding site or small mass. For lesions previously identified with colonoscopy, intraoperative colonoscopy can often be avoided if the area with the lesion is marked during the colonoscopy (",
"      <a class=\"graphic graphic_picture graphicRef77062 graphicRef69334 graphicRef78733 \" href=\"mobipreview.htm?43/20/44359\">",
"       picture 2A-C",
"      </a>",
"      ). In such cases, lesions are typically tattooed a few centimeters distal to the lesion. Exactly where the tattoo was performed in relationship to the lesion must be clearly documented and communicated to the surgeon. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/51/30519?source=see_link\">",
"       \"Tattooing and other methods for localizing colonic lesions\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Inflammatory bowel disease &ndash; Colonoscopy is often performed in patients with inflammatory bowel disease to assess the extent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      severity of disease and to assess treatment responses. In addition, patients with colitis require routine surveillance for colonic dysplasia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14089?source=see_link\">",
"       \"Endoscopic diagnosis of inflammatory bowel disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25722?source=see_link&amp;anchor=H19#H19\">",
"       \"Colorectal cancer surveillance in inflammatory bowel disease\", section on 'Surveillance'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Evaluation of the terminal ileum &ndash; In patients with suspected disease involving the distal small bowel, such as Crohn's disease, carcinoid, and bleeding, colonoscopy can be used to evaluate the terminal ileum.",
"     </li>",
"     <li>",
"      Therapeutic indications &ndash; Therapeutic indications for colonoscopy include foreign body removal, decompression of sigmoid volvulus or colonic pseudoobstruction, balloon dilation of strictures, palliative treatment of bleeding or stenosed neoplasms, and percutaneous endoscopic cecostomy tube placement. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/46/39654?source=see_link\">",
"       \"Rectal foreign bodies\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26453?source=see_link\">",
"       \"Sigmoid volvulus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/50/22311?source=see_link\">",
"       \"Acute colonic pseudo-obstruction (Ogilvie's syndrome)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/5/4186?source=see_link\">",
"       \"Management of anastomotic complications of colorectal surgery\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/34/5673?source=see_link\">",
"       \"Enteral stents for the management of malignant colorectal obstruction\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H133249373\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonoscopy is contraindicated in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      When the risks of the colonoscopy outweigh the expected benefits",
"     </li>",
"     <li>",
"      Consent cannot be obtained for a non-urgent procedure",
"     </li>",
"     <li>",
"      A perforation is known or suspected",
"     </li>",
"     <li>",
"      Documented acute diverticulitis",
"     </li>",
"     <li>",
"      Fulminant colitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If a patient cannot be adequately sedated despite a reasonable attempt at sedation, colonoscopy should be delayed until adequate sedation can be provided (eg, monitored anesthesia care or general anesthesia). Finally, a suspected poor preparation is a relative contraindication to colonoscopy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/2/43049?source=see_link\">",
"     \"Alternatives and adjuncts to moderate procedural sedation for gastrointestinal endoscopy\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H133249380\">",
"     'Patient preparation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H133249697\">",
"    <span class=\"h2\">",
"     Important considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before the procedure, patients should be evaluated for factors that may affect the ability to perform a colonoscopy safely and successfully, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anatomic issues, such as recent colonic surgery, history of abdominal",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      pelvic surgeries, abdominal hernias, and presence of a colostomy",
"     </li>",
"     <li>",
"      Comorbidities that may increase the risks associated with sedation (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/22/24936?source=see_link&amp;anchor=H2#H2\">",
"       \"Overview of procedural sedation for gastrointestinal endoscopy\", section on 'Preprocedure preparation and assessment'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Comorbidities that may impact the ability of an assistant to apply abdominal pressure",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      position the patient during colonoscopy",
"     </li>",
"     <li>",
"      Presence of an implanted cardiac defibrillator and some pacemakers that may require special management during application of electrocautery (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/54/37737?source=see_link&amp;anchor=H18157871#H18157871\">",
"       \"Overview of electrosurgery\", section on 'Electrosurgery and implantable devices'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Chronic use of medications such as benzodiazepines or narcotics that may increase a patient's tolerance to the effects of sedation",
"     </li>",
"     <li>",
"      A history of difficult intubation by anesthesia",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H133249380\">",
"    <span class=\"h1\">",
"     PATIENT PREPARATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H133249388\">",
"    <span class=\"h2\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients need to consume a low residue diet or clear liquids for at least one day prior to elective colonoscopy. A low residue diet is low in fiber, and patients should be instructed to avoid foods that are high in fiber, such as fruits, vegetables, and whole grains (",
"    <a class=\"graphic graphic_table graphicRef51448 \" href=\"mobipreview.htm?17/2/17453\">",
"     table 3",
"    </a>",
"    ). Clear liquids include water, clear broth, coffee or tea (without milk), ices, gelatin, and fruit juices, such as apple, grapefruit, and lemonade. Liquids that are red can be mistaken for blood in the colon or can obscure mucosal details and should be avoided. One trial found that there was no significant difference in preparation quality between patients treated with 4L of polyethylene glycol who were assigned to receive either a low residue diet or clear liquids the day prior to the examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/4\">",
"     4",
"    </a>",
"    ]. Similarly, a randomized trial with 230 patients who were receiving a sodium sulfate based preparation assigned patients to either a low residue diet for breakfast and lunch the day prior to the colonoscopy or to clear liquids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/5\">",
"     5",
"    </a>",
"    ]. Again, there was no difference between the groups with regard to preparation quality. However, patients in the low residue arm reported greater satisfaction with the preparation and were less likely to cancel their procedure (9 versus 20 percent). Whether similar results would be seen outside of a randomized trial is not yet known. Our approach is to recommend a low residue diet for five days prior to colonoscopy, with only clear liquids allowed the day prior to the examination.",
"   </p>",
"   <p>",
"    Patients typically take no food by mouth for four to eight hours prior to the procedure (sometimes longer if there is known or suspected delayed gastric emptying) and no liquids (other than sips with medications) for two hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/6\">",
"     6",
"    </a>",
"    ]. Recommendations differ with regard to preprocedure fasting for elective procedures. The American Society for Anesthesiology (ASA) guidelines state that prior to a procedure, patients should fast a minimum of two hours following clear liquid ingestion or six hours for a light meal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/7\">",
"     7",
"    </a>",
"    ]. By contrast, the American College of Emergency Physicians states \"recent food intake is not a contraindication for administering procedural sedation and analgesia, but should be considered in choosing the timing and target level of sedation\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/8\">",
"     8",
"    </a>",
"    ]. Our practice is to follow the ASA approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H133249395\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most medications may be continued up to the time of colonoscopy and are taken with a small sip of water the day of the colonoscopy. Some medications may need to be adjusted prior to colonoscopy, such as medications for diabetes, due to decreased oral intake prior to the procedure. Oral iron should also be stopped at least five days before the colonoscopy, since it makes the residual feces black, viscous, and difficult to purge.",
"   </p>",
"   <p>",
"    Decisions regarding the management of antiplatelet agents or anticoagulants must weigh the risks of bleeding from the procedure with the probability of a thromboembolic event occurring while the antithrombotic medication is interrupted (",
"    <a class=\"graphic graphic_table graphicRef50700 \" href=\"mobipreview.htm?43/43/44731\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef77634 \" href=\"mobipreview.htm?40/0/40971\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/9\">",
"     9",
"    </a>",
"    ]. Furthermore, the urgency of the procedure and the availability of alternative tests must be evaluated. Management decisions about antithrombotic agents should be made following discussion with the patient and the clinician prescribing the medication.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    &nbsp;and nonsteroidal anti-inflammatory drugs in standard doses may be continued safely in patients having colonoscopy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/33/21014?source=see_link\">",
"     \"Management of anticoagulants in patients undergoing endoscopic procedures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/36/5702?source=see_link\">",
"     \"Management of antiplatelet agents in patients undergoing endoscopic procedures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/13/31959?source=see_link\">",
"     \"Endoscopic procedures in patients with disorders of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because the risk of infection related to routine diagnostic or therapeutic colonoscopy is low, antibiotic prophylaxis is not recommended for colonoscopy (",
"    <a class=\"graphic graphic_table graphicRef51133 \" href=\"mobipreview.htm?30/19/31037\">",
"     table 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/25/41367?source=see_link\">",
"     \"Antibiotic prophylaxis for gastrointestinal endoscopic procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H133249409\">",
"    <span class=\"h2\">",
"     Bowel preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An excellent bowel preparation is critical for colonoscopy because it permits visualization of the entire colonic mucosa and increases the safety of therapeutic maneuvers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. However, inadequate or poor preparation occurs in approximately 20 to 25 percent of colonoscopies in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/12\">",
"     12",
"    </a>",
"    ]. Poor preparation leads to increased procedure time, risk of complications, and probability of missing lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/13\">",
"     13",
"    </a>",
"    ]. Multiple bowel preparations exist, with the ideal preparation being effective, safe, and palatable. It is important to consider the patient's comorbid illnesses and the timing of the preparation when choosing an appropriate preparation or combination of preparations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/39/27258?source=see_link\">",
"     \"Bowel preparation for colonoscopy and flexible sigmoidoscopy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H133249416\">",
"    <span class=\"h1\">",
"     SEDATION ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Options for sedation for colonoscopy include no sedation, moderate procedural sedation, or deep sedation. Deciding upon the appropriate approach requires an assessment of the patient's sedation needs and risks prior to the colonoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. This includes a complete history of factors that might make sedation more difficult, such as prior difficulties with sedation, chronic narcotic or benzodiazepine use, diminished mental capacity, and agitation or severe anxiety. Special attention should be paid to whether the patient has an increased risk for difficult airway management (eg, obesity, non-visibility of the uvula, prior history of difficult intubation), or increased cardiopulmonary complications of endoscopy (eg, co-morbidities, obesity, older age). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/22/24936?source=see_link\">",
"     \"Overview of procedural sedation for gastrointestinal endoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/2/43049?source=see_link\">",
"     \"Alternatives and adjuncts to moderate procedural sedation for gastrointestinal endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although deep sedation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/25/17816?source=see_link\">",
"     propofol",
"    </a>",
"    is associated with greater patient satisfaction, faster post-procedure recovery time, and in some studies shorter procedure time, it does not lead to improvements in other clinically important outcomes such as cecal intubation rates or adenoma detection rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Furthermore, when administered by an anesthesiologist or dedicated nurse, deep sedation substantially increases the total cost of the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/18\">",
"     18",
"    </a>",
"    ]. It is important to note that in some cases the additional costs associated with the administration of deep sedation may not be covered by a patient's health insurance. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/2/43049?source=see_link&amp;anchor=H7#H7\">",
"     \"Alternatives and adjuncts to moderate procedural sedation for gastrointestinal endoscopy\", section on 'Propofol'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H133249423\">",
"    <span class=\"h1\">",
"     INFORMED CONSENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Informed consent is a process, not merely a form, and it encompasses all the interactions between the healthcare provider and the patient. Informed consent includes full disclosure with a clear and complete explanation of all portions of the procedure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43094?source=see_link\">",
"     \"Informed consent\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Five essential elements to discuss in preparation for any procedure include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nature of the procedure",
"     </li>",
"     <li>",
"      Benefits",
"     </li>",
"     <li>",
"      Risks",
"     </li>",
"     <li>",
"      Alternatives",
"     </li>",
"     <li>",
"      Limitations of the procedure",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of clear and simple language is critical during the process of obtaining consent. For example, colonoscopy may be explained as \"a procedure in which a doctor passes a flexible tube with a light and a camera through your anus into your colon.\" Discussion of the possible risks of colonoscopy, including frequent and less frequent but severe complications, must occur and be tailored to the specific patient and procedure. Incidences of possible complications should be mentioned. (See",
"    <a class=\"local\" href=\"#H133249458\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Written documentation of the consent process is mandatory. In addition, when needed, the use of translators and materials written in a language in which the patient is fluent are also important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60870331\">",
"    <span class=\"h1\">",
"     EQUIPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine colonoscopy is performed using a high-definition white-light colonoscope. Both adult and pediatric colonoscopes are used for colonoscopy in adults (with pediatric colonoscopes often being used for women or patients with a history of abdominal surgery). The choice of colonoscope does not affect cecal intubation rates or times [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/20\">",
"     20",
"    </a>",
"    ]. Adult colonoscopes have a diameter of approximately 13 mm, whereas pediatric colonoscopes have a diameter of approximately 11 mm. Use of a pediatric colonoscope may enable easier passage through narrowed or fixed areas of the colon. However, the smaller diameter makes the pediatric colonoscope more flexible, which predisposes to loop formation. The choice of an adult versus pediatric colonoscope is typically a matter of endoscopist preference. Occasionally the endoscopist may need to change from one type of colonoscope to the other to facilitate completion of the colonoscopy. (See",
"    <a class=\"local\" href=\"#H63022593\">",
"     'Looping'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Variable stiffness colonoscopes allow the endoscopist to stiffen the shaft of the colonoscope and appear to increase cecal intubation rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/21\">",
"     21",
"    </a>",
"    ]. Often the colonoscope is stiffened after passage through the sigmoid colon to reduce loop formation. The colonoscope is typically loosened during withdrawal, retroflexion, or passage around tight turns.",
"   </p>",
"   <p>",
"    Various accessories are available that can be passed through the accessory channel of a colonoscope. These include biopsy forceps, brushes, snares, baskets, nets, injection needles, hemostatic clips, and argon plasma coagulation probes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60870338\">",
"    <span class=\"h1\">",
"     COLONOSCOPE ADVANCEMENT AND MUCOSAL INSPECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonoscopy routinely begins with the patient in the left lateral decubitus position, with the exception of patients with a colostomy, who typically remain supine. The first step is inspection of the perianal region and digital rectal examination. Topical anesthetic lubricating gel should be used for patients with perianal discomfort, whereas standard lubricant can be used for patients without discomfort. The tip of the colonoscope is then inserted into the rectum with air insufflation, suctioning of residual fluid, and pulling back of the colonoscope to enable visualization. The rectosigmoid junction is at approximately 15 to 20 cm, at which point the colon enters the peritoneum. Particular care must be taken when advancing the colonoscope in patients with colonic strictures or significant diverticulosis, as air insufflation can increase the risk of perforation in such patients. (See",
"    <a class=\"local\" href=\"#H133249479\">",
"     'Perforation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Important techniques used during colonoscopy include aspirating air and using the up-down and left-right knobs. Although gentle air insufflation helps visualization as the colonoscope is advanced, filling the colon with air lengthens and distends the colon, which may cause discomfort and increase the difficulty of the procedure. Aspirating the air will deflate and shorten the colon, bringing the next fold closer to the tip of the colonoscope, reducing abdominal discomfort and often aiding with scope advancement. The use of carbon dioxide instead of air to insufflate may reduce distension and patient discomfort as well. Using the knobs is particularly helpful in negotiating turns.",
"   </p>",
"   <p>",
"    Distending the lumen of the colon with water may facilitate advancement of the colonoscope with decreased pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/22\">",
"     22",
"    </a>",
"    ]. This technique may be especially helpful when navigating a left colon filled with numerous diverticula that make it difficult to identify the colonic lumen. Some studies suggest decreased sedation requirements and improved patient tolerance with the use of water rather than air insufflation, whereas other studies suggest decreased adenoma detection rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intubating the terminal ileum can be performed with two different approaches. The colonoscope may be advanced through the opening of the valve by direct visualization during forward movement. Alternatively, the colonoscope may be positioned in the cecum near the appendiceal orifice and slowly withdrawn, with the tip of the colonoscope angled toward the direction of the valve opening in an attempt to \"hook\" the valve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63022593\">",
"    <span class=\"h2\">",
"     Looping",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major barrier to successful advancement of the colonoscope to the cecum is looping. Looping occurs due to the attachment of the sigmoid and transverse colon to a mobile mesentery (",
"    <a class=\"graphic graphic_figure graphicRef82950 \" href=\"mobipreview.htm?7/60/8131\">",
"     figure 2",
"    </a>",
"    ). Advancing the colonoscope becomes more difficult, and in some cases, attempts to advance the colonoscope result in reverse movement of the colonoscope tip, termed paradoxical movement. In addition to impeding advancement of the colonoscope, looping can cause pain and perforation. Pain occurs due to the presence of sensory receptors in the mesentery responding to torsion, distension, compression, and stretching. Repeated loop reduction during the colonoscopy is critical and requires pulling back the colonoscope while applying torque, often clockwise. Stopping any maneuver if it causes significant pain, pressure, or difficulty is important to decrease the risk of complications. Loops formed in the instrument shaft outside the patient should be removed by rotating the colonoscope, keeping the lumen in view.",
"   </p>",
"   <p>",
"    Applying abdominal pressure and changing the patient's position are important adjunctive techniques to enable passage of the colonoscope to the cecum. Abdominal pressure was the most important non-instrumental factor for cecal intubation in patients referred for incomplete colonoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/25\">",
"     25",
"    </a>",
"    ]. Loops should be removed before the assistant applies pressure to help prevent loop further formation.",
"   </p>",
"   <p>",
"    Asking the patient to demonstrate the location of abdominal discomfort may also help identify the appropriate area to apply pressure. In addition, abdominal pressure should be applied to abdominal hernias. In such patients, loops that form within the hernia may lead to entrapment of the colonoscope [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While not widely available, an alternative method for determining where to apply pressure is magnetic endoscopic imaging. Magnetic endoscopic imaging provides real-time three-dimensional views of the colonoscope shaft configuration and its location within the abdomen. This information can aid with loop reduction and can be used to identify where to provide external pressure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/56/30598?source=see_link\">",
"     \"Magnetic endoscopic imaging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Changing the patient's position also may aid advancement of the colonoscope. In addition to the standard left lateral position, patients may be positioned in a supine, right lateral, or prone position. One study demonstrated that position changes were effective two-thirds of the time in allowing forward advancement of the colonoscope or improved luminal visualization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63022615\">",
"    <span class=\"h2\">",
"     Inspection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Careful inspection of the colonic mucosa is primarily performed during withdrawal of the colonoscope. In addition to polyps (and tumors if present), the presence of erythema, erosions, ulcers, diverticula, melanosis coli, hemorrhoids, and condyloma should be noted. A withdrawal time of at least six minutes improves adenoma detection rates, but inspection technique appears to be as important as time spent inspecting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/2,28\">",
"     2,28",
"    </a>",
"    ]. The following techniques are important for ensuring optimal visualization:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cleaning the colon of residual fluid during insertion and withdrawal. Residual stool may be aspirated into a plastic trap for microbiology analysis if needed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Clearing bubbles with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/35/33332?source=see_link\">",
"       simethicone",
"      </a>",
"      in the water flushes used during insertion and withdrawal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Adequate insufflation during withdrawal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Visualizing the entire circumference of the colon by moving the tip of colonoscope in a systematic \"circular\" pattern.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inspecting behind and in between folds.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Repeated inspection of areas by back and forth movement of the colonoscope, especially around turns.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reducing colonic contractions by cleaning during colonoscope advancement to minimize suctioning upon withdrawal. Antispasmodics may also be used, although studies have failed to demonstrate improved adenoma detection rates with their use [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Changing the patient's position during withdrawal has been shown to improve adenoma detection rates, with the following positions used based upon the location of the tip of the colonoscope: cecum to hepatic flexure, left lateral position; transverse colon, supine position; splenic flexure and descending colon, right lateral position [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Careful inspection of vascularity and areas with mucus, since flat lesions may manifest only as subtle changes to the vascular pattern or may be obscured by adherent mucus.",
"     </li>",
"     <li>",
"      Having experienced nurses and assistants examine the colonic mucosa simultaneously with the endoscopist has led to improved adenoma detection rates [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/31,32\">",
"       31,32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The endoscopist cannot always accurately identify the location of the colonoscope tip in the colon. Identifying position by the distances marked on the shaft of the colonoscope is not reliable due to looping, although approximately 60 to 80 cm of the instrument will typically be inserted upon reaching the cecum once loops have been removed. Only the terminal ileum (",
"    <a class=\"graphic graphic_picture graphicRef83345 \" href=\"mobipreview.htm?33/32/34306\">",
"     picture 3",
"    </a>",
"    ), cecum (",
"    <a class=\"graphic graphic_picture graphicRef83347 \" href=\"mobipreview.htm?0/48/770\">",
"     picture 4",
"    </a>",
"    ), and rectum (",
"    <a class=\"graphic graphic_picture graphicRef83343 \" href=\"mobipreview.htm?13/30/13793\">",
"     picture 5",
"    </a>",
"    ) can be recognized 100 percent of the time by experienced endoscopists. The appendiceal orifice (",
"    <a class=\"graphic graphic_picture graphicRef83339 \" href=\"mobipreview.htm?3/11/3251\">",
"     picture 6",
"    </a>",
"    ) and ileocecal valve (",
"    <a class=\"graphic graphic_picture graphicRef83342 \" href=\"mobipreview.htm?2/61/3027\">",
"     picture 7",
"    </a>",
"    ) with two lipomatous lips identify the cecum. Care must be taken not to confuse the cecum with a tight turn or the appendiceal orifice with a diverticulum. The hepatic and splenic flexures may be identified by the bluish hue of adjacent organs (the liver and spleen, respectively) visualized through the colonic mucosa (",
"    <a class=\"graphic graphic_picture graphicRef83341 \" href=\"mobipreview.htm?13/16/13570\">",
"     picture 8",
"    </a>",
"    ). The transverse colon typically has a triangular fold configuration (",
"    <a class=\"graphic graphic_picture graphicRef83346 \" href=\"mobipreview.htm?27/55/28530\">",
"     picture 9",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Multiple options are available to enhance visualization during colonoscopy, though many require specialized equipment and training. These techniques are not routinely used but may be employed in certain circumstances (eg, detecting dysplasia in patients with inflammatory bowel disease). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/9/4248?source=see_link\">",
"     \"Magnification endoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/0/15370?source=see_link\">",
"     \"Chromoendoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/2/3113?source=see_link\">",
"     \"Confocal laser endomicroscopy and endocytoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H133249437\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC AND THERAPEUTIC MANEUVERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of diagnostic and therapeutic maneuvers can be performed during colonoscopy. The most common maneuver is tissue sampling. Other interventions include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endoscopic hemostasis (",
"      <a class=\"graphic graphic_picture graphicRef58198 \" href=\"mobipreview.htm?39/23/40319\">",
"       picture 10",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30841?source=see_link&amp;anchor=H5#H5\">",
"       \"Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient\", section on 'Colonoscopy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34695?source=see_link\">",
"       \"Argon plasma coagulation in the management of gastrointestinal hemorrhage\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/23/14712?source=see_link\">",
"       \"Endoclip therapy in the gastrointestinal tract: Bleeding lesions and beyond\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Dilation of colonic or anastomotic strictures (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/5/4186?source=see_link&amp;anchor=H800412#H800412\">",
"       \"Management of anastomotic complications of colorectal surgery\", section on 'Strictures'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Stent placement for malignant disease (",
"      <a class=\"graphic graphic_picture graphicRef55070 \" href=\"mobipreview.htm?13/38/13922\">",
"       picture 11",
"      </a>",
"      and",
"      <a class=\"graphic graphic_movie graphicRef69586 \" href=\"mobipreview.htm?17/32/17935\">",
"       movie 1",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/34/5673?source=see_link\">",
"       \"Enteral stents for the management of malignant colorectal obstruction\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Endoscopic mucosal resection of gastrointestinal tumors (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/54/4970?source=see_link\">",
"       \"Overview of endoscopic resection of gastrointestinal tumors\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Foreign body removal (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef58085 \" href=\"mobipreview.htm?41/4/42048\">",
"       image 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef61271 graphicRef76634 \" href=\"mobipreview.htm?24/6/24682\">",
"       picture 12A-B",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/46/39654?source=see_link&amp;anchor=H14#H14\">",
"       \"Rectal foreign bodies\", section on 'Endoscopy'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Placement of a colonic decompression tube (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/50/22311?source=see_link&amp;anchor=H109746916#H109746916\">",
"       \"Acute colonic pseudo-obstruction (Ogilvie's syndrome)\", section on 'Colonoscopic decompression'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Percutaneous endoscopic cecostomy tube placement (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/50/22311?source=see_link&amp;anchor=H12#H12\">",
"       \"Acute colonic pseudo-obstruction (Ogilvie's syndrome)\", section on 'Percutaneous tube cecostomy'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H133249444\">",
"    <span class=\"h2\">",
"     Tissue sampling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visible lesions identified during colonoscopy should be sampled or removed for pathology. Because the colonic mucosa lacks pain receptors, patients generally do not feel pain with these maneuvers. Tissue sampling includes biopsies, brushings, and polypectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/33\">",
"     33",
"    </a>",
"    ]. Specimens obtained can be sent for histology, cytology, microbiology, or virology, depending upon the clinical situation. When submitting samples, the endoscopist should provide the pathologist, cytologist, or microbiologist with the patient's clinical history, endoscopic findings, and questions to be answered. Access to the endoscopy report and photographs of the sampled area may also be helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70097991\">",
"    <span class=\"h3\">",
"     Polypectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most polyps less than 2 cm in size can be removed endoscopically, as well as many larger polyps, although larger polyps may require referral to an endoscopist with expertise in the removal of large polyps. Small polyps may be completely removed using biopsy forceps, while larger polyps require snare resection, with or without electrocautery. Advanced endoscopic mucosal resection techniques are used for large polyps (typically greater than 2 cm) (",
"    <a class=\"graphic graphic_picture graphicRef62455 \" href=\"mobipreview.htm?9/8/9348\">",
"     picture 13",
"    </a>",
"    ). Nearly all pedunculated polyps without invasive cancer can be removed endoscopically. If polyps are too numerous for removal, representative samples should be obtained. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/18/28968?source=see_link\">",
"     \"Endoscopic removal of large colonic polyps\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/39/17016?source=see_link&amp;anchor=H11752517#H11752517\">",
"     \"Clinical manifestations and diagnosis of familial adenomatous polyposis\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endoscopists should not attempt removal of polyps beyond their skill or comfort level. In such cases, the lesion should be sampled with biopsies, the area tattooed, and the patient referred to an endoscopist with expertise in the removal of large or difficult polyps. In some cases, endoscopic removal is not possible, and surgical resection is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H133249451\">",
"    <span class=\"h1\">",
"     PHOTODOCUMENTATION AND REPORTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;All colonoscopic procedures should include a complete report detailing the extent of the colon examined, quality of the preparation, and all normal and abnormal findings encountered. Photodocumentation greatly enhances the record and should be included when possible. The following are components of a complete report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/34\">",
"     34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient name along with the names of the personnel performing the procedure (endoscopist, nurses, assistants).",
"     </li>",
"     <li>",
"      Date and time of procedure.",
"     </li>",
"     <li>",
"      Patient's age and gender.",
"     </li>",
"     <li>",
"      Documentation of informed consent.",
"     </li>",
"     <li>",
"      Type of facility where the colonoscopy was performed.",
"     </li>",
"     <li>",
"      American Society of Anesthesiologists classification (",
"      <a class=\"graphic graphic_table graphicRef56098 \" href=\"mobipreview.htm?8/33/8733\">",
"       table 7",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Indication(s) for the procedure.",
"     </li>",
"     <li>",
"      Sedation details, including the type, dose, level of sedation, and the provider responsible for sedation.",
"     </li>",
"     <li>",
"      Extent of the examination, including reasons for an incomplete procedure, if applicable, with photodocumentation of landmarks in the cecum (appendiceal orifice, ileocecal valve, and terminal ileum, if intubated).",
"     </li>",
"     <li>",
"      Bowel preparation type, dose, and quality.",
"     </li>",
"     <li>",
"      Difficulty of the procedure, patient tolerance, and any special maneuvers required to complete the examination.",
"     </li>",
"     <li>",
"      Type of instrument used, with model and instrument number either in the procedure or nursing report.",
"     </li>",
"     <li>",
"      Colonoscopic findings with descriptions of the location, size, and morphology of lesions and whether pathology samples were obtained. For polyps, removal method, completeness of removal, whether the tissue was retrieved, and tattoo placement (if done) should be documented.",
"     </li>",
"     <li>",
"      Unplanned events or complications, including any interventions performed as a result. This should include immediate events and, ideally, events occurring within 30 days following the colonoscopy.",
"     </li>",
"     <li>",
"      Endoscopist's assessment based on colonoscopy findings and available clinical data.",
"     </li>",
"     <li>",
"      Documentation of communication of pathology results with the patient and referring provider(s).",
"     </li>",
"     <li>",
"      Recommendations including further tests, referrals, medication changes, and appointments.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H133249458\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of serious complications following colonoscopy is low. In a review of 12 studies with 57,742 screening colonoscopies, serious harm occurred in 2.8 per 1000 examinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/35\">",
"     35",
"    </a>",
"    ]. Over 85 percent of the complications occurred in the setting of polypectomy. In a second study that used a database with 2.3 million colonoscopies performed between 1997 and 2004, the overall rate of complications resulting in hospitalization was 1.98 per 1000 examinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mortality rate related to colonoscopy is 0.007 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H133249465\">",
"    <span class=\"h2\">",
"     Complications related to sedation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiopulmonary complications are the most frequent complication related to procedural sedation. Reducing the risk of sedation-associated complications requires appropriate anesthesia risk assessment of patients; management of high-risk patients by qualified medical personnel; appropriate monitoring before, during, and after the procedure; and delay of non-urgent procedures in unstable patients. Complications related to procedural sedation are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/41/28310?source=see_link\">",
"     \"Complications of procedural sedation for gastrointestinal endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H133249472\">",
"    <span class=\"h2\">",
"     Complications related to preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;All bowel preparations can cause adverse effects, which include fluid and electrolyte disturbances, nausea, vomiting, abdominal bloating, abdominal discomfort, aspiration, and esophageal tears from vomiting. Complications related to the various colonoscopy preparations are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/39/27258?source=see_link\">",
"     \"Bowel preparation for colonoscopy and flexible sigmoidoscopy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70098074\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding is usually associated with polypectomy and rarely accompanies diagnostic colonoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/38\">",
"     38",
"    </a>",
"    ]. The reported rates of postpolypectomy bleeding vary (typically 1 to 2 percent), with higher rates seen with the removal of larger polyps [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/38-44\">",
"     38-44",
"    </a>",
"    ]. The risk of postpolypectomy bleeding may be increased in patients with thrombocytopenia or coagulopathies. It has been suggested that overall, endoscopists should have postpolypectomy bleeding rates of less than one percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition to the increased risk seen with polypectomy, the risk of bleeding is increased with other therapeutic maneuvers such as stricture dilation and endoscopic mucosal resection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/13/31959?source=see_link&amp;anchor=H3#H3\">",
"     \"Endoscopic procedures in patients with disorders of hemostasis\", section on 'Procedure-related bleeding risk'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Postpolypectomy bleeding may be immediate or delayed. Immediate bleeding is associated with polypectomy techniques that do not use cautery or when blended (instead of coagulation) current is used for polypectomy. It often is recognized during the colonoscopy, in which case it typically can be treated immediately using endoscopic hemostatic methods. If not recognized at the time of colonoscopy, it can usually be managed by a repeat colonoscopy to identify and treat the bleeding site. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/2/11304?source=see_link&amp;anchor=H2#H2\">",
"     \"Bleeding after colonic polypectomy\", section on 'Immediate bleeding'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/23/14712?source=see_link&amp;anchor=H15#H15\">",
"     \"Endoclip therapy in the gastrointestinal tract: Bleeding lesions and beyond\", section on 'Postpolypectomy bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Delayed bleeding is typically seen five to seven days after the procedure, but it has been reported up to 29 days later. It is thought to occur due to sloughing of an eschar that was covering a blood vessel or due to extension of the zone of thermal necrosis to non-injured tissue, which could result in bleeding if it involves a blood vessel. Patients may present with hematochezia or with melena, depending upon the location of the bleeding (bleeding from the right colon may present as melena). As with immediate bleeding, delayed bleeding can often be managed with colonoscopy to identify and treat the bleeding site. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/2/11304?source=see_link&amp;anchor=H14#H14\">",
"     \"Bleeding after colonic polypectomy\", section on 'Delayed bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H133249479\">",
"    <span class=\"h2\">",
"     Perforation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perforations typically occur by one of three mechanisms: (1) mechanical trauma from pressure exerted by the colonoscope on the wall of the colon (often in the rectosigmoid region) or at the site of a stricture; (2) barotrauma, where pressure in the colon exceeds the bursting pressure of a colonic region (typically the cecum); or (3) from electrocautery injury during polypectomy. Perforation rates during colonoscopy vary with the procedure being performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/35,36,45\">",
"     35,36,45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Screening colonoscopy: 0.01 to 0.1 percent",
"     </li>",
"     <li>",
"      Anastomotic stricture dilation: 0 to 6 percent",
"     </li>",
"     <li>",
"      Crohn's disease stricture dilation: 0 to 18 percent",
"     </li>",
"     <li>",
"      Stent placement: 4 percent",
"     </li>",
"     <li>",
"      Colonic decompression tube placement: 2 percent",
"     </li>",
"     <li>",
"      Colonic endoscopic mucosal resection 0 to 5 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Due to the mechanism of injury (mechanical trauma or barotrauma), perforations from a diagnostic colonoscopy are typically large. On the other hand, perforations from a therapeutic colonoscopy may be small and located at the site of the therapeutic intervention, though such patients may also suffer perforations due to mechanical trauma or barotrauma.",
"   </p>",
"   <p>",
"    Mortality rates from iatrogenic colonic perforation range from 0 to 0.65 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/46\">",
"     46",
"    </a>",
"    ]. Risk factors for perforation include advanced age, multiple comorbidities, diverticulosis, obstruction, resection of polyps over 1 cm in size that are located in the right colon, and other therapeutic maneuvers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/35,36,47\">",
"     35,36,47",
"    </a>",
"    ]. Additional risk factors for perforation include reduced mobility of the colon, existing weakness in the colon wall, previous incomplete attempt at endoscopic removal of a colonic lesion, and endoscopist inexperience [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/36,48-51\">",
"     36,48-51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduced colon mobility can result from adhesions, diverticula, radiation therapy, malignancy, or infection.",
"     </li>",
"     <li>",
"      Mucosal abnormalities may occur as a result of inflammatory bowel disease, malignancy, infection, radiation therapy, necrosis, or a partial tear. These abnormalities may cause weakness in the colon wall and predispose to perforation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Endoscopists with low procedure volume have increased rates of perforation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/48,49\">",
"       48,49",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, perforation rates greater than 1 in 1000 screening colonoscopies or 1 in 500 for all colonoscopies should initiate evaluation of the endoscopist's technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H60870301\">",
"     'Quality indicators'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Techniques to decrease the risk of perforation include creating a fluid cushion by injection of submucosal fluid underneath large or flat polyps before resection, avoiding dilation in patients with significant inflammation in the area to be dilated, minimizing air insufflation during placement of a colonic stent, and avoiding colonic stent placement in patients who are or will be receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/34,52\">",
"     34,52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/34/5673?source=see_link&amp;anchor=H9#H9\">",
"     \"Enteral stents for the management of malignant colorectal obstruction\", section on 'Perforation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptoms will vary depending upon the location and size of perforation, the degree of fecal seepage into the peritoneum, and the patient's comorbidities. Colonic perforation may be retro- or intraperitoneal. The ascending colon, hepatic and splenic flexures, and descending colon are retroperitoneal, whereas the distal rectum is below the peritoneum (",
"    <a class=\"graphic graphic_figure graphicRef81248 \" href=\"mobipreview.htm?39/23/40309\">",
"     figure 3",
"    </a>",
"    ). The most common symptom of a colonic perforation is abdominal pain. Other symptoms include fever, nausea, vomiting, dyspnea, chest pain, scapular pain, and neck pain. However, patients with retroperitoneal perforations may have minimal or atypical symptoms. Hoj l;jThe physical examination may be notable for diffuse or localized abdominal tenderness with peritoneal signs.",
"   </p>",
"   <p>",
"    If perforation is suspected, immediate abdominal radiographs (plain and upright or lateral decubitus) and an upright chest radiograph should be obtained to look for free air under the diaphragm, retroperitoneal air, pneumomediastinum, pneumothorax, or subcutaneous emphysema. If plain films are normal but there is a high suspicion of perforation, an abdominopelvic computed tomography scan with water-soluble contrast should be obtained since it has higher sensitivity for detecting extraluminal air than plain films (particularly for retroperitoneal perforations) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management includes giving the patient nothing by mouth and starting intravenous fluids and intravenous broad-spectrum antibiotics. Surgical consultation should be obtained immediately. Large perforations typically require surgery. A minority of patients can be managed nonsurgically. Such patients have a clean colon with no signs of peritonitis and improve symptomatically over 24 hours. Usually these patients have a retroperitoneal perforation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sustained the perforation during a therapeutic colonoscopy. Reported success rates for nonsurgical management are variable (between 33 to 64 percent in some series) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/54-56\">",
"     54-56",
"    </a>",
"    ]. Successful endoscopic clip closure of perforations has been reported and may be attempted if the perforation is visualized at the time of the colonoscopy and is accessible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. However, colonoscopy is contraindicated in patients with a suspected perforation and is not used to treat perforations recognized after completion of the colonoscopy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/34/5673?source=see_link&amp;anchor=H9#H9\">",
"     \"Enteral stents for the management of malignant colorectal obstruction\", section on 'Perforation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/18/28968?source=see_link&amp;anchor=H17#H17\">",
"     \"Endoscopic removal of large colonic polyps\", section on 'Perforation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/23/14712?source=see_link&amp;anchor=H17#H17\">",
"     \"Endoclip therapy in the gastrointestinal tract: Bleeding lesions and beyond\", section on 'Perforations and fistulas'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical treatment is indicated in patients with diffuse peritonitis, patients who deteriorate while undergoing nonsurgical treatment, and patients with a concomitant colonic lesion that requires surgery (eg, colorectal cancer) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/47\">",
"     47",
"    </a>",
"    ]. Pneumoperitoneum alone is not an indication for surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H577158100\">",
"    <span class=\"h2\">",
"     Postpolypectomy syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postpolypectomy syndrome results from electrocoagulation injury to the bowel wall, creating a transmural burn and focal peritonitis without frank perforation. Clinical manifestations include fever, focal abdominal tenderness, and leukocytosis one to five days following polypectomy. Management includes intravenous hydration, antibiotics, and bowel rest. Outpatient management has been reported in reliable patients with mild symptoms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/56/3971?source=see_link\">",
"     \"Postpolypectomy electrocoagulation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H133249493\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of infection related to gastrointestinal endoscopy is very low. Cases of hepatitis B, hepatitis C, and bacterial transmission related to defective equipment",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    breaches in protocols for proper endoscope reprocessing have been reported. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/25/41367?source=see_link\">",
"     \"Antibiotic prophylaxis for gastrointestinal endoscopic procedures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/10/6312?source=see_link\">",
"     \"Endoscope disinfection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2169?source=see_link&amp;anchor=H12#H12\">",
"     \"Epidemiology and transmission of hepatitis C virus infection\", section on 'Other'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H577158150\">",
"    <span class=\"h2\">",
"     Gas explosion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gas explosion is exceedingly rare and results from the ignition of hydrogen or methane gas in the colonic lumen from use of electrosurgical energy. The gas results from an incomplete or poor preparation or from the use of incompletely absorbable carbohydrate preparations, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    . The use of argon plasma coagulation (APC) for bleeding control from radiation-induced proctitis has been associated with gas explosions when enemas were used before a sigmoidoscopy or the colonoscopy preparation was poor quality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/59\">",
"     59",
"    </a>",
"    ]. A death has been reported as a result of gas explosion during colonoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gas explosion has also been reported in a patient who had previously undergone colectomy for Gardner syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/61\">",
"     61",
"    </a>",
"    ]. The patient was found to have rectal polyps on proctoileoscopy. The polyps were treated with APC, resulting in the explosion, with multiple rectal and ileal perforations. The patient had not received a preparation prior to the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60870301\">",
"    <span class=\"h1\">",
"     QUALITY INDICATORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple quality indicators have been proposed for colonoscopy, including cecal intubation rates, withdrawal times, and adenoma detection rates. Adenoma detection rates are calculated based upon screening colonoscopies in asymptomatic patients &ge;50 years of age who are at average-risk for colon polyps and colon cancer. In addition, adenoma detection rates are based only upon complete examinations with adequate preparations.",
"   </p>",
"   <p>",
"    The following quality indicators were identified by a consensus panel from the American Society of Gastrointestinal Endoscopy in 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is an appropriate indication for the colonoscopy. (See",
"      <a class=\"local\" href=\"#H133249366\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Informed consent is obtained, including specific discussion of the risks associated with colonoscopy. (See",
"      <a class=\"local\" href=\"#H133249423\">",
"       'Informed consent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recommended postpolypectomy and post-cancer resection surveillance intervals are followed. (See",
"      <a class=\"local\" href=\"#H133249366\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recommended ulcerative",
"      <span class=\"nowrap\">",
"       colitis/Crohn's",
"      </span>",
"      disease surveillance intervals are followed. (See",
"      <a class=\"local\" href=\"#H133249366\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The quality of the preparation is documented in the procedure note. (See",
"      <a class=\"local\" href=\"#H133249451\">",
"       'Photodocumentation and reporting'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Colonoscopists have acceptable cecal intubation rates (visualization of the cecum by notation of landmarks and photodocumentation of landmarks should be present in every procedure). Effective colonoscopists should be able to intubate the cecum in &ge;90 percent of all cases and in &ge;95 percent of cases when the indication is screening in a healthy adult. This does not include procedures aborted due to poor preparation or severe colitis, or those performed for the focused intent of managing strictures or large, previously diagnosed polyps.",
"     </li>",
"     <li>",
"      Colonoscopists have adenoma detection rates of at least 25 percent in men and 15 percent in women who are over the age of 50 years and are undergoing screening colonoscopy.",
"     </li>",
"     <li>",
"      The mean withdrawal time is &ge;6 minutes in colonoscopies with normal results that are performed in patients with intact anatomy.",
"     </li>",
"     <li>",
"      Biopsies specimens are obtained in patients with chronic diarrhea. (See",
"      <a class=\"local\" href=\"#H133249366\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An appropriate number and distribution of biopsy samples are obtained in patients undergoing ulcerative colitis and Crohn's colitis surveillance. The goal is four biopsies per 10 cm section of involved colon, or approximately 32 specimens per case of pancolitis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25722?source=see_link&amp;anchor=H21#H21\">",
"       \"Colorectal cancer surveillance in inflammatory bowel disease\", section on 'Colonoscopy with biopsy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mucosally based pedunculated polyps and sessile polyps &lt;2 cm in size are endoscopically resected, or documentation of unresectability is obtained. (See",
"      <a class=\"local\" href=\"#H70097991\">",
"       'Polypectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Perforation rates by procedure type (all indications versus screening) are monitored. In general, the perforation rate should not exceed 1 in 500 colonoscopies overall, and 1 in 1000 screening colonoscopies. (See",
"      <a class=\"local\" href=\"#H133249479\">",
"       'Perforation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Incidence of postpolypectomy bleeding is monitored. In general, the incidence of postpolypectomy bleeding should be less than 1 percent. (See",
"      <a class=\"local\" href=\"#H70098074\">",
"       'Bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Postpolypectomy bleeding is managed nonoperatively in &ge;90 percent of cases. (See",
"      <a class=\"local\" href=\"#H70098074\">",
"       'Bleeding'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One factor that has received significant attention is withdrawal time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/62-65\">",
"     62-65",
"    </a>",
"    ]. In a study of 2053 screening colonoscopies, endoscopists with a mean withdrawal time of &ge;6 minutes had a higher neoplasia detection rate than those with a withdrawal time of less than 6 minutes (28 versus 12 percent), including advanced neoplasia (6 versus 3 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/62\">",
"     62",
"    </a>",
"    ]. Similarly, in a prospective study of 315 gastroenterologists and 15,955 patients, endoscopists with a mean withdrawal time of &ge;6 minutes were 1.8 times more likely to detect one or more polyps [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/63\">",
"     63",
"    </a>",
"    ]. However, another prospective study that included 4429 consecutive colonoscopies performed by 67 endoscopists failed to find a statistically significant difference in polyp detection for polyps &ge;5 mm for those who had median withdrawal times of &ge;6 minutes compared with those with shorter withdrawal times (odds ratio 1.2; 95% confidence interval 0.9-1.6) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the guidelines suggest adenoma detection rates of 25 percent for men and 15 percent for women, some studies suggest that these benchmarks may be too low. In a prospective series of 864 average-risk patients undergoing colonoscopy, the adenoma detection rate for men was 41 percent and for women was 25 percent (with advanced adenoma detection rates of 15 and 9 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/28/31178/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5th&nbsp;to 6th&nbsp;grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th&nbsp;to 12th&nbsp;grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/11/18611?source=see_link\">",
"       \"Patient information: Colonoscopy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/30/9698?source=see_link\">",
"       \"Patient information: Colonoscopy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H133249507\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Colonoscopy includes visualization of the rectum, colon, and the distal portion of terminal ileum, with real time assessment and interpretation of the findings encountered. (See",
"      <a class=\"local\" href=\"#H133249352\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Colonoscopy is indicated for the diagnostic evaluation of signs and symptoms of a wide variety of gastrointestinal disorders, for colon cancer screening, and for therapeutic interventions (",
"      <a class=\"graphic graphic_table graphicRef83296 \" href=\"mobipreview.htm?27/0/27659\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H133249366\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preparation for colonoscopy typically involves the ingestion of a low residue diet or clear liquids for at least one day prior to the examination, combined with an oral gastrointestinal lavage. Most medications may be continued up to the time of colonoscopy, but management of antiplatelet agents and anticoagulants must take into account the procedure-related risk of bleeding and the risk of thrombosis. Antibiotic prophylaxis is not required for patients undergoing colonoscopy. (See",
"      <a class=\"local\" href=\"#H133249380\">",
"       'Patient preparation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/36/5702?source=see_link\">",
"       \"Management of antiplatelet agents in patients undergoing endoscopic procedures\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/33/21014?source=see_link\">",
"       \"Management of anticoagulants in patients undergoing endoscopic procedures\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Routine colonoscopy is performed using a high-definition white-light colonoscope. Multiple accessories are available to aid with diagnostic and therapeutic maneuvers. In addition, options are available to enhance visualization during colonoscopy (eg, chromoendoscopy), although many require specialized equipment and training. (See",
"      <a class=\"local\" href=\"#H60870331\">",
"       'Equipment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A variety of diagnostic and therapeutic maneuvers can be performed during colonoscopy. The most common maneuver is tissue sampling, including routine polypectomy. (See",
"      <a class=\"local\" href=\"#H133249437\">",
"       'Diagnostic and therapeutic maneuvers'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Other interventions include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Endoscopic hemostasis",
"     </li>",
"     <li>",
"      Dilation of colonic strictures",
"     </li>",
"     <li>",
"      Stent placement for malignant disease",
"     </li>",
"     <li>",
"      Endoscopic mucosal resection of large colonic polyps",
"     </li>",
"     <li>",
"      Colonic decompression tube placement",
"     </li>",
"     <li>",
"      Percutaneous endoscopic cecostomy tube placement",
"     </li>",
"     <li>",
"      Foreign body removal",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serious complications of colonoscopy are rare (approximately 3 per 1000 screening colonoscopies) and include complications of sedation, complications related to the preparation, bleeding, and perforation. (See",
"      <a class=\"local\" href=\"#H133249458\">",
"       'Complications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/41/28310?source=see_link\">",
"       \"Complications of procedural sedation for gastrointestinal endoscopy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/39/27258?source=see_link\">",
"       \"Bowel preparation for colonoscopy and flexible sigmoidoscopy in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Bleeding is usually associated with polypectomy and rarely accompanies diagnostic colonoscopy. Postpolypectomy bleeding occurs in approximately 1 to 2 percent of polypectomies, with higher rates seen with the removal of larger polyps. Patients may present with hematochezia or melena days to weeks after the colonoscopy. The majority of patients can be managed with a repeat colonoscopy to both identify and treat the source of bleeding. (See",
"      <a class=\"local\" href=\"#H70098074\">",
"       'Bleeding'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/2/11304?source=see_link\">",
"       \"Bleeding after colonic polypectomy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Perforation rates vary with the procedure being performed, with rates of 0.01 to 0.1 percent for screening colonoscopy. The most common symptom of a colonic perforation is abdominal pain. Other symptoms include fever, nausea, vomiting, dyspnea, chest pain, scapular pain, and neck pain. However, patients with retroperitoneal perforations may have minimal or atypical symptoms. The physical examination may be notable for diffuse or localized abdominal tenderness with peritoneal signs. (See",
"      <a class=\"local\" href=\"#H133249479\">",
"       'Perforation'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      If perforation is suspected, immediate abdominal radiographs (plain and upright or lateral decubitus) and an upright chest radiograph should be obtained. If plain films are normal but there is a high suspicion of perforation, an abdominopelvic computed tomography scan with water-soluble contrast should be obtained. All patients with perforations should receive intravenous fluids and broad spectrum antibiotics. Many patients with perforations will require surgery, though nonsurgical management may be possible in those with small perforations without evidence of peritonitis.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/1\">",
"      Bjorkman DJ, Popp JW Jr. Measuring the quality of endoscopy. Gastrointest Endosc 2006; 63:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/2\">",
"      Rex DK, Petrini JL, Baron TH, et al. Quality indicators for colonoscopy. Gastrointest Endosc 2006; 63:S16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/3\">",
"      Appropriate use of gastrointestinal endoscopy. American Society for Gastrointestinal Endoscopy. Gastrointest Endosc 2000; 52:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/4\">",
"      Park DI, Park SH, Lee SK, et al. Efficacy of prepackaged, low residual test meals with 4L polyethylene glycol versus a clear liquid diet with 4L polyethylene glycol bowel preparation: a randomized trial. J Gastroenterol Hepatol 2009; 24:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/5\">",
"      Sipe BW, Fischer M, Baluyut AR, et al. Effect of low residual diet on colonoscopy bowel preparation. Gastrointest Endosc 2012; 75:AB163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/6\">",
"      Faigel DO, Eisen GM, Baron TH, et al. Preparation of patients for GI endoscopy. Gastrointest Endosc 2003; 57:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/7\">",
"      Committee on Obstetric Practice, American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 441: Oral intake during labor. Obstet Gynecol 2009; 114:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/8\">",
"      Godwin SA, Caro DA, Wolf SJ, et al. Clinical policy: procedural sedation and analgesia in the emergency department. Ann Emerg Med 2005; 45:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/9\">",
"      ASGE Standards of Practice Committee, Anderson MA, Ben-Menachem T, et al. Management of antithrombotic agents for endoscopic procedures. Gastrointest Endosc 2009; 70:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/10\">",
"      Wexner SD, Beck DE, Baron TH, et al. A consensus document on bowel preparation before colonoscopy: prepared by a task force from the American Society of Colon and Rectal Surgeons (ASCRS), the American Society for Gastrointestinal Endoscopy (ASGE), and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES). Gastrointest Endosc 2006; 63:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/11\">",
"      Landreneau SW, Di Palma JA. Update on preparation for colonoscopy. Curr Gastroenterol Rep 2010; 12:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/12\">",
"      Ness RM, Manam R, Hoen H, Chalasani N. Predictors of inadequate bowel preparation for colonoscopy. Am J Gastroenterol 2001; 96:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/13\">",
"      Chokshi RV, Hovis CE, Hollander T, et al. Prevalence of missed adenomas in patients with inadequate bowel preparation on screening colonoscopy. Gastrointest Endosc 2012; 75:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/14\">",
"      Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy, Lichtenstein DR, Jagannath S, et al. Sedation and anesthesia in GI endoscopy. Gastrointest Endosc 2008; 68:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/15\">",
"      Cohen LB, Delegge MH, Aisenberg J, et al. AGA Institute review of endoscopic sedation. Gastroenterology 2007; 133:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/16\">",
"      Paspatis GA, Tribonias G, Manolaraki MM, et al. Deep sedation compared with moderate sedation in polyp detection during colonoscopy: a randomized controlled trial. Colorectal Dis 2011; 13:e137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/17\">",
"      Sipe BW, Rex DK, Latinovich D, et al. Propofol versus midazolam/meperidine for outpatient colonoscopy: administration by nurses supervised by endoscopists. Gastrointest Endosc 2002; 55:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/18\">",
"      Rex DK, Deenadayalu VP, Eid E, et al. Endoscopist-directed administration of propofol: a worldwide safety experience. Gastroenterology 2009; 137:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/19\">",
"      Standards of Practice Committee, Zuckerman MJ, Shen B, et al. Informed consent for GI endoscopy. Gastrointest Endosc 2007; 66:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/20\">",
"      Shumaker DA, Zaman A, Katon RM. A randomized controlled trial in a training institution comparing a pediatric variable stiffness colonoscope, a pediatric colonoscope, and an adult colonoscope. Gastrointest Endosc 2002; 55:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/21\">",
"      Othman MO, Bradley AG, Choudhary A, et al. Variable stiffness colonoscope versus regular adult colonoscope: meta-analysis of randomized controlled trials. Endoscopy 2009; 41:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/22\">",
"      Leung FW, Harker JO, Jackson G, et al. A proof-of-principle, prospective, randomized, controlled trial demonstrating improved outcomes in scheduled unsedated colonoscopy by the water method. Gastrointest Endosc 2010; 72:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/23\">",
"      Leung J, Mann S, Siao-Salera R, et al. A randomized, controlled trial to confirm the beneficial effects of the water method on U.S. veterans undergoing colonoscopy with the option of on-demand sedation. Gastrointest Endosc 2011; 73:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/24\">",
"      Radaelli F, Paggi S, Amato A, Terruzzi V. Warm water infusion versus air insufflation for unsedated colonoscopy: a randomized, controlled trial. Gastrointest Endosc 2010; 72:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/25\">",
"      Rex DK, Chen SC, Overhiser AJ. Colonoscopy technique in consecutive patients referred for prior incomplete colonoscopy. Clin Gastroenterol Hepatol 2007; 5:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/26\">",
"      Koltun WA, Coller JA. Incarceration of colonoscope in an inguinal hernia. \"Pulley\" technique of removal. Dis Colon Rectum 1991; 34:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/27\">",
"      Shah SG, Saunders BP, Brooker JC, Williams CB. Magnetic imaging of colonoscopy: an audit of looping, accuracy and ancillary maneuvers. Gastrointest Endosc 2000; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     National Health Service Bowel Cancer Screening Programme Endoscopy Quality Assurance Group. Quality assurance guidelines for colonoscopy publication no.6. National Health Service file://www.cancerscreening.nhs.uk/bowel/publications/nhsbcsp06.pdf (Accessed on March 23, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/29\">",
"      Lee JM, Cheon JH, Park JJ, et al. Effects of Hyosine N-butyl bromide on the detection of polyps during colonoscopy. Hepatogastroenterology 2010; 57:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/30\">",
"      East JE, Bassett P, Arebi N, et al. Dynamic patient position changes during colonoscope withdrawal increase adenoma detection: a randomized, crossover trial. Gastrointest Endosc 2011; 73:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/31\">",
"      Lee CK, Park DI, Lee SH, et al. Participation by experienced endoscopy nurses increases the detection rate of colon polyps during a screening colonoscopy: a multicenter, prospective, randomized study. Gastrointest Endosc 2011; 74:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/32\">",
"      Rogart JN, Siddiqui UD, Jamidar PA, Aslanian HR. Fellow involvement may increase adenoma detection rates during colonoscopy. Am J Gastroenterol 2008; 103:2841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/33\">",
"      Faigel DO, Eisen GM, Baron TH, et al. Tissue sampling and analysis. Gastrointest Endosc 2003; 57:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/34\">",
"      Williams JE, Faigel DO. Colonoscopy reports and current state of performance measures. Gastrointest Endosc Clin N Am 2010; 20:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/35\">",
"      Whitlock EP, Lin JS, Liles E, et al. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2008; 149:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/36\">",
"      Chukmaitov A, Bradley CJ, Dahman B, et al. Association of polypectomy techniques, endoscopist volume, and facility type with colonoscopy complications. Gastrointest Endosc 2013; 77:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/37\">",
"      ASGE Standards of Practice Committee, Fisher DA, Maple JT, et al. Complications of colonoscopy. Gastrointest Endosc 2011; 74:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/38\">",
"      Fr&uuml;hmorgen P, Demling L. Complications of diagnostic and therapeutic colonoscopy in the Federal Republic of Germany. Results of an inquiry. Endoscopy 1979; 11:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/39\">",
"      Silvis SE, Nebel O, Rogers G, et al. Endoscopic complications. Results of the 1974 American Society for Gastrointestinal Endoscopy Survey. JAMA 1976; 235:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/40\">",
"      Waye JD, Lewis BS, Yessayan S. Colonoscopy: a prospective report of complications. J Clin Gastroenterol 1992; 15:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/41\">",
"      Nivatvongs S. Complications in colonoscopic polypectomy. An experience with 1,555 polypectomies. Dis Colon Rectum 1986; 29:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/42\">",
"      Zubarik R, Fleischer DE, Mastropietro C, et al. Prospective analysis of complications 30 days after outpatient colonoscopy. Gastrointest Endosc 1999; 50:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/43\">",
"      Waye JD. Saline injection colonoscopic polypectomy. Am J Gastroenterol 1994; 89:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/44\">",
"      Hurlstone DP, Sanders DS, Cross SS, et al. Colonoscopic resection of lateral spreading tumours: a prospective analysis of endoscopic mucosal resection. Gut 2004; 53:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/45\">",
"      Gastrointest Endosc 2013; 77:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/46\">",
"      Putcha RV, Burdick JS. Management of iatrogenic perforation. Gastroenterol Clin North Am 2003; 32:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/47\">",
"      Lohsiriwat V. Colonoscopic perforation: incidence, risk factors, management and outcome. World J Gastroenterol 2010; 16:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/48\">",
"      Dafnis G, Ekbom A, Pahlman L, Blomqvist P. Complications of diagnostic and therapeutic colonoscopy within a defined population in Sweden. Gastrointest Endosc 2001; 54:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/49\">",
"      Rabeneck L, Paszat LF, Hilsden RJ, et al. Bleeding and perforation after outpatient colonoscopy and their risk factors in usual clinical practice. Gastroenterology 2008; 135:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/50\">",
"      Foliente RL, Chang AC, Youssef AI, et al. Endoscopic cecal perforation: mechanisms of injury. Am J Gastroenterol 1996; 91:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/51\">",
"      Iqbal CW, Cullinane DC, Schiller HJ, et al. Surgical management and outcomes of 165 colonoscopic perforations from a single institution. Arch Surg 2008; 143:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/52\">",
"      Panteris V, Haringsma J, Kuipers EJ. Colonoscopy perforation rate, mechanisms and outcome: from diagnostic to therapeutic colonoscopy. Endoscopy 2009; 41:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/53\">",
"      Kim DH, Pickhardt PJ, Taylor AJ, Menias CO. Imaging evaluation of complications at optical colonoscopy. Curr Probl Diagn Radiol 2008; 37:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/54\">",
"      Araghizadeh FY, Timmcke AE, Opelka FG, et al. Colonoscopic perforations. Dis Colon Rectum 2001; 44:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/55\">",
"      Cobb WS, Heniford BT, Sigmon LB, et al. Colonoscopic perforations: incidence, management, and outcomes. Am Surg 2004; 70:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/56\">",
"      Orsoni P, Berdah S, Verrier C, et al. Colonic perforation due to colonoscopy: a retrospective study of 48 cases. Endoscopy 1997; 29:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/57\">",
"      Jovanovic I, Zimmermann L, Fry LC, M&ouml;nkem&uuml;ller K. Feasibility of endoscopic closure of an iatrogenic colon perforation occurring during colonoscopy. Gastrointest Endosc 2011; 73:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/58\">",
"      Yang DH, Byeon JS, Lee KH, et al. Is endoscopic closure with clips effective for both diagnostic and therapeutic colonoscopy-associated bowel perforation? Surg Endosc 2010; 24:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/59\">",
"      Manner H, Plum N, Pech O, et al. Colon explosion during argon plasma coagulation. Gastrointest Endosc 2008; 67:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/60\">",
"      Bigard MA, Gaucher P, Lassalle C. Fatal colonic explosion during colonoscopic polypectomy. Gastroenterology 1979; 77:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/61\">",
"      Lin OS, Biehl T, Jiranek GC, Kozarek RA. Explosion from argon cautery during proctoileoscopy of a patient with a colectomy. Clin Gastroenterol Hepatol 2012; 10:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/62\">",
"      Barclay RL, Vicari JJ, Doughty AS, et al. Colonoscopic withdrawal times and adenoma detection during screening colonoscopy. N Engl J Med 2006; 355:2533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/63\">",
"      Overholt BF, Brooks-Belli L, Grace M, et al. Withdrawal times and associated factors in colonoscopy: a quality assurance multicenter assessment. J Clin Gastroenterol 2010; 44:e80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/64\">",
"      Moritz V, Bretthauer M, Ruud HK, et al. Withdrawal time as a quality indicator for colonoscopy - a nationwide analysis. Endoscopy 2012; 44:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/65\">",
"      Lee TJ, Blanks RG, Rees CJ, et al. Longer mean colonoscopy withdrawal time is associated with increased adenoma detection: evidence from the Bowel Cancer Screening Programme in England. Endoscopy 2013; 45:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/28/31178/abstract/66\">",
"      Coe SG, Wallace MB. Assessment of adenoma detection rate benchmarks in women versus men. Gastrointest Endosc 2013; 77:631.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13927 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-641A5F4110-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_28_31178=[""].join("\n");
var outline_f30_28_31178=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H133249507\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H133249352\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H133249359\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H133249366\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H133249373\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H133249697\">",
"      Important considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H133249380\">",
"      PATIENT PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H133249388\">",
"      Diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H133249395\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H133249409\">",
"      Bowel preparation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H133249416\">",
"      SEDATION ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H133249423\">",
"      INFORMED CONSENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H60870331\">",
"      EQUIPMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H60870338\">",
"      COLONOSCOPE ADVANCEMENT AND MUCOSAL INSPECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H63022593\">",
"      Looping",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H63022615\">",
"      Inspection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H133249437\">",
"      DIAGNOSTIC AND THERAPEUTIC MANEUVERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H133249444\">",
"      Tissue sampling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H70097991\">",
"      - Polypectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H133249451\">",
"      PHOTODOCUMENTATION AND REPORTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H133249458\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H133249465\">",
"      Complications related to sedation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H133249472\">",
"      Complications related to preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H70098074\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H133249479\">",
"      Perforation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H577158100\">",
"      Postpolypectomy syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H133249493\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H577158150\">",
"      Gas explosion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H60870301\">",
"      QUALITY INDICATORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H133249507\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/13927\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/13927|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?12/22/12640\" title=\"algorithm 1\">",
"      Algorithm for CRC screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/13927|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?27/3/27697\" title=\"diagnostic image 1\">",
"      Thickening of distal ileum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?8/14/8431\" title=\"diagnostic image 2\">",
"      Annular CA descend colon BE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?10/14/10478\" title=\"diagnostic image 3\">",
"      Rectal cancer BE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?9/60/10191\" title=\"diagnostic image 4\">",
"      Sigmoid cancer in UC BE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?41/4/42048\" title=\"diagnostic image 5\">",
"      Plain film billie club",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/13927|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/12/40131\" title=\"figure 1\">",
"      Colon cancer on CT and colonoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/60/8131\" title=\"figure 2\">",
"      Looping during colonoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/23/40309\" title=\"figure 3\">",
"      Peritoneum colon rectum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/13927|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/18/3374\" title=\"picture 1\">",
"      Polyp on virtual colonoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/27/38335\" title=\"picture 2A\">",
"      Ink stains at polypectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/48/4866\" title=\"picture 2B\">",
"      India ink marking a flat lesion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/35/23103\" title=\"picture 2C\">",
"      India ink persistent staining",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/32/34306\" title=\"picture 3\">",
"      Terminal ileum endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/48/770\" title=\"picture 4\">",
"      Cecum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/30/13793\" title=\"picture 5\">",
"      Rectum endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/11/3251\" title=\"picture 6\">",
"      Appendiceal orifice endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/61/3027\" title=\"picture 7\">",
"      Ileocecal valve endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/16/13570\" title=\"picture 8\">",
"      Hepatic flexure endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/55/28530\" title=\"picture 9\">",
"      Transverse colon endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/23/40319\" title=\"picture 10\">",
"      Endoscopic treatment bleeding diverticulum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/38/13922\" title=\"picture 11\">",
"      Colonic stent Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/29/473\" title=\"picture 12A\">",
"      Endoscopy snare billie club",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/36/35395\" title=\"picture 12B\">",
"      Snare extract billie club",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/8/9348\" title=\"picture 13\">",
"      Resection sessile polyp Endosc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/13927|MOV\">",
"      <a href=\"#\" title=\"MOVIES\">",
"       MOVIES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_movie\" href=\"mobipreview.htm?17/32/17935\" title=\"movie 1\">",
"      Colonic stent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/13927|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/0/27659\" title=\"table 1\">",
"      Indications for colonoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/46/6892\" title=\"table 2A\">",
"      Guidelines after polypectomy I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/31/3580\" title=\"table 2B\">",
"      Guidelines after polypectomy II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/53/21341\" title=\"table 2C\">",
"      Postop surv ASCO NCCN rec",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/2/17453\" title=\"table 3\">",
"      Dietary fiber in foods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/43/44731\" title=\"table 4\">",
"      Bleeding risk GI procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/0/40971\" title=\"table 5\">",
"      Risk GI procedure conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/19/31037\" title=\"table 6\">",
"      ASGE guidelines Abx prophylxs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/33/8733\" title=\"table 7\">",
"      American Society of Anesthesiologists physical status scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/50/22311?source=related_link\">",
"      Acute colonic pseudo-obstruction (Ogilvie's syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/2/43049?source=related_link\">",
"      Alternatives and adjuncts to moderate procedural sedation for gastrointestinal endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/25/41367?source=related_link\">",
"      Antibiotic prophylaxis for gastrointestinal endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/7/30841?source=related_link\">",
"      Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/55/43897?source=related_link\">",
"      Approach to the adult with chronic diarrhea in developed countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/62/32746?source=related_link\">",
"      Approach to the patient with colonic polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/56/34695?source=related_link\">",
"      Argon plasma coagulation in the management of gastrointestinal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/2/11304?source=related_link\">",
"      Bleeding after colonic polypectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/39/27258?source=related_link\">",
"      Bowel preparation for colonoscopy and flexible sigmoidoscopy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/39/26234?source=related_link\">",
"      Causes and diagnosis of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/0/15370?source=related_link\">",
"      Chromoendoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/39/17016?source=related_link\">",
"      Clinical manifestations and diagnosis of familial adenomatous polyposis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/7/25722?source=related_link\">",
"      Colorectal cancer surveillance in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/41/28310?source=related_link\">",
"      Complications of procedural sedation for gastrointestinal endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/49/36632?source=related_link\">",
"      Computed tomographic colonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/2/3113?source=related_link\">",
"      Confocal laser endomicroscopy and endocytoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/36/19018?source=related_link\">",
"      Diagnostic approach to abdominal pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/23/14712?source=related_link\">",
"      Endoclip therapy in the gastrointestinal tract: Bleeding lesions and beyond",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/10/6312?source=related_link\">",
"      Endoscope disinfection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/48/14089?source=related_link\">",
"      Endoscopic diagnosis of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/13/31959?source=related_link\">",
"      Endoscopic procedures in patients with disorders of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/18/28968?source=related_link\">",
"      Endoscopic removal of large colonic polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/34/5673?source=related_link\">",
"      Enteral stents for the management of malignant colorectal obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/7/2169?source=related_link\">",
"      Epidemiology and transmission of hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/22/13673?source=related_link\">",
"      Etiology and evaluation of chronic constipation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43094?source=related_link\">",
"      Informed consent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/56/30598?source=related_link\">",
"      Magnetic endoscopic imaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/9/4248?source=related_link\">",
"      Magnification endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/5/4186?source=related_link\">",
"      Management of anastomotic complications of colorectal surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/33/21014?source=related_link\">",
"      Management of anticoagulants in patients undergoing endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/36/5702?source=related_link\">",
"      Management of antiplatelet agents in patients undergoing endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/54/37737?source=related_link\">",
"      Overview of electrosurgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/54/4970?source=related_link\">",
"      Overview of endoscopic resection of gastrointestinal tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/22/24936?source=related_link\">",
"      Overview of procedural sedation for gastrointestinal endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?9/30/9698?source=related_link\">",
"      Patient information: Colonoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/11/18611?source=related_link\">",
"      Patient information: Colonoscopy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/56/3971?source=related_link\">",
"      Postpolypectomy electrocoagulation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/46/39654?source=related_link\">",
"      Rectal foreign bodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/10/37034?source=related_link\">",
"      Screening for colorectal cancer: Strategies in patients at average risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/41/9881?source=related_link\">",
"      Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/53/26453?source=related_link\">",
"      Sigmoid volvulus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28634?source=related_link\">",
"      Surveillance after colorectal cancer resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/51/30519?source=related_link\">",
"      Tattooing and other methods for localizing colonic lesions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_28_31179="Thin smear malaria dx";
var content_f30_28_31179=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F77935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F77935&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clues to species diagnosis via thin smear",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        P. falciparum",
"       </td>",
"       <td class=\"subtitle1\">",
"        P. vivax",
"       </td>",
"       <td class=\"subtitle1\">",
"        P. ovale",
"       </td>",
"       <td class=\"subtitle1\">",
"        P. malariae",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Size of",
"RBCs",
"       </td>",
"       <td>",
"        Normal size (sometimes distorted and crenated)",
"       </td>",
"       <td>",
"        Enlarged",
"       </td>",
"       <td>",
"        Enlarged, and usually oval in shape (with fimbriated",
"ends)",
"       </td>",
"       <td>",
"        Normal size",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Number",
"of parasites per RBC",
"       </td>",
"       <td>",
"        May be multiple",
"       </td>",
"       <td>",
"        Usually one",
"       </td>",
"       <td>",
"        Usually one",
"       </td>",
"       <td>",
"        Usually one",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Typical",
"form of trophozoite",
"       </td>",
"       <td>",
"        Rings",
"       </td>",
"       <td>",
"        Amoeboid, often fragmented",
"       </td>",
"       <td>",
"        Compact and regular",
"       </td>",
"       <td>",
"        Compact",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other",
"characteristics",
"       </td>",
"       <td>",
"        Banana-shaped gametocytes; black pigment in RBCs;",
"schizonts rare",
"       </td>",
"       <td>",
"        Schuffner's granules; often see gametocytes and",
"schizonts",
"       </td>",
"       <td>",
"        Schuffner's granules; often see gametocytes and",
"schizonts",
"       </td>",
"       <td>",
"        Often see gametocytes and schizonts",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     RBC: red blood cell.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_28_31179=[""].join("\n");
var outline_f30_28_31179=null;
var title_f30_28_31180="Causes of erythroderma";
var content_f30_28_31180=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87714&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87714&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of erythroderma (exfoliative dermatitis)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Idiopathic erythroderma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Inflammatory dermatoses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psoriasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Atopic dermatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dermatitis (other than atopic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pityriasis rubra pilaris",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lichen planus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic actinic dermatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Papuloerythroderma of Ofuji",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Drug reactions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Malignancies: hematologic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cutaneous T-cell lymphoma, Sezary syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other lymphomas (Hodgkin's, non-Hodgkin's)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leukemias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Malignancies: solid organ",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Renal cell carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatocellular carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lung",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Immunobullous disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pemphigus foliaceus, vulgaris",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bullous pemphigoid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paraneoplastic pemphigus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Connective tissue disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dermatomyositis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Subacute lupus erythematosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Infections",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Scabies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dermatophytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital cutaneous candidiasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Staphylococcus scalded skin syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beta-hemolytic streptococcal erythroderma syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Blood disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypereosinophilic syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mastocytosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Graft versus host disease (GVHD)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_28_31180=[""].join("\n");
var outline_f30_28_31180=null;
var title_f30_28_31181="Agents other than intravenous for pediatric sedation";
var content_f30_28_31181=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83889&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83889&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Commonly used agents for pediatric procedural sedation administered by oral, sublingual, rectal, or intranasal routes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"15%\">",
"     </colgroup>",
"     <colgroup width=\"55%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"5\">",
"        <strong>",
"         Sedation with these agents can result in significant respiratory depression and other adverse effects. Children should receive appropriate monitoring by personnel skilled in pediatric resuscitation until full recovery has occurred. Please refer to UpToDate topics on procedural sedation in children for more details.",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Onset (minutes)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Duration (minutes)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Midazolam",
"       </td>",
"       <td>",
"        <p>",
"         0.25 to 0.5 mg/kg PO or SL, maximum 20 mg",
"        </p>",
"        <p>",
"         0.2 to 0.3 mg/kg IN, maximum 10 mg*",
"        </p>",
"        <p>",
"         Buccal dosing is as for IN",
"        </p>",
"       </td>",
"       <td>",
"        20 to 30",
"       </td>",
"       <td>",
"        30 to 60",
"       </td>",
"       <td>",
"        <p>",
"         Midazolam has poor oral bioavailability (15 to 35 percent). IN, SL, and buccal has bioavailability approaching 70 to 80 percent during gradual administration.",
"        </p>",
"        <p>",
"         Provides amnesia, mild anxiolysis, and mild sedation for procedures that do not require full immobility (eg, laceration repair with local topical anesthesia)",
"        </p>",
"        <p>",
"         Flumazenil can reverse effects but should be avoided in patients with seizure disorder or who are chronically maintained on benzodiazepines",
"        </p>",
"        Common adverse effects: Respiratory depression and apnea, especially if combined with opioids or other sedatives; paradoxical reactions, including hyperactivity, aggressive behavior, and inconsolable crying",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pentobarbital&bull;",
"       </td>",
"       <td>",
"        <p>",
"         Younger than 4 years: 3 to 6 mg/kg PO/PR, maximum 100 mg",
"        </p>",
"        4 years and older: 1.5 to 3 mg/kg PO/PR, maximum 100 mg",
"       </td>",
"       <td>",
"        15&nbsp;to 45",
"       </td>",
"       <td>",
"        60&nbsp;to 240",
"       </td>",
"       <td>",
"        <p>",
"         Short-acting barbiturate option for noninvasive diagnostic procedures. Better efficacy seen in children &lt;8 years old",
"        </p>",
"        <p>",
"         Common adverse effects: Respiratory depression, hypotension, and increased heart rate, especially with intravenous use or combination with opioid or benzodiazepine",
"        </p>",
"        <p>",
"         Relatively contraindicated in patients with cardiac or hepatic insufficiency or hypovolemic shock",
"        </p>",
"        Absolute contraindications: Porphyria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methohexital&Delta;",
"       </td>",
"       <td>",
"        25 mg/kg PR, maximum 500 mg",
"       </td>",
"       <td>",
"        5 to 10",
"       </td>",
"       <td>",
"        30 to 90",
"       </td>",
"       <td>",
"        <p>",
"         Short-acting barbiturate option for noninvasive diagnostic procedures. More adverse events than pentobarbital",
"        </p>",
"        <p>",
"         Common adverse effects: Respiratory depression, hypotension, and myocardial depression",
"        </p>",
"        <p>",
"         Relative contraindications: Patients with cardiac, liver, or renal insufficiency",
"        </p>",
"        Absolute contraindications: Porphyria or partial seizure disorder (may precipitate seizures)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thiopental&loz;",
"       </td>",
"       <td>",
"        5 to 30 mg/kg PR, maximum 700 mg",
"       </td>",
"       <td>",
"        10 to 15",
"       </td>",
"       <td>",
"        30 to 60",
"       </td>",
"       <td>",
"        <p>",
"         Short-acting barbiturate that is less commonly used.",
"        </p>",
"        <p>",
"         Common adverse effects: Respiratory depression, Hypotension, and myocardial depression",
"        </p>",
"        <p>",
"         Relative contraindications: Patients with cardiac, liver, or renal insufficiency",
"        </p>",
"        Absolute contraindications: Porphyria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chloral hydrate&sect;",
"       </td>",
"       <td>",
"        <p>",
"         50 to&nbsp;75 mg/kg PO/PR, maximum 1 gram",
"        </p>",
"        May give repeat dose of 50 mg/kg (maximum 500 mg) 30 minutes after initial dose if needed",
"       </td>",
"       <td>",
"        10 to 15",
"       </td>",
"       <td>",
"        60 to 240",
"       </td>",
"       <td>",
"        <p>",
"         Traditional option for noninvasive diagnostic procedures in infants and young children but inferior to other options listed above because of prolonged effect and greater risk for adverse reactions. Also, not available in some countries, due to concern for potential carcinogenicity",
"        </p>",
"        <p>",
"         Less reliable sedation in patients older than 3 years of age",
"        </p>",
"        <p>",
"         Common adverse effects: Gastrointestinal irritation and vomiting with oral use, prolonged sedation, coma, paradoxical agitation, respiratory depression, especially in young term and preterm infants",
"        </p>",
"        <p>",
"         Tachyarrhythmia with excessive dosing",
"        </p>",
"        Relative contraindications: Patients with cardiac, liver, or renal insufficiency",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PO: oral; SL: sublingual; IN: intranasal; PR: rectal.",
"     <br>",
"      * Pretreatment with lidocaine spray (10 mg/puff) one minute prior to intranasal midazolam decreases nasal mucosal irritation. Intranasal preparation is not commercially available in the USA; 5 mg/mL injectable solution may be given IN.",
"      <br>",
"       &bull; Oral and rectal preparations of pentobarbital&nbsp;are not commercially available in the USA but may be prepared by pharmacy.",
"       <br>",
"        &Delta; Rectal preparation of methohexital is not commercially available in the USA. Injection solution may be diluted with water to a maximum concentration of 10 percent for rectal administration. Rectal administration is associated with defecation. Lower concentration solutions (1 to 2 percent) are less irritating.",
"        <br>",
"         &loz; Thiopental is not available in the USA or Canada but may be available in other countries.",
"         <br>",
"          &sect; Oral syrup and rectal preparation are not commercially available in the USA but may be prepared by pharmacy. Oral syrup has a bitter taste.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_28_31181=[""].join("\n");
var outline_f30_28_31181=null;
var title_f30_28_31182="Iatrogenic distal impaction";
var content_f30_28_31182=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56891&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Potential complications of foreign body extraction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 311px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Accidental wedging of the foreign body into a distal position.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_28_31182=[""].join("\n");
var outline_f30_28_31182=null;
var title_f30_28_31183="Mogan clamp applied to foreskin";
var content_f30_28_31183=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F55011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F55011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mogan clamp applied to foreskin",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David G Weismiller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_28_31183=[""].join("\n");
var outline_f30_28_31183=null;
